ࡱ> }~ ~2bjbj 7hxxK] 998L E%=h@!&^&&&&***PaRaRaRaRaRaRa}kn2Ra*)@***Ra99&&*g:::*9&9R&Pa:*Pa::["^&L09F^>40; (iii) immune abnormalities: eosinophilia, ! IgE, ! TH17 responses, B-cell abnormalities, defects in tissue remodeling. Authors evaluated the clinical and immunologic features of patients with AD (n=14), DOCK8-HIES (n=6), STAT3-HIES (n=7), and healthy controls (n=14) ! (i) overall, clinical allergy and SPT results complied with serum specific IgE results; (ii) total serum IgE levels were similarly increased in AD, DOCK8-HIES and STAT3-HIES patients; (iii) AD patients showed the highest specific serum IgE levels against aeroallergens; (iv) DOCK8-HIES patients showed the highest specific serum IgE levels against food allergens; (v) TH2-cell numbers and clinical allergies were significantly increased in DOCK8-HIES and AD patients compared to STAT3-HIES patients and controls; (vi) natural Treg-cell counts were significantly increased in AD patients compared to DOCK8-HIES, STAT3-HIES and control individuals; (vii) STAT3-HIES patients had decreased TH17-cell counts and allergic diseases; (viii) in STAT3-HIES patients, serum IgE correlated negatively to eosinophils and TH2-cell counts; (ix) in DOCK8-HIES patients, serum IgE correlated positively to eosinophils and TH2-cell counts. EFFICACY OF IGE-TARGETED VS EMPIRIC SIX-FOOD ELIMINATION DIETS FOR ADULT EOSINOPHILIC OESOPHAGITIS (Rodrguez-Snchez J, Gmez Torrijos E, Lpez Viedma B, de la Santa Belda E, Martn Dvila F, Garca Rodrguez C, Feo Brito F, Olmedo Camacho J, Reales Figueroa P, Molina-Infante J. Allergy 2014; 69: 936942): Eosinophilic esophagitis (EoE): (i) prevalence in the general population: ~1/2,000 subjects; (ii) incidence is rising; (iii) male to female ratio=3:1; (iv) impact: significant morbidity, ! QoL, high cost; (v) pathogenesis: genetic susceptibility, environmental insults to the esophageal epithelium (e.g. allergens, infections, irritants) ! epithelial barrier dysfunction (e.g. ! expression of the cell adhesion protein DSG-1), ! secretion of TSLP and IL-33 ! ! allergen entry through the epithelium ! immune reaction to food or respiratory allergens ! infiltration of eosinophils into esophageal mucosa ! chronic inflammatory infiltrate (eosinophils, mast cells, a special basophil population, TH2 cells, iNKT cells) ! esophageal fibrosis, remodelling (e.g. transdifferentiation of epithelial cells to a myofibroblast phenotype) and dysfunction; (vi) common causal foods in children: milk, egg, soy, wheat, beef, chicken; (vii) common causal foods in adults: legumes, nuts, fruits, wheat, milk, soy, egg; (viii) frequent association (40-90%) with other atopic diseases (asthma, allergic rhinitis, food allergy, atopic dermatitis). Diagnosis of EoE: (i) clinical history: abdominal pain, vomiting, dysphagia, heartburn, cough, choking, food aversion; (ii) complications: food impaction, failure to thrive, esophageal perforation, mental affectation; (iii) esophageal endoscopy: edema, white exudative plaques, mucosal rings (trachealization), strictures, linear furrows, mucosal tearing; (iv) esophageal biopsy (positive result: e"15 eosinophils per high-power field; other findings: superficial layering, microabscesses, extracellular eosinophil granules, basal cell hyperplasia, dilated intercellular spaces, lamina propria fibrosis); (v) allergy testing (skin prick test [SPT], serum specific IgE, atopy patch test [APT]) with food and respiratory allergens; (vi) food elimination-reintroduction trials; (vii) detection of eosinophil-mediated inflammation (e.g. cationic eosinophil granule proteins) by SPECT imaging. Treatment of EoE: (i) diet options: 6-food elimination diet (milk, egg, wheat, soy, fish/seafood, peanut/tree nuts), diet guided by allergy tests, aminoacid formula; (ii) topical corticosteroids: low bioavailability and low potential for systemic adverse effects but ! risk of local fungal infection; (iii) systemic corticosteroids: effective, severe side effects; (iv) biologic therapies targeting the eosinophil (e.g. anti-IL-5 mAb, anti-IL-5R mAb); (v) esophageal dilation: might provide short-term symptomatic relief, only used if dietary and medical therapy has failed. Efficacy of dietary therapies in EoE: (i) elemental diet (in both children and adults): ~90%; (ii) empiric 6-food elimination diet (SFED) (in both children and adults): ~70%; (iii) diet guided by skin testing (SPT and atopy patch test): ~75% in children, ~30% in adults. Authors compared the efficacy of food-specific serum IgE-targeted elimination diet (sIgE-ED) and SFED in 43 adults with EoE ! (i) mean number of eliminated foods per patient was significantly lower in sIgE-ED (3.81) than in SFED (6); (ii) most commonly foods withdrawn by sIgE-ED: wheat (85%), nuts (73%), cow s milk (61%); (iii) sIgE-ED was effective, comparable to SFED in terms of clinical and histological remission; (iv) causative foods identified by food challenge: cows milk (64%), wheat (28%), egg (21%), legumes (7%); (v) serum specific IgE was more accurate than SPT and APT to detect offending foods (sensitivity 87.5%, specificity 68%), especially for cows milk. FATAL ANAPHYLAXIS WITH NEUROMUSCULAR BLOCKING AGENTS: A RISK FACTOR AND MANAGEMENT ANALYSIS (Reitter M, Petitpain N, Latarche C, Cottin J, Massy N, Demoly P, Gillet P, Mertes PM, the French Network of Regional Pharmacovigilance Centres. Allergy 2014; 69: 954959): Anaphylaxis: (i) definition: acute life-threatening systemic hypersensitivity reaction; (ii) lifetime prevalence: 0.05-2%; (iii) mechanisms: release of mediators from mast cells and basophils (IgE-mediated, IgG-mediated, complement mediated, idiopathic); (iv) most common culprits: foods, drugs, hymenoptera venom, latex; (v) augmentation factors: exercise, alcohol, infections, NSAIDs, drugs, menses, stress; (vi) diagnosis: clinical history (NIAID/FAAN criteria: sensitivity=96.7%, specificity=82.4%), measurement of allergy mediators (e.g. serum tryptase, serum/urinary histamine or metabolites, serum PAF), allergy testing (e.g. sIgE detection by skin and in vitro tests); (vii) treatment in the acute setting: epinephrine (1st line therapy), antihistamines, corticosteroids, 2-agonists, oxygen, intravenous fluids; (viii) long-term management: allergen avoidance, epinephrine autoinjectors, immunotherapy. Neuromuscular blocking agents (NMBAs): frequent causal agents of anaphylaxis in the general anesthesia setting. Authors analyzed 2022 reports of NMBA-related anaphylaxis in the French National Pharmacovigilance Database ! (i) 1247 reactions were severe (grades 3 and 4); (ii) 84 reactions (4.1%) were fatal, despite guideline-based therapy; (iii) independent risk factors associated with a fatal outcome: male gender (female gender: OR=0.4), emergency setting (OR=2.6), history of hypertension (OR=2.5) or other cardiovascular disease (OR=4.4), obesity (OR=2.4), ongoing beta-blocker treatment (OR=4.2). REFRACTORY ASTHMA: MECHANISMS, TARGETS, AND THERAPY (Trevor JL, Deshane JS. Allergy 2014; 69: 817827): Asthma: (i) definition: chronic inflammatory respiratory disease characterized by small airways inflammation, hyperresponsiveness, obstruction and remodeling; (ii) prevalence: ~300 million people worldwide; (iii) impact: significant morbidity, ! QoL, mortality risk (250,000 deaths/year worldwide), high costs; (iv) several endotypes and phenotypes (e.g. TH2/eosinophilic inflammation; TH17/neutrophilic inflammation); (v) conventional therapy: inhaled glucocorticoids (IGCs), 2-adrenergic receptor agonists, antileukotrienes. A patient with uncontrolled asthma may have: (i) unawareness of disease severity; (ii) a physician who is undertreating; (iii) comorbidities (e.g. GERD, obesity, chronic rhinosinusitis, vocal cord dysfunction); (iv) low adherence to treatment; (v) treatment-resistant disease; (vi) an alternative diagnosis. ~10% of asthma patients do not benefit with conventional therapy (refractory asthma) ! it is important to develop new therapies based on asthma pathogenesis. Pathogenesis of allergic asthma: (i) disruption of airway epithelial tight junctions and activation of epithelial cells by allergens (e.g. house dust mite proteases, fungal spores, pollen germination), pollutants (e.g. cigarette smoke) and virus (e.g. respiratory syncytial virus) in a genetically susceptible subject ! (ii) entry of allergens through the disrupted epithelium or intact epithelial cells (transcytosis) ! (iii) secretion of TSLP, IL-25 and IL-33 from activated epithelial cells ! (iv) activation of type 2 innate lymphoid cells (ILCs) by TSLP, IL-25 and IL-33 ! (v) secretion of TH2-cytokines (IL-3, IL-4, IL-5, IL-13) from type 2 ILCs ! (vi) activation of dendritic cells (DCs) by cytokines (TSLP, IL-25, IL-33) and PRR-mediated signalling ! (vii) maturation of DCs (expression of TH2-favoring costimulatory molecules [OX-40L]; secretion of TH2-attracting cytokines [CCL17, CCL22]; presentation of allergen-derived peptides in MHC-II molecules) ! (viii) attraction and differentiation of TH2 cells via antigen presentation, costimulatory molecules (OX40L, CD80/CD86) and cytokine signalling (IL-4) ! (ix) secretion of TH2-cytokines (IL-3, IL-4, IL-5, IL-13) from TH2 lymphocytes ! (x) IgE production from B cells; attraction and activation of effector allergy cells (mast cells, eosinophils, basophils); mucus secretion by epithelial cells ! (xi) airway inflammation, epithelial injury, bronchoconstriction, air trapping, airway remodeling (goblet cell hyperplasia, thickening of the reticular basement membrane, subbasement fibrosis, smooth muscle hypertrophy/hyperplasia, angiogenesis). Risk factors for refractory asthma: (i) genetic variants affecting epithelial barrier, innate immunity or adaptive immunity (variants that ! asthma risk in one environment may ! risk in another environment), (ii) comorbidities (e.g. nasosinusal disease, obesity, GERD), (iii) respiratory infections (e.g. Mycoplasma pneumoniae), (iv) pollutants (e.g. smoking, particulate matter), (v) sensitization to fungi (e.g. severe asthma with fungal sensitization), (vi) airway TH17/neutrophilic inflammation; (vii) multiple allergies; (viii) marked airway remodeling. Therapies for refractory asthma: (i) small-particle ICSs and LABAs targeting small airways; (ii) once daily LABAs (e.g. vilanterol); (iii) inhaled long-acting anticholinergics (e.g. tiotropium); (iv) HDAC2 inducers: theophylline (! steroid resistance); (v) vit D (immunomodulatory effects); (vi) macrolides (antimicrobial and immunomodulatory action); (vii) antifungal therapy (in patients with fungal sensitization); (viii) CRTH2 antagonists (block PGD2 action on TH2 cells, eosinophils and mast cells); (ix) antagonists of chemokine receptors (e.g. CCR3, expressed largely on eosinophils); (x) inhibitors of kinases such as p38MAPK; (xi) biologic therapies; (xii) bronchial thermoplasty (not approved for children <12 yrs of age). Biologic therapies for asthma: (i) important for patients who do not respond to conventional therapy; (ii) may benefit specific asthma endotypes/phenotypes (e.g. lebrikizumab in patients with ! periostin/IL-13); (iii) ~30 drugs are currently in clinical trials and dozens in development; (iv) outcomes of most trials have been disappointing; (v) main problems: lack of efficacy, high cost, low accessibility, side effects. Examples of biologic therapies for asthma: (i) anti-IgE mAb: omalizumab (the only FDA-approved biologic to treat asthma), (ii) anti-IL-4R mAb: dupilumab (blocks IL-4 and IL-13 pathways), AMG-317; (iii) IL-4R antagonist: pitrakinra (blocks IL-4 and IL-13 pathways); (iv) IL-4 trapping agent: altrakincept; (v) anti-IL-5 mAb: mepolizumab, reslizumab; (vi) anti-IL-5R mAb: benralizumab (reduce eosinophil and basophil count); (vii) anti-IL-13 mAb: lebrikizumab, tralokinumab, anrukinzumab; (viii) anti-TNF- therapies: etanercept, infliximab, adalimumab, golimumab (risk of severe side effects); (ix) TLR7 agonists: imiquimod, resiquimod; (x) TLR9 agonist: QbG10; (xi) inhibitors of the TH17 pathway: anti-IL-17, anti-IL-23. Mechanism of action of GCs: diffusion across the cell membrane ! binding to the glucocorticoid receptor  (GR) in the cytoplasm ! GR liberates from chaperone proteins (hsp-90) ! GR enters the nucleus through nuclear import proteins (importin ) ! GR homodimerizes and binds to the promoter region of many genes (glucocorticoid response element) ! the GC/GR complex switches off many activated inflammatory genes (cytokines, chemokines, adhesion molecules) and enhances anti-inflammatory genes. Mechanisms of corticosteroid resistance: (i) phosphorylation of the GR by kinases (p38MAPK, JNK1), ! activity of phosphatases (MKP-1, PP2A) ! ! nuclear translocation of GR; (ii) ! expression of the isoform GC receptor beta (GR), which competes with activated GR; (iii) ! proinflammatory transcription factors (NF-B, AP-1, JNK); (iv) oxidative stress ! activation of PI3K ! ! expression of histone deacetylase 2 (HDAC2), which normally switches off activated inflammatory genes; (v) polymorphisms of IL-10; (vi) vit D deficiency. Strategies for managing GC resistance: (i) anti-inflammatory drugs: phosphodiesterase 4 inhibitors (e.g. oral roflumilast for COPD), p38MAPK inhibitors, NF-kB inhibitors, macrolides; (ii) drugs that ! HDAC2 expression: theophylline, nortriptyline, PI3K inhibitors; (iii) long-acting 2-receptor agonists (! PP2A, ! GR phosphorylation, ! GR translocation to the nucleus); (iv) antioxidants: Nrf2 activators; (v) vit D supplementation. Asthma is a complex clinical syndrome with multiple genotypes, endotypes and phenotypes ! it is very unlikely that there is one  magic bullet to cure all patients with asthma. Futuristic approach in asthma/wheezing: use of clinical data and biomarkers to identify specific asthma/wheezing phenotypes and endotypes ! give individualized therapy (e.g. leukotriene-induced asthma ! give antileukotrienes). THE EAACI/GA2LEN/EDF/WAO GUIDELINE FOR THE DEFINITION, CLASSIFICATION, DIAGNOSIS, AND MANAGEMENT OF URTICARIA: THE 2013 REVISION AND UPDATE (Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Gimnez-Arnau A, Godse K, Goncalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Nast A, Saini SS, Snchez-Borges M, Schmid-Grendelmeier P, Simons FER, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Maurer M. Allergy 2014; 69: 868887): Authors present a 20-page guideline about the definition, classification, diagnosis and treatment of urticaria. Definition of urticaria: sudden appearance of wheals angioedema. Typical features of a wheal: (i) central swelling of variable size, almost invariably surrounded by a reflex erythema; (ii) associated with itching or sometimes a burning sensation; (iii) duration usually between 124 hrs. Features of angioedema: (i) sudden, pronounced erythematous or skin-colored swelling of the lower dermis and subcutis with frequent involvement below mucous membranes; (ii) sometimes pain rather than itching; (iii) slower resolution that wheals (up to 72 hrs). It is very important to exclude other diseases with similar features: autoinflammatory diseases, urticarial vasculitis, hereditary angioedema, acquired angioedema, etc. Classification of urticaria: (i) spontaneous: acute (<6 wks) or chronic (>6 wks); (ii) inducible. Lifetime prevalence of urticaria: 1% of the population (chronic urticaria); 20% of the population (acute urticaria). Impact of chronic urticaria: significant morbidity, ! QoL (similar to angina pectoris; scores to measure QoL are useful), ! performance at school or work, high costs. Chronic spontaneous urticaria (CSU): (i) no clear triggers; (ii) 50% of cases have  autoimmune features [IgG1/IgG3 to FcRI or IgE; ! frequency of HLA DRB1*04]; (iii) coagulation, fibrinolysis and complement systems may have a role in pathogenesis; (iv) wheals usually last between 4 and 24 hrs; (v) concomitant angioedema may occur in ~50% of cases. Inducible urticaria: (i) triggered by stimuli such as cold, heat, touch, pressure, vibration, sunlight, water or exercise; (ii) wheals usually last <2 hrs after stimuli ceases, except for delayed pressure urticaria (similar to CSU wheals). Treatment of chronic urticaria: (i) 1st-line treatment: nonsedating anti-H1 at usual dosing (50% of patients may not respond); (ii) 2nd-line treatment: up to quadruple dose of anti-H1, such as desloratadine or levocetirizine (50% of patients may not respond ! antihistamine-refractory CU); (iii) 3rd-line treatment: omalizumab, cyclosporin A (only FDA-approved immunosuppressant drug for CU), montelukast; (iv) other reported therapies: mast cell-stabilizing drugs (e.g. ketotifen), topical corticosteroids, systemic corticosteroids (3-10 days to control severe flares), biologic therapies (e.g. anti-TNF-), intravenous immunoglobulin, epinephrine, desensitization, moisturizers, UV phototherapy, sulfasalazine, dapsone, colchicine, chloroquine, hydroxychloroquine, calcineurin inhibitors, mycophenolate, pseudoallergen-free diet, anticholinergics, androgens, selective serotonin reuptake inhibitors, tranexamic acid, psoralens, plasmapheresis, anticoagulants. Prognosis of chronic urticaria: 50% of cases may resolve within 1 yr; 75% of cases within 5 yrs. ANNALS OF ALLERGY, ASTHMA & IMMUNOLOGY: A CASE OF TRANSIENT ACQUIRED C1 INHIBITOR DEFICIENCY (Melamed J, Ahuja-Malik A. Ann Allergy Asthma Immunol 2014; 113: 116-117): C1 inhibitor (C1-INH): serine protease that ! complement and contact (kallikrein-kinin) systems. Acquired angioedema with C1-INH deficiency (ACID): (i) recurrent episodes of bradykinin-mediated angioedema due to C1-INH consumption; (ii) pathophysiology: lymphoproliferative disorders, autoimmune diseases (e.g. SLE, Sjgren syndrome, vasculitis), monoclonal gammopathies ! autoantibody production (including to C1-INH) ! activation of the classical complement pathway ! consumption of C1q, C1-INH and C4 ! ! activity of FXII and kallikrein ! ! bradykinin production ! ACID; (iii) usually presents after 40 yrs of age; (iv) clinical manifestations: recurrent swelling of subcutaneous tissues (face, extremities, buttocks, genitals), abdominal organs (stomach, gut, bladder) or upper airways (larynx), unresponsive to antihistamines or corticosteroids. Transient ACID: (i) rare entity; (ii) has been associated with HIV and parvovirus B17 infections in case reports; (iii) may be misdiagnosed as anaphylaxis. Authors report the case of a 55-yr-old woman with a suspected isolated episode of transient ACID (massive angioedema of the right forearm; nausea, diarrhea, abdominal pain; hypotension; an erythematous, macular, patchy rash on the right flank and abdomen; ! C1-INH level, ! C4 level, ! activated partial thromboplastin time, ! D-dimer level) ! previous clinical history: Lyme disease some months earlier, alcohol-induced hepatitis one month earlier, hypertension (lisinopril and amlodipine therapy for years) ! successful treatment: intravenous fluids, methylprednisolone, piperacillin, diphenhydramine, famotidine ! follow up some wks later: normal levels of complement proteins, no active infections detected. Proposed contributing factors for transient ACID in this case: (i) vigorous IgM response to Borrelia burgdorferi (in antigen excess), with associated complement fixation and C1-INH consumption; (ii) treatment with lisinopril. ALLERGIC CONTACT DERMATITIS (Fonacier LS, Sher JM. Ann Allergy Asthma Immunol 2014; 113: 9-12): Contact dermatitis: (i) definition: skin inflammation after direct contact with a substance; (ii) 2 main types: irritant contact dermatitis (most common form, direct irritation by substances, no immunologic sensitization), allergic contact dermatitis (ACD). ACD: (i) type IV hypersensitivity reaction, (ii) skin inflammation usually occurs 8 to 48 hrs after contact with the allergen (can occur as early as 2 hrs and as late as 96 hrs), (iii) ACD and atopic dermatitis (AD) frequently coexist. Risk factors for ACD: (i) AD (3-fold risk of contact dermatitis in hands); (ii) other skin barrier defects; (iii) repetitive contact with potential contact allergens. Pathophysiology of ACD: (i) 1st exposure to a contact allergen ! allergen entry through the skin ! allergen processing by antigen-presenting cells (APCs) ! allergen carrying by APCs to regional lymph nodes ! allergen presentation to allergen-specific T cells ! activation and proliferation of allergen-specific T cells; (ii) subsequent exposures to the allergen ! entry through the skin ! activation of skin-homing memory T cells ! inflammation ! ACD. Diagnosis of ACD: (i) clinical history: history of AD, occupational history, hobbies, ACD lesions (time of onset, course, duration, triggers, response to treatment); (ii) examination of the lesions: distribution (high-yield locations: eyelids, face, lips, hands, dorsal feet, upper back, proximal and lateral regions of the arms), morphology (acute lesions: pruritic, erythematous plaques and vesicles; chronic lesions: pink-red, dry, fissured and lichenified skin); (iii) patch testing: gold standard for diagnosis, standardized panels exist (e.g. the thin-layer rapid use epicutaneous test [T.R.U.E. Test]: FDA-approved, contains 35 antigens or mixes plus a negative control), all relevant allergens should be tested (e.g. fragrance mix-I and balsam of Peru [Myroxylon pereirae] only detect up to 70% of fragrance-allergic individuals; some rubber allergens are often missed with TRUE test), testing personal products can be useful (most important chemical classes: fragrances, preservatives, excipients, nickel, sun blocks). Distribution of ACD lesions is the key to diagnosis (e.g. ACD of periorbital areas and eyelids is commonly due to fragrances, the most common sensitizers in cosmetics). Patch testing with nonstandardized antigens (always review material safety): (i) agents applied to normal skin and left on (e.g. make-ups, moisturizers, lipsticks, sunscreens, perfumes, topical medications) should be tested as is; (ii) wash-off products (e.g. soap, shampoo, cream rinses) can be diluted to 1:100 or 1:10; (iii) only expert physicians should test household (e.g. detergents) and industrial products; (iv) recommended patch test concentration and vehicles can be found in [De Groot AC. Patch Testing: Test Concentrations and Vehicles for 4350 Chemicals. 3rd ed. Wapserveen, the Netherlands: Acdegroot Publishing; 2008]. Treatment: (i) identification and avoidance of the culprit allergen (online databases of allergen-free products are useful;  HYPERLINK "http://www.contactderm.org" www.contactderm.org,  HYPERLINK "http://www.AllergyFreeSkin.com" www.AllergyFreeSkin.com), (ii) topical corticosteroids, (iii) topical emollients, (iv) systemic corticosteroids. Systemic contact dermatitis (SCD): (i) definition: acute dermatitis (e.g. baboon syndrome, dermatitis at sites of previous allergen exposure, dyshydrotic hand eczema) after a systemic exposure to a contact allergen; (ii) most common causes: metals (e.g. mercury, nickel, gold), drugs (e.g. aminoglycosides, corticosteroids, aminophylline), plants (e.g. the Compositae and Anacardiaceae plant families); (iii) food allergens can cause ACD and SCD (e.g. nickel, flavoring agents [balsam of Peru, oil of cinnamon, vanilla]); (iv) avoidance diets can be effective (e.g. foods to avoid in a balsam-restricted diet: citrus fruits, flavoring agents, spices [cinnamon, cloves, vanilla, curry, allspice, anise, ginger], spicy condiments, flavored tea and tobacco, chocolate, certain cough medicines, ice cream, spiced drinks, tomato-containing products). CHANGING ROLES OF EOSINOPHILS IN HEALTH AND DISEASE (Furuta GT, Atkins FD, Lee NA, Lee JJ. Ann Allergy Asthma Immunol 2014; 113: 3-8): Dynamic history of eosinophils (4 eras since Paul Erlich named them based on eosin staining): (i) Paul Erlich to the Mid-20th Century (1880-1960): eosinophils are innate defense cells (destruction of large nonphagocytable parasites) and causal agents of allergic diseases and tissue damage; (ii) The Early Anti-inflammatory Years (1960-1980): eosinophils are recruited to inflamed tissues to ! the inflammatory activity of resident leukocytes (e.g. mastocytes); (iii) The  Gleich Era (1980-2000): rebirth of the nonspecific and destructive nature of eosinophils contributing to host defense and diseases (enzymatic and cytotoxic activity of granule proteins); (iv) The LIAR Hypothesis (2000-present): eosinophils contribute to tissue homeostasis through local immune and remodeling/repair activities (e.g. liver and skeletal muscle regeneration) Eosinophil functions: (i) proinflammatory: cytotoxicity, tissue damage, angiogenesis; (ii) antiinflammatory: tissue repair and remodeling, immunomodulation. Diseases with ! eosinophils: (i) allergic diseases (atopic dermatitis, asthma, allergic rhinitis); (ii) hypereosinophilic syndrome; (iii) eosinophilic organ diseases; (iv) eosinophilic vasculitis (Churg-Strauss syndrome); (v) eosinophilic leukemia; (vi) other inflammatory processes. Eosinophilic activity in disease: (i) measurement methods: blood or tissue eosinophil counts, levels of eosinophil proteins in tissues or fluids; (ii) ! eosinophilic activity is usually associated with disease remission; (iii) to date, no eosinophil-related biomarker has proved sufficient utility as a surrogate of disease symptomatology, natural history, outcome or therapeutic success. Specific therapies targeting the eosinophil: (i) molecules: anti-IL-5 mAbs (mepolizumab, reslizumab), anti-IL-5R mAb (benralizumab, which also depletes basophils); (ii) variable efficacy in studies of patients with asthma, eosinophilic GI diseases, atopic dermatitis, Churg-Strauss syndrome and FIP1L1/PDGFRA-negative HES (outcomes appear to depend on the patient phenotype and/or primary end point examined); (iii) more research is necessary. Additional therapeutic targets to ! eosinophils: eotaxins, CCR3, CRTH2 (Chemoattractant Receptor-homologous molecule expressed on TH2 cells), TH2-associated cytokines. Absence of eosinophils in mice or humans ! no significant deleterious effect on health (apparently). OMALIZUMAB EFFECTIVELY PREVENTS RECURRENT REFRACTORY ANAPHYLAXIS IN A PATIENT WITH MONOCLONAL MAST CELL ACTIVATION SYNDROME (Jagdis A, Vadas P. Ann Allergy Asthma Immunol 2014; 113: 115-116): Monoclonal mast cell activation syndrome (MMAS): (i) 1st described in 2007; (ii) definition: clonal mast cell disorder characterized by recurrent symptoms of mast cell degranulation (urticaria, bronchospasm, abdominal symptoms, hypotension) in patients who do not fulfill criteria for systemic mastocytosis (SM); (iii) patients with MMAS meet only 1 or 2 of the minor criteria for SM and do not exhibit the clusters of bone marrow mast cells; (iv) unknown natural history (some patients eventually fulfill the 3 minor criteria for SM); (v) therapy: antihistamines, antileukotrienes, mast cell stabilizers, corticosteroids; (vi) disease control can be difficult. Omalizumab: (i) recombinant humanized anti-IgE mAb ! binds to free IgE ! ! IgE binding to its receptors, ! expression of IgE receptors ! ! IgE-mediated inflammation; (ii) FDA-approved for severe asthma and antihistamine-refractory CU; (iii) efficacy has also been reported in mast cell activation disorders, anaphylaxis, eosinophilic chronic rhinosinusitis and atopic dermatitis. Authors report the case of a 31-yr-old woman with recurrent unprovoked life-threatening anaphylaxis (urticaria, swelling, cough, dyspnea, chest tightness, dysphonia, abdominal pain, vomiting, hypotension, syncope, marked ! of serum tryptase) ! laboratory: normal CBC, minimal ! of baseline serum tryptase, IgE=68 IU/mL ! bone marrow biopsy: mild ! of mast cells and eosinophils, one compact cluster of mast cells (not meeting major criterion for SM), occasional mast cells with spindled morphology, rare mast cells with weak anti-CD25 staining ! cytogenetic analysis: Asp816Val c-KIT mutation ! diagnosis: MMAS ! unsuccessful therapy: cetirizine (20 mg/d), ranitidine (150 mg bid), sodium cromoglycate (200 mg tid), montelukast (10 mg/d), ketotifen (4 mg bid), desloratadine (5 mg/d), hydroxychloroquine (200 mg/d) ! partially successful therapy: omalizumab 300 mg SC every 4 wks continuously ! follow-up at 11 months: 1 anaphylactic reaction requiring epinephrine, 2 milder reactions, no adverse effects of omalizumab, ! use of ketotifen (3 mg bid) and montelukast (suspended). Author s commentaries: (i) 3rd reported case of omalizumab efficacy in MMAS (unclear mechanism of action); (ii) omalizumab may help patients with life-threatening refractory MMAS. SKIN TESTING ONLY WITH PENICILLIN G IN CHILDREN WITH A HISTORY OF PENICILLIN ALLERGY (Picard M, Paradis L, Bgin P, Paradis J, Des Roches A. Ann Allergy Asthma Immunol 2014; 113: 75-81): Penicillin (PNC): (i) discovered by Alexander Fleming from the fungus Penicillium; (ii) core structure: the -lactam ring with the variable side chain R attached to the amide bridge to the ring carbon 6 atom; (iii) modifications at the R site ! PNC-derivative antibiotics (e.g. the aminopenicillins amoxicillin and ampicillin contain an amine group in their side chain). IgE-mediated PNC allergy: (i) self-reported in 5% of children and 10% of the population; (ii) confirmed in <1% of the population; (iii) incidence of anaphylaxis to PNCs=0.015-0.004% (fatality rate=0.002-0.0015%); (iv) major PNC allergen: benzylpenicilloyl determinant (95% of the PNC that is bound to proteins; commercially available as penicilloyl-polylysine [PPL]); (v) minor PNC allergens (minor determinant mixture, MDM): benzylpenicilloate, benzylpenilloate, benzylpenicilloyl-n-propylamine, PNC G; (vi) false-positive diagnosis of PNC allergy ! unnecessary use of alternative antibiotics (e.g. quinolones, vancomycin, clindamycin, cephalosporins) that ! cost, bacterial resistance (e.g. methicillin-resistant S aureus, vancomycin-resistant enterococcus) and Clostridium difficile infection; (vii) reasons for false-positive diagnosis of PNC allergy: assumption that every rash during PNC therapy is caused by PNC allergy, wrong interpretation of skin or in vitro allergy tests; (viii) appropriate PNC skin testing and interpretation can ! the rate of false-positive diagnosis of PNC allergy. Evaluation of a suspected IgE-mediated PNC allergy: (i) clinical history (often not reliable); (ii) in vitro testing (serum specific IgE, basophil activation testing); (iii) skin testing (reagents: PPL, benzylpenicilloate, benzylpenilloate, PNC G); (iv) drug challenge (up to 31% of patients require it to identify PNC allergy; it provides reassurance to subjects who might not be convinced by negative skin test results). Commercial PPL, the major PNC antigenic determinant, is not widely available. Authors evaluated 563 children with a history of PNC allergy ! (i) skin testing only with PNC G had a good NPV (95.2% in all the sample; 82.4% in patients with a history of anaphylaxis); (ii) in patients with negative skin testing, a 3-dose graded challenge to the incriminated PNC was relatively safe ! this approach can be useful when PPL is not available. THE DRY NEEDLE TECHNIQUE (Coop CA, Yip SK, Tankersley MS. Ann Allergy Asthma Immunol 2014; 113: 120-121): Allergen immunotherapy (AIT): (i) only therapy that can change the natural history of IgE-mediated allergies (e.g. sublingual aeroallergen IT for 4-5 yrs generated sustained benefits for 7-12 yrs); (ii) method: administration of the specific allergen progressively to induce tolerance; (iii) widely used to treat asthma, allergic rhinitis and venom allergy; (iv) promising therapy for atopic dermatitis and food allergy; (v) mechanisms: ! Treg cells, ! specific IgG1 and IgG4, ! specific IgE, ! reactivity of mast cells and basophils; (vi) most used modalities: subcutaneous (SCIT), sublingual [it is unclear which modality has better outcomes]; (vii) limitations: allergic reactions (especially with SCIT), long treatment duration (e"3 yrs), insufficient efficacy (except for venom IT [e"90% efficacy]); (viii) it is necessary to ! AIT efficacy, convenience and safety. Methods to prevent local and systemic reactions caused by AIT (little evidence): (i) premedication with antihistamines, leukotriene antagonists or NSAIDs; (ii) use of topical corticosteroids over the injection site; (iii) use of cold compresses immediately after allergen injection; (iv) mixing epinephrine with the allergen extract at the time of injection; (v) dose adjustments for persistent large local reactions; (vi) depression of the plunger at a rate that does not result in wheal formation or excessive pain; (vii) application of mild pressure at the injection site for 1 min after needle removal to ! extract leakage; (viii) the dry needle technique. Dry needle technique: (i) definition: use of a separate needle to inject the allergen extract into the patient s arm rather than using the needle from which the extract was drawn up into the syringe; (ii) objective: ! local reactions to immunotherapy; (iii) non-evidenced-based. Authors surveyed 344 patients receiving SCIT (aeroallergen IT or venom IT) to assess their perceptions about the dry needle technique ! (i) most patients believed that the dry needle technique decreased or completely resolved their local reactions, systemic reactions and pain after injection; (ii) further research is needed. UNLOCKING THE STRESS-ALLERGY PUZZLE: NEED FOR A MORE COMPREHENSIVE STRESS MODEL (Wright RJ, Berin MC. Ann Allergy Asthma Immunol 2014; 113: 1-2): Stress: (i) individual level: fear, anxiety, depression; (ii) family level: family violence, family instability; (iii) community level: neighborhood violence, terrorism. Relation between stress and allergies: (i) allergic diseases ! ! stress, ! QoL; (ii) stress ! worsening of allergic diseases (asthma, allergic rhinitis, atopic dermatitis, food allergy, anaphylaxis) and chronic urticaria; (iii) stress ! activation of coronary artery-associated mast cells ! cardiac events. Proposed pathogenic mechanisms of stress: (i) ! production of CRH (corticotropin-releasing hormone) ! mast cell activation through CRHR-1, ! IL-10 secretion by Tregs; (ii) ! secretion of neuropeptides (substance P, neurotensin) ! ! expression of functional CRHR-1 on mast cells, mast cell degranulation through NTR (neurotensin receptor) and NK1R (neurokin-1 receptor); (iii) dysfunctional HPA; (iv) ! cortisol production; (v) cortisol insensitivity; (vi) ! epithelial barrier function ! ! allergen entry. Almost all leukocytes have receptors for hormones and neuropeptides released during stress (e.g. glucocorticoids, substance P, neuropeptide Y, CRH, prolactin, epinephrine, serotonin). Superior cervical ganglion neurons can express Fc receptors for IgE and IgG, with calcium signaling after IgE-allergen crosslinking ! nerves can be directly activated by allergen. Stress and anxiety: therapeutic targets to improve management of patients with allergies. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY: A CASE OF PARTIAL DEDICATOR OF CYTOKINESIS 8 DEFICIENCY WITH ALTERED EFFECTOR PHENOTYPE AND IMPAIRED CD8+ AND NATURAL KILLER CELL CYTOTOXICITY (Ruiz-Garca R, Lermo-Rojo S, Martnez-Lostao L, Mancebo E, Mora-Daz S, Paz-Artal E, Ruiz-Contreras J, Anel A, Gonzlez-Granado LI, Allende LM. J Allergy Clin Immunol 2014; 134: 218-221): Dedicator of cytokinesis 8 (DOCK8) gene encodes a guanine nucleotide exchange factor essential for the actin cytoskeleton functions (e.g. formation of the immunological synapse ! T-cell activation). DOCK8 deficiency: (i) autosomal recessive hyper-IgE syndrome (HIES) with features of combined immunodeficiency; (ii) clinical features: severe viral infections (especially by HSV, VZV, HPV, molluscum contagiosum virus and JC viruses), fungal and bacterial infections, severe eczema, severe allergies, cancer susceptibility (e.g. squamous cell carcinoma, lymphoma); (iii) immune abnormalities: eosinophilia, ! IgE, ! T-cell migration, activation and function, ! T-cell and B-cell memory, ! CD8+ T-cell and NK-cell cytotoxicity, exhausted T-cell phenotype, impaired antibody production, impaired lymphoproliferation to antigens. Authors report the case of a patient with clinical and immunological parameters of HIES due to a partial DOCK8 deficiency (milder clinical phenotype, no life-threatening infections, altered effector T-cell phenotype, impaired CD8+ T-cell and NK-cell cytotoxicity). COMBINED NEWBORN SCREENING FOR FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND SEVERE T- AND B-CELL IMMUNODEFICIENCIES (Borte S, Meeths M, Liebscher I, Krist K, Nordenskjld M, MD Hammarstrm L, MD, von Dbeln U, Henter J-I, Bryceson YT. J Allergy Clin Immunol 2014; 134: 226-228): Severe combined immunodeficiency (SCID): (i) definition: genetic defects causing marked ! in T-cell development and function ! lack of cellular and humoral immunity ! severe infections (including opportunistic), fatal course if not treated (HSCT, gene therapy, enzyme replacement therapy); (ii) newborns can be screened for SCID by measuring TRECs (T-cell receptor excision circles) in dried blood spot samples (DBSS) obtained from regular Guthrie cards. Agammaglobulinemia: (i) definition: genetic mutations that block B-cell maturation ! ! circulating B cells (<2% of peripheral blood lymphocytes) ! ! production of immunoglobulins ! severe infections; (ii) newborns can be screened for agammaglobulinemia by measuring KRECs (kappa-deleting recombination excision circles) in DBSS. Familial hemophagocytic lymphohistiocytosis (FHL): (i) often-fatal hyperinflammatory disorder caused by mutations in different genes; (ii) incidence: 1/50,000 live births; (iii) diagnosis: family history, clinical history, immune abnormalities (e.g. impaired lymphocyte cytotoxicity), genetic testing; (iv) acute treatment: immunosuppressive therapy, including chemotherapeutic agents; (v) curative treatment: HSCT; (vi) early diagnosis and treatment is life-saving ! FHL is a candidate for population-scale newborn screening (limitation: large diversity of mutations); (vii) in Sweden, ~50% of FHL cases are homozygous for an inversion straddling the UNC13D locus (candidate gene for newborn screening). Authors report a successful combined newborn screening assay for: (i) an UNC13D aberration endemic to Scandinavia; (ii) SCID (TRECs); (iii) agammaglobulinemia (KRECs). Authors commentary: (i) merging disease screening markers in a single assay is likely to improve the cost-efficacy of newborn screening programs; (ii) genetic screening may be customized to indigenous genetic disease predisposition. CURE OF HIV INFECTION: IS THE LONG WAIT OVER? (Shearer WT. J Allergy Clin Immunol 2014; 134: 20-22): This Journal issue has 2 reviews about progress in HIV-vaccine development and HIV-reservoir targeting. HIV: (i) impact: fatal pandemic involving >35 million patients in the past 34 yrs; (ii) the 9 HIV genes have escaped carefully designed vaccines and antiviral therapy despite years of research and billions of dollars spent. Reasons for vaccine failure: (i) HIV heterogeneity; (ii) high mutation rate of HIV peptides; (iii) inability of vaccine-induced antibodies to neutralize HIV. Strategies to improve HIV vaccines: (i) building antigens that induce broad neutralizing HIV antibodies; (ii) targeting conserved viral sites (common to both original and variant viruses) and mosaics (multiple conserved sites); (iii) improving antibody affinity-maturation while preventing autoimmunity risk; (iv) improving generation of VIH-specific cytotoxic CD8+ T cells. Reason for failure of antiretroviral therapy: survival of HIV virus in sanctuaries, principally resting CD4+ T lymphocytes (frequency=1 in a million cells; half-life=44 months). Strategies to improve HIV therapy: (i)  shock and kill approach to eradicate HIV from viral sanctuaries (combination of latency-reversing agents plus high-level ART); (ii) ! concentration of antiretroviral drugs in lymphatic tissue. Latency-reversing agents: (i) histone deacetylase inhibitors (insufficient evidence), (ii) protein kinase agonists inducing NF- B activation (prostratin, bryostatin). FLOW CYTOMETRY DIAGNOSIS OF DEDICATOR OF CYTOKINESIS 8 (DOCK8) DEFICIENCY (Pai S-Y, de Boer H, Massaad MJ, Chatila TA, Keles S, Jabara HH, Janssen E, Lehmann LE, Hanna-Wakim R, Dbaibo G, McDonald DR, Al-Herz W, Geha RS. J Allergy Clin Immunol 2014; 134: 221-223): Dedicator of cytokinesis 8 (DOCK8) gene deficiency: (i) autosomal recessive hyper-IgE syndrome with features of combined immunodeficiency; (ii) clinical features: sinopulmonary infections, skin and systemic viral infections, eczema, food allergy, cancer susceptibility; (iii) diagnosis: clinical history, immune abnormalities on laboratory testing, immunoblotting, gene sequencing (the 2 later are not widely available); (iv) the vast majority of patients lack DOCK8 expression and many have deletions in the DOCK8 gene; (v) DOCK8 deficiency can lead to early death from infection and malignancy ! early diagnosis and treatment can be life-saving. Authors report a simple and robust flow cytometry assay for DOCK8 protein expression ! advantages: rapid (can be completed in hours), uses commercially available reagents and standard techniques, may also detect carriers; potential disadvantages: missense mutations or in-frame small deletions that do not affect protein expression may not be detected (minority of patients) ! promising assay for diagnosis and post-transplant monitoring of DOCK8 deficiency. GAIN-OF-FUNCTION SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) MUTATIONRELATED PRIMARY IMMUNODEFICIENCY IS ASSOCIATED WITH DISSEMINATED MUCORMYCOSIS (Kumar N, Hanks ME, Chandrasekaran P, Davis BC, Hsu AP, Wagoner NJV, Merlin JS, Spalding Ch, La Hoz RM, Holland SM, Zerbe CS, Sampaio EP. J Allergy Clin Immunol 2014; 134: 236-239): STAT1: transcription factor that mediate growth factor and cytokine signaling (e.g. interferon signaling). (i) Complete AR STAT1 deficiency ! severe impairment of IFN--mediated and IFN-/-mediated immunity ! life-threatening intracellular bacterial, mycobacterial and viral diseases. (ii) Partial AR STAT1 deficiency ! mild impairment of IFN--mediated and IFN-/-mediated immunity ! milder intracellular bacterial, mycobacterial and viral diseases; (iii) Dominant negative STAT1 mutations ! impairment of IFN--mediated immunity ! susceptibility to mycobacterial diseases; (iv) AD gain-of-function (GOF) STAT1 mutations ! ! production of TH17 cells ! fungal infections, autoimmunity, esophageal carcinoma. GOF STAT1 mutations ! ! response to interferons and IL-27, ! STAT3 function ! TH17-cell deficiency, susceptibility to certain fungal (e.g. CMC) and bacterial infections, autoimmunity (e.g. hypothyroidism, autoimmune hepatitis, SLE, type I diabetes mellitus), malignancy (e.g. squamous cell cancers), arterial aneurysms. New reported phenotypes: IPEX-like syndrome; disseminated coccidioidomycosis, histoplasmosis and fusariosis; ! B-cell function. Apophysomyces trapeziformis infection has been related to penetrating trauma and diabetes. Authors report the case of a 24-yr-old man with disseminated mucormycosis (lymph nodes, muscle, heart, lungs and brain affectation) caused by Apophysomyces trapeziformis ! previous clinical history: no CMC, no conditions predisposing to mucormycosis ! laboratory analysis: ! STAT1 phosphorylation, delay in STAT1 dephosphorylation, hyperresponsiveness to IFN-, ! IL-17-producing T cells ! genetic analysis: novel heterozygous mutation c.1110G>C; p.E370D in the DNA-binding domain of STAT1 ! successful acute treatment: liposomal amphotericin, micafungin, posaconazole, subcutaneous IFN-. Author s commentaries: (i) 1st report of a primary immunodeficiency presenting as disseminated mucormycosis (STAT1 GOF mutations have not previously been associated with ! susceptibility to infections by filamentous molds); (ii) STAT1 GOF mutations can result in disseminated infections by Apophysomyces trapeziformis. IMMUNODEFICIENCY AND DISSEMINATED MYCOBACTERIAL INFECTION ASSOCIATED WITH HOMOZYGOUS NONSENSE MUTATION OF IKK (Burns SO, Plagnol V, Morillo Gutierrez B, Al Zahrani D, Curtis J, Gaspar M, Hassan A, Jones AM, Malone M, Rampling D, McLatchie A, Doffinger R, Gilmour KC, Henriquez F, Thrasher AJ, Gaspar HB, Nejentsev S. J Allergy Clin Immunol 2014; 134: 215-218): Nuclear factor kappa B (NF-B): (i) essential transcription factor for host defense; (ii) in resting cells, inhibitory IB proteins (IB, IB, IB) sequester NF-B complexes in the cytoplasm. IB kinase (IKK) complex: (i) composition: 2 catalytically active kinases (IKK, IKK), one regulatory subunit (IKK, also known as NF-B essential modulator [NEMO]); (ii) function: phosphorylation and degradation of IB proteins. Canonical pathway of NF-B activation: several cell-activation signals ! activation of the IKK complex ! phosphorylation of IB by IKK ! degradation of phosphorylated IB ! liberation of NF-B ! translocation of NF-B to the nucleus. NEMO hypomorphic hemizygote mutations (X-linked) and IkB hypermorphic mutations (autosomal dominant) have been reported to cause immunodeficiency (susceptibility to severe bacterial, mycobacterial and viral infections), usually associated with ectodermal dysplasia (EDA). An autosomal-recessive mutation in IKK has been associated with an in utero lethal Cocoon syndrome characterized by multiple fetal malformations. Authors report the case of a 18-month-old female born to 1st-degree consanguineous parents ! positive family history: brother died at age 1 month from E coli sepsis and meningitis, 3 paternal grand uncles died in infancy with febrile illnesses ! clinical manifestations: severe early-onset infections (omphalitis, delayed separation of the umbilical cord, disseminated BCGosis>cfɷoT9!9/hB*CJ OJPJQJ^JaJ mH phsH 5hhB*CJ OJPJQJ^JaJ mH phsH 5hzhB*CJ OJPJQJ^JaJ mH phsH 5hzhPB*CJ(OJPJQJ^JaJ(mH php0sH 5hzhB*CJ(OJPJQJ^JaJ(mH php0sH #h B*CJOJPJQJ^Jphp0#h#B*CJOJPJQJ^Jphp0#hPB*CJOJPJQJ^Jphp0)h@5hPB*OJPJQJmH (php0sH (jhnPJUmHnHu  2 3 4 5 T t $ B#9!a$gdP 3gdP$ 33^3a$gdP$ & F OOV^O`Va$gdzL$ & F OOV^O`Va$gd ^`gd ^`gdPgde9   ) a  1 2 3 ɮxx\>;h#k6hP5>*B*CJOJPJQJ^JaJmH phsH 7h{96hP5>*B*CJOJPJQJ^JmH phsH ;hzLhzL5>*B*CJ OJPJQJ^JaJ mH phsH /hzLB*CJ OJPJQJ^JaJ mH phsH 5hzLhzLB*CJ OJPJQJ^JaJ mH phsH ;hhP5>*B*CJ OJPJQJ^JaJ mH phsH /hNB*CJ OJPJQJ^JaJ mH phsH 3 4 5 G O T   ƲxxeQ@xQ!h; ?5CJ OJQJaJ mH sH 'h; ?h; ?5CJ OJQJaJ mH sH $h; ?h; ?CJOJQJaJmH sH $h0h; ?CJOJQJaJmH sH $h0hPCJOJQJaJmH sH 'h^4Jh; ?5CJ OJQJaJ mH sH 'h^4JhP5CJ OJQJaJ mH sH 5hzLhPB*CJOJPJQJ^JaJmH phsH ;h#k6h>,5>*B*CJOJPJQJ^JaJmH phsH   0  <EA( j$ & F V^`Va$gdj $`a$gdM$ B#9!a$gd; ?$ B#9!a$gdP    # $ / 0 f   j ;Dy̳̗~bJ/J/J/J/J/5hjhjB*CJOJPJQJ^JaJmH php0sH /hjhj5CJOJPJQJ^JaJmH sH 7hMh>,5>*B* CJOJPJQJ^JmH phsH 1hZ95>*B* CJOJPJQJ^JmH phsH 7hMhP5>*B* CJOJPJQJ^JmH phsH 1h?5>*B* CJOJPJQJ^JmH phsH 1h{$5>*B* CJOJPJQJ^JmH phsH 3h; ?h t5>*B*CJPJ^JaJmH phsH 9@]'= ].b3iqth&Y !D!!C""""^###$<%&8&&&='':(((W)))*g****̱/he he 5CJOJPJQJ^JaJmH sH 5hjhe B*CJOJPJQJ^JaJmH php0sH 5hjhjB*CJOJPJQJ^JaJmH php0sH /hjhj5CJOJPJQJ^JaJmH sH ';(()***P+$ & F V^`Va$gd{$$a$gd[Sf$ & F V^`Va$gdj****+++M+N+O+P+ƨ|cJc4(h{$h0OJPJQJ^JaJmH sH +h{$h05OJPJQJ^JaJmH sH 1h0Tuh0TuB*OJPJQJ^JaJmH php0sH 1h{$h0B*OJPJQJ^JaJmH php0sH +h{$h{$5OJPJQJ^JaJmH sH +h0Tuh0Tu5OJPJQJ^JaJmH sH ;h5kh^^5>*B* CJOJPJQJ^JaJmH phsH 5h^^5>*B* CJOJPJQJ^JaJmH phsH ;h3:hU+E5>*B* CJOJPJQJ^JaJmH phsH  P+g+h+w++++,L,`,d,h,,,,,,,,2-l---..../01ѸѸѸѦѦѦѦѦѸє{fQ(hh0TuOJPJQJ^JaJmH sH (h=h0TuOJPJQJ^JaJmH sH 1h!)h0TuB*OJPJQJ^JaJmH php0sH "h0TuOJPJQJ^JaJmH sH "h=OJPJQJ^JaJmH sH 1h3|h0TuB*OJPJQJ^JaJmH php0sH (h3|h0TuOJPJQJ^JaJmH sH 1h3|h0TuB* OJPJQJ^JaJmH phsH 1L1P1^111111112&222*3T3X3v344a4q4ٯٯٚفlSl1h3|h0TuB* OJPJQJ^JaJmH ph `sH (h3|h0TuOJPJQJ^JaJmH sH 1h3|h0TuB*OJPJQJ^JaJmH php0sH (hSvh0TuOJPJQJ^JaJmH sH (h h0TuOJPJQJ^JaJmH sH (h0h0TuOJPJQJ^JaJmH sH "h0TuOJPJQJ^JaJmH sH (hli<h0TuOJPJQJ^JaJmH sH q4r4(5*5,5-5A5B5K5Q5R5S5V5W5зlVlVlA(A1hgh0TuB*OJPJQJ^JaJmH php0sH (hgdh0TuOJPJQJ^JaJmH sH +h0TuB* OJPJQJ^JaJmH phsH 1hgh0TuB* OJPJQJ^JaJmH phsH 1h3|h0TuB* OJPJQJ^JaJmH phsH 1haQhaQB*OJPJQJ^JaJmH phsH 1haQh0TuB*OJPJQJ^JaJmH phsH (h3|h0TuOJPJQJ^JaJmH sH 4h3|h0Tu5B*OJPJQJ^JaJmH php0sH  P+-5$8:<>tC$ILQRu^$ & F V^`Va$gd>R$ & F SSW^S`Wa$gd $ & F SSW^S`Wa$gdL$ & F SSW^S`Wa$gd's[$ & F V^`Va$gd1z&$ & F SSW^S`Wa$gd:$ & F SSW^S`Wa$gd0Tu W5l5n5y5|5555560626>6T6r6x666666677 747l7r7t777ԿԿԪԿԪԑԿx_1hE h0TuB*OJPJQJ^JaJmH php0sH 1h h0TuB*OJPJQJ^JaJmH php0sH 1hgh0TuB*OJPJQJ^JaJmH php0sH (hgdh0TuOJPJQJ^JaJmH sH (hSvh0TuOJPJQJ^JaJmH sH "h0TuOJPJQJ^JaJmH sH 1hE h0TuB* OJPJQJ^JaJmH ph `sH 7788"8$848z8|8888888899ٯvdO61haQh0TuB* OJPJQJ^JaJmH phsH (h:hQXOJPJQJ^JaJmH sH "haQOJPJQJ^JaJmH sH "hQXOJPJQJ^JaJmH sH "h:OJPJQJ^JaJmH sH (h:h:OJPJQJ^JaJmH sH (h:h0TuOJPJQJ^JaJmH sH (hbh0TuOJPJQJ^JaJmH sH "h0TuOJPJQJ^JaJmH sH (h+Jh0TuOJPJQJ^JaJmH sH 99$9&9.9`9b9d99999999999٫Ēy`G`.1hh:hdEB* OJPJQJ^JaJmH ph `sH 1hh:h]B* OJPJQJ^JaJmH ph `sH 1hh:hQXB* OJPJQJ^JaJmH ph `sH 1h.hdEB*OJPJQJ^JaJmH php0sH 1h.h0TuB* OJPJQJ^JaJmH phsH 1h.hdEB* OJPJQJ^JaJmH phsH (h:h0TuOJPJQJ^JaJmH sH (h:hdEOJPJQJ^JaJmH sH "h.OJPJQJ^JaJmH sH 999::O:P:R:T:U:V:X:f:::::::::::ԿԪx_ԿԿԿF1h.hdEB* OJPJQJ^JaJmH phsH 1hh:hQXB* OJPJQJ^JaJmH ph `sH 1hQXhQXB*OJPJQJ^JaJmH php0sH 1hQXhdEB*OJPJQJ^JaJmH php0sH (h:hdEOJPJQJ^JaJmH sH (h:h0TuOJPJQJ^JaJmH sH "hQXOJPJQJ^JaJmH sH 1hh:h.B* OJPJQJ^JaJmH ph `sH :::::::<<<,<0<><@<P<X<Z<\<r<t<|<ʹmXFXFFmX4"h]OJPJQJ^JaJmH sH "h.OJPJQJ^JaJmH sH (hdEh0TuOJPJQJ^JaJmH sH 1h.h0TuB* OJPJQJ^JaJmH ph `sH 1h.hdEB* OJPJQJ^JaJmH ph `sH (hdEhdEOJPJQJ^JaJmH sH 1h.hdEB*OJPJQJ^JaJmH php0sH 1h.hdEB* OJPJQJ^JaJmH phsH 1h.h.B* OJPJQJ^JaJmH phsH |<~<<<d=f=h=>>>>>>ʴlW>)(h-ljh's[OJPJQJ^JaJmH sH 1h-ljh's[B* OJPJQJ^JaJmH phsH (h1z&h:OJPJQJ^JaJmH sH 1h1z&h1z&B*OJPJQJ^JaJmH php0sH 1h1z&h:B*OJPJQJ^JaJmH php0sH +h1z&h:5OJPJQJ^JaJmH sH +h1z&h1z&5OJPJQJ^JaJmH sH "h}2OJPJQJ^JaJmH sH "hQXOJPJQJ^JaJmH sH "h.OJPJQJ^JaJmH sH  >>>?? ?@"@*@,@.@<@h@@@@@AA^A`AAB濩wbIѿ1h1z&h's[B*OJPJQJ^JaJmH php0sH (h@r>h's[OJPJQJ^JaJmH sH 1hr)h's[B*OJPJQJ^JaJmH php0sH 1hi<h's[B*OJPJQJ^JaJmH php0sH +h's[B*OJPJQJ^JaJmH php0sH "h's[OJPJQJ^JaJmH sH (h-ljh's[OJPJQJ^JaJmH sH 1h-ljh's[B*OJPJQJ^JaJmH php0sH B BB.BFBpBzBBBtC~CCCCCCCêܕzaH2H2a+hLB* OJPJQJ^JaJmH phsH 1hLhLB* OJPJQJ^JaJmH phsH 1hLh:B* OJPJQJ^JaJmH phsH 4hLh:6B* OJPJQJ^JaJmH phsH (h1z&h's[OJPJQJ^JaJmH sH 1hU h's[B*OJPJQJ^JaJmH php0sH 1h1z&h's[B*OJPJQJ^JaJmH php0sH "h's[OJPJQJ^JaJmH sH "hh:OJPJQJ^JaJmH sH CCCCDDDD,DGDKDLD^D5EFHII"I$I.I0I뽨ҖfM1hLh:B* OJPJQJ^JaJmH phsH 4hLh:6B* OJPJQJ^JaJmH phsH (hhOJPJQJ^JaJmH sH "hOJPJQJ^JaJmH sH (hLh's[OJPJQJ^JaJmH sH (hLha%OJPJQJ^JaJmH sH 1hLh:B*OJPJQJ^JaJmH php0sH (hLh:OJPJQJ^JaJmH sH 0IIIIIIIIIIIII JJJ+J5J>J?JAJLJVJeJJзt_J_J_J_J_t_(hLhLOJPJQJ^JaJmH sH (hLh:OJPJQJ^JaJmH sH (hLh's[OJPJQJ^JaJmH sH (hLha%OJPJQJ^JaJmH sH 1hLha%B*OJPJQJ^JaJmH php0sH 1hLh:B* OJPJQJ^JaJmH phsH +hLB* OJPJQJ^JaJmH phsH 1hLhLB* OJPJQJ^JaJmH phsH JJJLPLxLLLLLLLLL٫٫oZE0(h h OJPJQJ^JaJmH sH (h hLOJPJQJ^JaJmH sH (h h1z&OJPJQJ^JaJmH sH (hLh:OJPJQJ^JaJmH sH (hn|hn|OJPJQJ^JaJmH sH "hn|OJPJQJ^JaJmH sH (hLh1z&OJPJQJ^JaJmH sH 1hLha%B*OJPJQJ^JaJmH php0sH (hLha%OJPJQJ^JaJmH sH "hRBOJPJQJ^JaJmH sH  LL,M.MHMNM\M`MtMvMMMMMMMMMMMMī}īd}īK}}d1hh's[B* OJPJQJ^JaJmH phsH 1hhLB* OJPJQJ^JaJmH phsH (h hLOJPJQJ^JaJmH sH 1hh1z&B* OJPJQJ^JaJmH phsH 1hh@r>B* OJPJQJ^JaJmH phsH (h h@r>OJPJQJ^JaJmH sH (h h OJPJQJ^JaJmH sH "hOJPJQJ^JaJmH sH MMMNN.N4NJNKNLNNNONPNeNNҽydK21hh1z&B* OJPJQJ^JaJmH ph `sH 1hh@r>B* OJPJQJ^JaJmH ph `sH (h h@r>OJPJQJ^JaJmH sH 1hhB*OJPJQJ^JaJmH php0sH 1hh@r>B*OJPJQJ^JaJmH php0sH "hOJPJQJ^JaJmH sH (h h OJPJQJ^JaJmH sH 1hh B*OJPJQJ^JaJmH php0sH (h h1z&OJPJQJ^JaJmH sH NNNNNNNNNNNOOOOO OO>O?OFONO\O뽤y뽤`GyG1hh1z&B* OJPJQJ^JaJmH ph `sH 1hh's[B* OJPJQJ^JaJmH ph `sH "hOJPJQJ^JaJmH sH 1hhB* OJPJQJ^JaJmH ph `sH 1hhB*OJPJQJ^JaJmH php0sH 1hh's[B*OJPJQJ^JaJmH php0sH (h h1z&OJPJQJ^JaJmH sH (h h's[OJPJQJ^JaJmH sH \O]O^OaObOcOdOrOsOwOOOOOOOO٧|jQj||81hn|h's[B*OJPJQJ^JaJmH php0sH 1hZ*(hZ*(B* OJPJQJ^JaJmH ph `sH "hZ*(OJPJQJ^JaJmH sH (h h1z&OJPJQJ^JaJmH sH +hn|B* OJPJQJ^JaJmH ph `sH 1hn|h1z&B* OJPJQJ^JaJmH ph `sH 1hh's[B*OJPJQJ^JaJmH php0sH (h h's[OJPJQJ^JaJmH sH "h OJPJQJ^JaJmH sH OPP1PHPTP[PyP~PPPPPPPPPPѿ|jU<<1hn|h B* OJPJQJ^JaJmH ph `sH (h h OJPJQJ^JaJmH sH "hZ*(OJPJQJ^JaJmH sH 1hn|h's[B*OJPJQJ^JaJmH php0sH (h h's[OJPJQJ^JaJmH sH (h h1z&OJPJQJ^JaJmH sH "hn|OJPJQJ^JaJmH sH (h hn|OJPJQJ^JaJmH sH 1hn|hn|B* OJPJQJ^JaJmH ph `sH PPPPPPPPPQQQQQ*Q,Q0Q1Q4Q9Q?Q͸xfMxfxfx4xx1hN:hN:B*OJPJQJ^JaJmH php0sH 1hN:hN:B* OJPJQJ^JaJmH ph `sH "hZ*(OJPJQJ^JaJmH sH "hN:OJPJQJ^JaJmH sH (h hN:OJPJQJ^JaJmH sH 1hZ*(hZ*(B*OJPJQJ^JaJmH php0sH (h h OJPJQJ^JaJmH sH 1hZ*(hn|B* OJPJQJ^JaJmH ph `sH 1hZ*(h B* OJPJQJ^JaJmH ph `sH ?QIQKQSQhQQQQQQRRRRgN8Ng+h>RB*OJPJQJ^JaJmH php0sH 1h>Rh>RB*OJPJQJ^JaJmH php0sH 1h>Rh's[B*OJPJQJ^JaJmH php0sH +h>Rh>R5OJPJQJ^JaJmH sH (h h0TuOJPJQJ^JaJmH sH (hN:hN:OJPJQJ^JaJmH sH 1hN:hN:B* OJPJQJ^JaJmH ph `sH (h hN:OJPJQJ^JaJmH sH "hN:OJPJQJ^JaJmH sH  RRRRRRR SSSSS$S%S3S8S;S=S?SYSZS[STRTԻweSe==+hB*OJPJQJ^JaJmH php0sH "h@mOJPJQJ^JaJmH sH "h>ROJPJQJ^JaJmH sH +hC'B*OJPJQJ^JaJmH php0sH 1hvoh>RB*OJPJQJ^JaJmH php0sH (hvoh>ROJPJQJ^JaJmH sH 1hvoh>RB* OJPJQJ^JaJmH phsH (h>Rh's[OJPJQJ^JaJmH sH +h>Rh's[5OJPJQJ^JaJmH sH RTtT UZU\U^U4VHVJVLVVVWWWnWpWrWRXTX0Y8YTYVYZY\Y^YYYYYYYYYYYZIZѿѦѿѦѦѦэѦѿwѦbwwѦ(h!kh>ROJPJQJ^JaJmH sH +hDB*OJPJQJ^JaJmH php0sH 1hvoh>RB*OJPJQJ^JaJmH phsH 1hvoh>RB* OJPJQJ^JaJmH ph `sH "h>ROJPJQJ^JaJmH sH (hvoh>ROJPJQJ^JaJmH sH 1hvoh>RB*OJPJQJ^JaJmH php0sH &IZJZNZOZYZjZkZsZZZZZZZ滢s^I01hTh>RB* OJPJQJ^JaJmH phsH (hjzhDOJPJQJ^JaJmH sH (hjzh>ROJPJQJ^JaJmH sH 1hvoh>RB* OJPJQJ^JaJmH ph `sH +h>RB*OJPJQJ^JaJmH phsH 1hvoh>RB*OJPJQJ^JaJmH phsH (hvoh>ROJPJQJ^JaJmH sH +hB*OJPJQJ^JaJmH php0sH 1hvoh>RB*OJPJQJ^JaJmH php0sH  RZA_bc4g=hNm.nqkquu$ & F SSW^S`Wa$gdx5$ & F SSW^S`Wa$gd\x$ & F V^`Va$gd\x$ & F SSW^S`Wa$gdO$ & F SSW^S`Wa$gdw}$ & F SSW^S`Wa$gd>R ZZZZZZZZ[>[Q[R[\[u[v[[[[Оw^wL7(h7h>ROJPJQJ^JaJmH sH "hOJPJQJ^JaJmH sH 1hNh>RB*OJPJQJ^JaJmH php0sH (h4Jh>ROJPJQJ^JaJmH sH "h>ROJPJQJ^JaJmH sH 1h Rh>RB*OJPJQJ^JaJmH php0sH 1h!h>RB*OJPJQJ^JaJmH php0sH +h>RB* OJPJQJ^JaJmH phsH 1h4Jh>RB* OJPJQJ^JaJmH phsH [[[[[[[[[[[[[\&\X\Z\`\\\\\\\\\л{{{{{f颻M1hEh>RB* OJPJQJ^JaJmH ph `sH (hC{ih>ROJPJQJ^JaJmH sH (h Rh>ROJPJQJ^JaJmH sH "h>ROJPJQJ^JaJmH sH 1h Rh>RB*OJPJQJ^JaJmH php0sH (h4Jh>ROJPJQJ^JaJmH sH 1h!h>RB*OJPJQJ^JaJmH php0sH +h>RB*OJPJQJ^JaJmH php0sH \]]"^#^%^'^(^)^5^8^:^K^N^O^Q^ԿԔ{bI77"hnOJPJQJ^JaJmH sH 1hxh>RB*OJPJQJ^JaJmH php0sH 1hjqh>RB* OJPJQJ^JaJmH ph `sH 1h!h>RB*OJPJQJ^JaJmH php0sH +h>RB*OJPJQJ^JaJmH php0sH (h4Jh>ROJPJQJ^JaJmH sH (hd.wh>ROJPJQJ^JaJmH sH "h>ROJPJQJ^JaJmH sH 1hd.wh>RB* OJPJQJ^JaJmH ph `sH Q^V^X^_^`^e^k^u^{^^^^^^^^^^^^^^IJIJIJjU<<1hmch>RB*OJPJQJ^JaJmH php0sH (hdh>ROJPJQJ^JaJmH sH 1hxh>RB*OJPJQJ^JaJmH php0sH 1h!h>RB*OJPJQJ^JaJmH php0sH +h>RB*OJPJQJ^JaJmH php0sH "h>ROJPJQJ^JaJmH sH "hnOJPJQJ^JaJmH sH (hnh>ROJPJQJ^JaJmH sH (hnhnOJPJQJ^JaJmH sH ^^__ _ _8_@_A_R_S_V_W_d____```aZaab}d}d}R}d<}d}d}+hTB*OJPJQJ^JaJmH php0sH "hTOJPJQJ^JaJmH sH 1h#mh>RB*OJPJQJ^JaJmH php0sH (h#mh>ROJPJQJ^JaJmH sH 1h#mh>RB* OJPJQJ^JaJmH phsH (hC{ih>ROJPJQJ^JaJmH sH "h>ROJPJQJ^JaJmH sH 1hxh>RB*OJPJQJ^JaJmH php0sH (hmch>ROJPJQJ^JaJmH sH bbb,bIbJbObTbkbxbbbbbbbbbbbѿѿѿѿ|cJ|5|5(h7fh7fOJPJQJ^JaJmH sH 1h7fh7fB*OJPJQJ^JaJmH php0sH 1h7fhw}B*OJPJQJ^JaJmH php0sH (h7fhw}OJPJQJ^JaJmH sH 1h7fhw}B* OJPJQJ^JaJmH phsH (hTh>ROJPJQJ^JaJmH sH "h>ROJPJQJ^JaJmH sH (h#mh>ROJPJQJ^JaJmH sH 1h#mh>RB*OJPJQJ^JaJmH php0sH bbb c c'c)c*c-c/c5c9cPcRcUcjckclcncuccʹu`uGu5`uu`u"hnOJPJQJ^JaJmH sH 1hhw}B*OJPJQJ^JaJmH php0sH (h7fhw}OJPJQJ^JaJmH sH (h7fh7fOJPJQJ^JaJmH sH (h7fhOJPJQJ^JaJmH sH (hhOJPJQJ^JaJmH sH 1h7fhw}B*OJPJQJ^JaJmH php0sH 1h7fh7fB*OJPJQJ^JaJmH php0sH 1hh7fB*OJPJQJ^JaJmH php0sH cccccccccddddd d"dǮgR9R1hOhnB*OJPJQJ^JaJmH php0sH (hOhnOJPJQJ^JaJmH sH 1hOh rB* OJPJQJ^JaJmH phsH (hOhw}OJPJQJ^JaJmH sH 1hOhw}B* OJPJQJ^JaJmH phsH 1hOh" B* OJPJQJ^JaJmH phsH (hOh" OJPJQJ^JaJmH sH "h7fOJPJQJ^JaJmH sH "hU! OJPJQJ^JaJmH sH "dbddddddddddd eROJPJQJ^JaJmH sH (hTh rOJPJQJ^JaJmH sH (hTh" OJPJQJ^JaJmH sH  JhYhhhhhhhhhhh i ii9iiViiiiiiiiiiiiѢѢѐѐw^1h@gh\xB* OJPJQJ^JaJmH ph `sH 1hSrh\xB*OJPJQJ^JaJmH php0sH "h\xOJPJQJ^JaJmH sH 1h#h\xB* OJPJQJ^JaJmH ph `sH +h\xB*OJPJQJ^JaJmH php0sH (h#h\xOJPJQJ^JaJmH sH 1h#h\xB*OJPJQJ^JaJmH php0sH i2j5jUjjjjjjjjjjjjkkkk٫ٕfPf71h@gh\xB*OJPJQJ^JaJmH php0sH +hOB*OJPJQJ^JaJmH php0sH 1hz?h\xB*OJPJQJ^JaJmH php0sH +h\xB* OJPJQJ^JaJmH ph `sH +h@gh\x6OJPJQJ^JaJmH sH (h@gh\xOJPJQJ^JaJmH sH 1h@gh\xB* OJPJQJ^JaJmH ph `sH "h\xOJPJQJ^JaJmH sH (hSrh\xOJPJQJ^JaJmH sH kklplllllllllJmLmNmmm°škUװ<*"hx5OJPJQJ^JaJmH sH 1hx5hx5B* OJPJQJ^JaJmH phsH +h\xB*OJPJQJ^JaJmH php0sH +hOB*OJPJQJ^JaJmH php0sH 1h@gh\xB*OJPJQJ^JaJmH php0sH +h\xB* OJPJQJ^JaJmH ph `sH "hOOJPJQJ^JaJmH sH (h@gh\xOJPJQJ^JaJmH sH "h\xOJPJQJ^JaJmH sH +h@gh\xH*OJPJQJ^JaJmH sH mnnn,n.nPnRnXnZnhnpnnnnnnoo oͻfMfMfMf88f(hx5hx5OJPJQJ^JaJmH sH 1hx5hx5B* OJPJQJ^JaJmH phsH 1hx5h\xB* OJPJQJ^JaJmH phsH (hx5h\xOJPJQJ^JaJmH sH (h\xhx5OJPJQJ^JaJmH sH "hx5OJPJQJ^JaJmH sH "hC'OJPJQJ^JaJmH sH 1hon hC'B* OJPJQJ^JaJmH ph `sH 1hon hx5B* OJPJQJ^JaJmH ph `sH  oooFoholoporotovo|ooooopp,p-pѸѦwbI0II01hC'hx5B* OJPJQJ^JaJmH ph `sH 1hC'h\xB* OJPJQJ^JaJmH ph `sH (hx5h\xOJPJQJ^JaJmH sH +hC'B*OJPJQJ^JaJmH php0sH 1hx5h\xB*OJPJQJ^JaJmH php0sH "hC'OJPJQJ^JaJmH sH 1hC'hC'B* OJPJQJ^JaJmH ph `sH (hx5hC'OJPJQJ^JaJmH sH 1hC'hC'B*OJPJQJ^JaJmH php0sH -p:p;ptNtttttttt͸zazaL:L:L:"h[OJPJQJ^JaJmH sH (h?-hfl^OJPJQJ^JaJmH sH 1h?-hfl^B*OJPJQJ^JaJmH php0sH +h[B*OJPJQJ^JaJmH php0sH +h7SB*OJPJQJ^JaJmH php0sH "h7SOJPJQJ^JaJmH sH (h?-hMOJPJQJ^JaJmH sH 1h?-hMB*OJPJQJ^JaJmH php0sH 1h7ShMB*OJPJQJ^JaJmH php0sH tttu:uNuPuVuXunu|uuuuuuuuuygNgg8ygNg+hqVB*OJPJQJ^JaJmH php0sH 1hhqVB* OJPJQJ^JaJmH ph `sH "hqVOJPJQJ^JaJmH sH 1hNhqVB*OJPJQJ^JaJmH php0sH (h\UhqVOJPJQJ^JaJmH sH 1hNhqVB* OJPJQJ^JaJmH phsH +hqVB* OJPJQJ^JaJmH phsH (h[h[OJPJQJ^JaJmH sH (h7Sh7SOJPJQJ^JaJmH sH kqtvxҏz^Xuuu$ & F SSW^S`Wa$gd;-'$ & F SSW^S`Wa$gd_$ & F SSW^S`Wa$gdQ$ & F SSW^S`Wa$gd[$ & F SSW^S`Wa$gdqV$ & F SSW^S`Wa$gdfl^ uuuvMvNvOvQvRvSv`vdvivnvovqvrvsvvvvvvvvvvvvԻԦwԦԦwԦwԻb(hhqVOJPJQJ^JaJmH sH +hqVB*OJPJQJ^JaJmH php0sH 1hNhqVB*OJPJQJ^JaJmH php0sH (h\UhqVOJPJQJ^JaJmH sH 1hhqVB* OJPJQJ^JaJmH ph `sH "hqVOJPJQJ^JaJmH sH 1hK*hqVB*OJPJQJ^JaJmH php0sH vvvvvx>xxxxxx澥wbI.4hhQ5B*OJPJQJ^JaJmH php0sH 1hhQB* OJPJQJ^JaJmH phsH (hh[OJPJQJ^JaJmH sH (hqVhqVOJPJQJ^JaJmH sH 1h[h[B*OJPJQJ^JaJmH php0sH 1h[h[B* OJPJQJ^JaJmH phsH "h[OJPJQJ^JaJmH sH +hqVB*OJPJQJ^JaJmH phsH 1h[h[B*OJPJQJ^JaJmH phsH  xx>yHyyz{{{{{ {D{{{{{{0|:|r|v|x|z|~|||}}} }"}V}}}}}}}}}}}}~~Ҍ빞ttt.hQ5B*OJPJQJ^JaJmH php0sH "hQOJPJQJ^JaJmH sH 4hhQ5B*OJPJQJ^JaJmH php0sH 1hhQB* OJPJQJ^JaJmH phsH 1h4phQB* OJPJQJ^JaJmH ph `sH (hhQOJPJQJ^JaJmH sH -~~~~~~~*,LNPXZā́n.024иtt[t1h$YhQB* OJPJQJ^JaJmH ph `sH "hQOJPJQJ^JaJmH sH 1hhQB* OJPJQJ^JaJmH phsH 1h4phQB* OJPJQJ^JaJmH ph `sH .hQ5B*OJPJQJ^JaJmH php0sH 4hhQ5B*OJPJQJ^JaJmH php0sH (hhQOJPJQJ^JaJmH sH #4<>dhЃԃ:<CEtu϶v`vK(h\UhqVOJPJQJ^JaJmH sH +hqVB* OJPJQJ^JaJmH phsH 1h\UhqVB* OJPJQJ^JaJmH phsH "hQOJPJQJ^JaJmH sH (hhQOJPJQJ^JaJmH sH 1h4phQB* OJPJQJ^JaJmH ph `sH +hhQ5OJPJQJ^JaJmH sH 4hhQ5B*OJPJQJ^JaJmH php0sH Ʉ2N >x| =AIʹ͟w͍w͍͟^1hK*hqVB*OJPJQJ^JaJmH php0sH +hqVB*OJPJQJ^JaJmH php0sH "hqVOJPJQJ^JaJmH sH (h\UhqVOJPJQJ^JaJmH sH 1h#hqVB* OJPJQJ^JaJmH ph `sH 1hgohqVB* OJPJQJ^JaJmH ph `sH 1hgohqVB*OJPJQJ^JaJmH php0sH #IginoĈňȈɈԻԻ榑{b{bM4M1hG%`h_B*OJPJQJ^JaJmH php0sH (h=h_OJPJQJ^JaJmH sH 1hG%`h_B* OJPJQJ^JaJmH phsH +hqVB* OJPJQJ^JaJmH phsH (h\UhqVOJPJQJ^JaJmH sH (hG%`hqVOJPJQJ^JaJmH sH 1hK*hqVB*OJPJQJ^JaJmH php0sH "hqVOJPJQJ^JaJmH sH 1hhkhqVB* OJPJQJ^JaJmH ph `sH ɈΈψ()*,./6Tfijkl{滢weewL1h"oh;-'B* OJPJQJ^JaJmH ph `sH "h_OJPJQJ^JaJmH sH (hyh_OJPJQJ^JaJmH sH +h_B*OJPJQJ^JaJmH php0sH 1hG%`h_B*OJPJQJ^JaJmH php0sH (h=h_OJPJQJ^JaJmH sH +h_B* OJPJQJ^JaJmH ph `sH 1hG%`h_B* OJPJQJ^JaJmH ph `sH {|*,068Bx|&(}k}kU}?+h_B* OJPJQJ^JaJmH ph `sH +h_B*OJPJQJ^JaJmH php0sH "h_OJPJQJ^JaJmH sH 1hyh_B* OJPJQJ^JaJmH ph `sH 1hG%`h_B*OJPJQJ^JaJmH php0sH (h=h_OJPJQJ^JaJmH sH (h=h;-'OJPJQJ^JaJmH sH (h"oh;-'OJPJQJ^JaJmH sH "h;-'OJPJQJ^JaJmH sH (z|ҼҪ{bII7"h;-'OJPJQJ^JaJmH sH 1h"oh;-'B*OJPJQJ^JaJmH php0sH 1h;-'h;-'B*OJPJQJ^JaJmH php0sH +h_B* OJPJQJ^JaJmH ph `sH 1hx/]h_B* OJPJQJ^JaJmH ph `sH "h_OJPJQJ^JaJmH sH +h;-'B*OJPJQJ^JaJmH php0sH 1hx/]h_B*OJPJQJ^JaJmH php0sH (hyh_OJPJQJ^JaJmH sH ;HhknoԿԦԿԦwaL31hG%`h_B*OJPJQJ^JaJmH php0sH (h=h_OJPJQJ^JaJmH sH +h;-'B* OJPJQJ^JaJmH ph `sH 1hG%`h_B* OJPJQJ^JaJmH ph `sH +h;-'B*OJPJQJ^JaJmH php0sH 1h"oh;-'B*OJPJQJ^JaJmH php0sH (h"oh;-'OJPJQJ^JaJmH sH "h;-'OJPJQJ^JaJmH sH 1h"oh;-'B* OJPJQJ^JaJmH ph `sH ˌ6\^bo,68ӺzdKz2zKz2zKz1hZ2h_B* OJPJQJ^JaJmH ph `sH 1h|h_B*OJPJQJ^JaJmH php0sH +h_B* OJPJQJ^JaJmH phsH "h_OJPJQJ^JaJmH sH 1hG%`h_B* OJPJQJ^JaJmH ph `sH (h=h_OJPJQJ^JaJmH sH 1hG%`h_B*OJPJQJ^JaJmH php0sH +h;-'B*OJPJQJ^JaJmH php0sH +h_B*OJPJQJ^JaJmH php0sH 8JRĎ̎Ύ,068TЏҏԿԦԑxcM7+hqVB* OJPJQJ^JaJmH phsH +h_B* OJPJQJ^JaJmH phsH (hIeh_OJPJQJ^JaJmH sH 1hH*h_B*OJPJQJ^JaJmH php0sH (hH*h_OJPJQJ^JaJmH sH 1hPh_B*OJPJQJ^JaJmH php0sH (hX`h_OJPJQJ^JaJmH sH "h_OJPJQJ^JaJmH sH 1hZ2h_B* OJPJQJ^JaJmH ph `sH &(.0JlƐΐАJX\fh48:>@\׾ץא׾ץ{׾ץ׾eץ{eץ׾+h_B*OJPJQJ^JaJmH php0sH (hX`h_OJPJQJ^JaJmH sH (h=jh_OJPJQJ^JaJmH sH 1hZ2h_B* OJPJQJ^JaJmH ph `sH 1hZ2h_B*OJPJQJ^JaJmH php0sH "h_OJPJQJ^JaJmH sH +h_B* OJPJQJ^JaJmH phsH  $.0Nܓxz|ԻԢԻԍԢt[E[+h_B*OJPJQJ^JaJmH php0sH 1hx/]h_B*OJPJQJ^JaJmH php0sH 1hx/]h_B* OJPJQJ^JaJmH ph `sH (hX`h_OJPJQJ^JaJmH sH 1hZ2h_B*OJPJQJ^JaJmH php0sH 1hZ2h_B* OJPJQJ^JaJmH ph `sH "h_OJPJQJ^JaJmH sH 1hPh_B*OJPJQJ^JaJmH php0sH ΔԔ֔ Hpxz澥澓zaL6+hMB* OJPJQJ^JaJmH phsH (hIeh"oOJPJQJ^JaJmH sH 1h"oh"oB* OJPJQJ^JaJmH ph `sH 1h"oh"oB*OJPJQJ^JaJmH php0sH "h"oOJPJQJ^JaJmH sH 1h?h_B*OJPJQJ^JaJmH php0sH "h_OJPJQJ^JaJmH sH +h_B* OJPJQJ^JaJmH ph `sH 1h?h_B* OJPJQJ^JaJmH ph `sH PVΖ֖ږRf268FޘѸѢѸѐzePѐ>"hIeOJPJQJ^JaJmH sH (hMhfl^OJPJQJ^JaJmH sH (hMhMOJPJQJ^JaJmH sH +hMB* OJPJQJ^JaJmH ph `sH "hMOJPJQJ^JaJmH sH +hMB* OJPJQJ^JaJmH ph `sH 1h5M4hfl^B* OJPJQJ^JaJmH ph `sH (hhfl^OJPJQJ^JaJmH sH 1hhfl^B* OJPJQJ^JaJmH phsH P\^`t|~DZmT?**(hhfl^OJPJQJ^JaJmH sH (hqVhfl^OJPJQJ^JaJmH sH 1hhfl^B* OJPJQJ^JaJmH ph `sH 1hqVhqVB*OJPJQJ^JaJmH php0sH "hqVOJPJQJ^JaJmH sH 1hhfl^B* OJPJQJ^JaJmH phsH +hfl^B* OJPJQJ^JaJmH phsH "hfl^OJPJQJ^JaJmH sH "hMOJPJQJ^JaJmH sH (h_hMOJPJQJ^JaJmH sH  Ěƚ,8t|~ī}hSh}ī:("hfl^OJPJQJ^JaJmH sH 1hqVhfl^B*OJPJQJ^JaJmH php0sH (h?-hqVOJPJQJ^JaJmH sH (hqVhqVOJPJQJ^JaJmH sH (hqVhfl^OJPJQJ^JaJmH sH 1hhfl^B* OJPJQJ^JaJmH ph `sH 1hqVhqVB*OJPJQJ^JaJmH php0sH (hhfl^OJPJQJ^JaJmH sH (hqVhOJPJQJ^JaJmH sH "hOJPJQJ^JaJmH sH қܛޛ&,.JNZ^ftIJ뙀gR벙=IJIJ(hqVhqVOJPJQJ^JaJmH sH (hqVhfl^OJPJQJ^JaJmH sH 1hhfl^B* OJPJQJ^JaJmH ph `sH 1hqVhfl^B*OJPJQJ^JaJmH php0sH 1hqVhqVB*OJPJQJ^JaJmH php0sH "hqVOJPJQJ^JaJmH sH (h?-hqVOJPJQJ^JaJmH sH "hfl^OJPJQJ^JaJmH sH (hhfl^OJPJQJ^JaJmH sH t؝ڝޝPhޞֽ|cNN9NN|c(h)hfl^OJPJQJ^JaJmH sH (h-Lhfl^OJPJQJ^JaJmH sH 1hqVhfl^B*OJPJQJ^JaJmH php0sH 1hqVhqVB*OJPJQJ^JaJmH php0sH "hfl^OJPJQJ^JaJmH sH +h7SB* OJPJQJ^JaJmH phsH 1h[Mhfl^B* OJPJQJ^JaJmH phsH (hhfl^OJPJQJ^JaJmH sH (hhqVOJPJQJ^JaJmH sH BZ|rtx~͸xbPPxͦ"hqVOJPJQJ^JaJmH sH +hqVB*OJPJQJ^JaJmH php0sH 1hqVhqVB*OJPJQJ^JaJmH php0sH (h-Lhfl^OJPJQJ^JaJmH sH "hfl^OJPJQJ^JaJmH sH (hs4hfl^OJPJQJ^JaJmH sH 1hqVhfl^B*OJPJQJ^JaJmH php0sH 1h)hfl^B* OJPJQJ^JaJmH ph `sH  ĠԠLêÕjU$hfl^OJPJQJ^JaJmH sH  X&8NjzѸwawaH3(hh;-'OJPJQJ^JaJmH sH 1hqVh;-'B* OJPJQJ^JaJmH ph `sH +h;-'B*OJPJQJ^JaJmH php0sH 1hAh;-'B*OJPJQJ^JaJmH php0sH "h;-'OJPJQJ^JaJmH sH +h;-'B* OJPJQJ^JaJmH phsH 1h%h;-'B* OJPJQJ^JaJmH phsH (h;-'h;-'OJPJQJ^JaJmH sH 1h;-'h;-'B*OJPJQJ^JaJmH php0sH  !"#=FQاxcQ?Q&1hHhh+[OB* OJPJQJ^JaJmH phsH "hHhOJPJQJ^JaJmH sH "h+[OOJPJQJ^JaJmH sH (h+[OhqOJPJQJ^JaJmH sH +h+[Ohq5OJPJQJ^JaJmH sH 1h+[Oh+[OB*OJPJQJ^JaJmH php0sH 1h+[OhqB*OJPJQJ^JaJmH php0sH .h+[Oh;-'5H*OJPJQJ^JaJmH sH +h+[Oh;-'5OJPJQJ^JaJmH sH "hfl^OJPJQJ^JaJmH sH  #cũt«B2UV $ a$gdW$a$gd+[O$ & F SSW^S`Wa$gdMh$ & F SSW^S`Wa$gdHh$ & F SSW^S`Wa$gdq$ & F V^`Va$gd+[O Ǧɦ֦KLMQgNN<"hcOJPJQJ^JaJmH sH 1hchHhB* OJPJQJ^JaJmH ph `sH 1hq4hHhB* OJPJQJ^JaJmH ph `sH 1hHhhHhB*OJPJQJ^JaJmH php0sH "hq4OJPJQJ^JaJmH sH (hHhhHhOJPJQJ^JaJmH sH 1hHhhHhB* OJPJQJ^JaJmH phsH "hqOJPJQJ^JaJmH sH (hq4hqOJPJQJ^JaJmH sH §̧ͧЧ[\]aeêّّmm[F(hq4hHhOJPJQJ^JaJmH sH "hHhOJPJQJ^JaJmH sH "hcOJPJQJ^JaJmH sH "hq4OJPJQJ^JaJmH sH 1hchHhB* OJPJQJ^JaJmH ph `sH 1hchHhB*OJPJQJ^JaJmH php0sH +hcB*OJPJQJ^JaJmH php0sH (hHhhHhOJPJQJ^JaJmH sH "hor$OJPJQJ^JaJmH sH bcĮqXB)B1hchMhB*OJPJQJ^JaJmH php0sH +hMhB*OJPJQJ^JaJmH php0sH 1hchMhB* OJPJQJ^JaJmH phsH (hHhhor$OJPJQJ^JaJmH sH "hor$OJPJQJ^JaJmH sH +h1mB* OJPJQJ^JaJmH phsH +hor$B* OJPJQJ^JaJmH phsH "hHhOJPJQJ^JaJmH sH (hq4hHhOJPJQJ^JaJmH sH (hq4hor$OJPJQJ^JaJmH sH  éũةxfM7+hHhB*OJPJQJ^JaJmH phsH 1hWhHhB*OJPJQJ^JaJmH phsH "hHhOJPJQJ^JaJmH sH (hWhHhOJPJQJ^JaJmH sH 1hWhHhB*OJPJQJ^JaJmH php0sH +hor$B* OJPJQJ^JaJmH phsH 1hchHhB* OJPJQJ^JaJmH phsH 1hchMhB*OJPJQJ^JaJmH php0sH "hMhOJPJQJ^JaJmH sH  PnrtܪbhlлsZZZA++h[fB*OJPJQJ^JaJmH phsH 1hWh[fB*OJPJQJ^JaJmH phsH 1hWhHhB*OJPJQJ^JaJmH phsH 1hchcB* OJPJQJ^JaJmH phsH +hcB* OJPJQJ^JaJmH phsH 1hchHhB* OJPJQJ^JaJmH phsH (htfhHhOJPJQJ^JaJmH sH +hHhB*OJPJQJ^JaJmH phsH 1hMhhHhB* OJPJQJ^JaJmH ph `sH « 8:B^fʬ֬лzhOz=z=z=((h$SAhHhOJPJQJ^JaJmH sH "hHhOJPJQJ^JaJmH sH 1hchcB*OJPJQJ^JaJmH php0sH "hcOJPJQJ^JaJmH sH (hWhHhOJPJQJ^JaJmH sH +hcB*OJPJQJ^JaJmH php0sH +hcB* OJPJQJ^JaJmH phsH (htfhHhOJPJQJ^JaJmH sH +hHhB*OJPJQJ^JaJmH phsH 1hWhHhB*OJPJQJ^JaJmH phsH FHv~­ @BCKVWZ[®02gQQ+hcB* OJPJQJ^JaJmH ph `sH 1hchHhB* OJPJQJ^JaJmH phsH 1hchcB* OJPJQJ^JaJmH phsH "hHhOJPJQJ^JaJmH sH (h] hHhOJPJQJ^JaJmH sH "hcOJPJQJ^JaJmH sH 1hchcB*OJPJQJ^JaJmH php0sH (hWhHhOJPJQJ^JaJmH sH 2ARSTWYjɯXlʹgNg9(hor$hHhOJPJQJ^JaJmH sH 1hor$hor$B*OJPJQJ^JaJmH phsH 1hor$hHhB*OJPJQJ^JaJmH phsH 4hor$hHhB*H*OJPJQJ^JaJmH php0sH 1hor$hor$B*OJPJQJ^JaJmH php0sH 1hor$hHhB*OJPJQJ^JaJmH php0sH 1hor$hor$B* OJPJQJ^JaJmH phsH 1hor$hcB* OJPJQJ^JaJmH phsH lڰrv̱ȲҲ&^޳ѸuuѸ\\G5G5G"hyqOJPJQJ^JaJmH sH (hor$hHhOJPJQJ^JaJmH sH 1hor$hHhB*OJPJQJ^JaJmH php0sH "hor$OJPJQJ^JaJmH sH 4hor$hor$B*H*OJPJQJ^JaJmH php0sH +hor$B*OJPJQJ^JaJmH php0sH 1hor$hor$B*OJPJQJ^JaJmH php0sH (hor$hor$OJPJQJ^JaJmH sH 1hor$hHhB* OJPJQJ^JaJmH ph `sH ޳SUVW~٫}kY>5hW5>*B* CJOJPJQJ^JaJmH phsH "hWOJPJQJ^JaJmH sH "hHhOJPJQJ^JaJmH sH (h~hHhOJPJQJ^JaJmH sH 1hor$hor$B* OJPJQJ^JaJmH phsH 1hor$hHhB* OJPJQJ^JaJmH phsH (hyqhHhOJPJQJ^JaJmH sH (hor$hHhOJPJQJ^JaJmH sH "h[fOJPJQJ^JaJmH sH  ~˵͵˵mmT>TTT+h(B*OJPJQJ^JaJmH php0sH 1hIRhv<B*OJPJQJ^JaJmH php0sH +hIRB*OJPJQJ^JaJmH php0sH 1hIRhIRB*OJPJQJ^JaJmH php0sH 1hxhv<B*OJPJQJ^JaJmH php0sH +hxhIR5OJPJQJ^JaJmH sH +hIRhIR5OJPJQJ^JaJmH sH ;h5khW5>*B* CJOJPJQJ^JaJmH phsH &(*2JVZvx$зsasOs=s=a=s"hzOJPJQJ^JaJmH sH "hav OJPJQJ^JaJmH sH "hrOJPJQJ^JaJmH sH (hzhzOJPJQJ^JaJmH sH 1h, BhzB* OJPJQJ^JaJmH phsH +hzB* OJPJQJ^JaJmH phsH 1hzhzB* OJPJQJ^JaJmH phsH 1hIRhv<B*OJPJQJ^JaJmH php0sH +hIRhv<5OJPJQJ^JaJmH sH R u$ & F SSW^S`Wa$gdm1$ & F SSW^S`Wa$gd$ & F SSW^S`Wa$gd&q$ & F SSW^S`Wa$gdIR$ & F SSW^S`Wa$gdz$ & F V^`Va$gdIR $&,Zη 8\vܸ24@Dع޹<>RThjnvxz맒뀧맒kҧ(h, BhSOJPJQJ^JaJmH sH "hSOJPJQJ^JaJmH sH (hzhzOJPJQJ^JaJmH sH "hzOJPJQJ^JaJmH sH 1hMJhzB* OJPJQJ^JaJmH ph `sH 1h, BhzB*OJPJQJ^JaJmH php0sH (h, BhzOJPJQJ^JaJmH sH 'κҺ 2dr/<=PR[ԻԐ~iԐԐԐW>1h<9hIRB* OJPJQJ^JaJmH phsH "hrOJPJQJ^JaJmH sH (hPhzOJPJQJ^JaJmH sH "hSOJPJQJ^JaJmH sH (h, BhzOJPJQJ^JaJmH sH +hSB*OJPJQJ^JaJmH php0sH 1h, BhzB*OJPJQJ^JaJmH php0sH "hzOJPJQJ^JaJmH sH 1hPhzB* OJPJQJ^JaJmH ph `sH [abeswxļɼ˼ ѸѸѣѣxcQ<(h~1hzOJPJQJ^JaJmH sH "hzOJPJQJ^JaJmH sH (h&qh&qOJPJQJ^JaJmH sH 1h&qh&qB*OJPJQJ^JaJmH php0sH "h&qOJPJQJ^JaJmH sH (hzhIROJPJQJ^JaJmH sH 1h<9hzB*OJPJQJ^JaJmH php0sH (hzhzOJPJQJ^JaJmH sH 1h<9hzB* OJPJQJ^JaJmH phsH  +,Nwxѽս渣uccuJ1h~1h<9B*OJPJQJ^JaJmH php0sH "h~1OJPJQJ^JaJmH sH 1h~1h<9B* OJPJQJ^JaJmH phsH (h~1h&qOJPJQJ^JaJmH sH (h~1h<9OJPJQJ^JaJmH sH (h~1hIROJPJQJ^JaJmH sH 1h~1hzB* OJPJQJ^JaJmH phsH 1h~1hIRB* OJPJQJ^JaJmH phsH *.<>LN`ؿ,.ѼѧѧѼѼ|cJѧѼ1h~1h<9B*OJPJQJ^JaJmH php0sH 1h~1h~1B*OJPJQJ^JaJmH php0sH "h~1OJPJQJ^JaJmH sH 1h~1h&qB* OJPJQJ^JaJmH phsH (h~1h<9OJPJQJ^JaJmH sH (h~1h&qOJPJQJ^JaJmH sH (h~1hIROJPJQJ^JaJmH sH 1h~1h<9B* OJPJQJ^JaJmH ph `sH \j 滩wbI4(h&qhav OJPJQJ^JaJmH sH 1h~1h~1B*OJPJQJ^JaJmH php0sH (h&qh&qOJPJQJ^JaJmH sH 1h~1h&qB* OJPJQJ^JaJmH phsH 1h~1h~1B* OJPJQJ^JaJmH phsH "h~1OJPJQJ^JaJmH sH (h~1h&qOJPJQJ^JaJmH sH +hav B*OJPJQJ^JaJmH php0sH 1h~1h&qB*OJPJQJ^JaJmH php0sH  &09:NOTUxҼygNg<"h&qOJPJQJ^JaJmH sH 1h~1h~1B*OJPJQJ^JaJmH php0sH "h~1OJPJQJ^JaJmH sH (h&qh~1OJPJQJ^JaJmH sH (h&qh&qOJPJQJ^JaJmH sH 1h hIRB* OJPJQJ^JaJmH ph `sH +h B* OJPJQJ^JaJmH ph `sH 1h~1hIRB* OJPJQJ^JaJmH ph `sH (h&qhIROJPJQJ^JaJmH sH  ԿzaKaK2K2K2K21hIRhIRB*OJPJQJ^JaJmH php0sH +hB*OJPJQJ^JaJmH php0sH 1hhB*OJPJQJ^JaJmH php0sH 1hxhIRB*OJPJQJ^JaJmH php0sH +hxh5OJPJQJ^JaJmH sH +hh5OJPJQJ^JaJmH sH (h&qh 'OJPJQJ^JaJmH sH "h&qOJPJQJ^JaJmH sH 1h~1h~1B* OJPJQJ^JaJmH ph `sH   /4\in| зwaHwwwwHw1hhB* OJPJQJ^JaJmH ph `sH +hB*OJPJQJ^JaJmH php0sH "hOJPJQJ^JaJmH sH 1hhB*OJPJQJ^JaJmH php0sH (hefghOJPJQJ^JaJmH sH 1hhB* OJPJQJ^JaJmH phsH 1hIRhIRB*OJPJQJ^JaJmH php0sH +hIRhIR5OJPJQJ^JaJmH sH  -:>?Y_`q_F_4"hOJPJQJ^JaJmH sH 1hGhGB*OJPJQJ^JaJmH php0sH "hGOJPJQJ^JaJmH sH "hav OJPJQJ^JaJmH sH "hM[OJPJQJ^JaJmH sH (h_!hOOJPJQJ^JaJmH sH (hefghOJPJQJ^JaJmH sH 1hOhOB*OJPJQJ^JaJmH php0sH +hOB* OJPJQJ^JaJmH phsH "hOOJPJQJ^JaJmH sH 9:CEIJPdfkl龬s^L^ss^sL^s"h^ OJPJQJ^JaJmH sH (hhm1OJPJQJ^JaJmH sH "hm1OJPJQJ^JaJmH sH (hhOJPJQJ^JaJmH sH "hOJPJQJ^JaJmH sH "hGOJPJQJ^JaJmH sH "hwaOJPJQJ^JaJmH sH 1hhm1B*OJPJQJ^JaJmH php0sH +hm1B* OJPJQJ^JaJmH phsH 渟qVq=$1hOhe(B* OJPJQJ^JaJmH ph `sH 1hOh(B* OJPJQJ^JaJmH ph `sH 4hOhB* H*OJPJQJ^JaJmH ph `sH 1hOhB* OJPJQJ^JaJmH ph `sH (h_!he(OJPJQJ^JaJmH sH 1hh_!B*OJPJQJ^JaJmH php0sH (h_!h_!OJPJQJ^JaJmH sH 1hhB* OJPJQJ^JaJmH phsH 1hhe(B* OJPJQJ^JaJmH phsH  HZx"4LNv TIJٲٲٝkY"h_!OJPJQJ^JaJmH sH 1hOh_!B* OJPJQJ^JaJmH ph `sH 1hOh_!B*OJPJQJ^JaJmH php0sH (h_!h_!OJPJQJ^JaJmH sH "hOOJPJQJ^JaJmH sH (h_!h(OJPJQJ^JaJmH sH (h_!he(OJPJQJ^JaJmH sH "hOJPJQJ^JaJmH sH " *,.XZtxê|jU@U."hZOJPJQJ^JaJmH sH (h07h(OJPJQJ^JaJmH sH (h07hwaOJPJQJ^JaJmH sH "hGOJPJQJ^JaJmH sH 1h07h_!B*OJPJQJ^JaJmH php0sH (h07h_!OJPJQJ^JaJmH sH 1h07h_!B* OJPJQJ^JaJmH phsH 1h07hwaB* OJPJQJ^JaJmH phsH "h_!OJPJQJ^JaJmH sH "hOOJPJQJ^JaJmH sH  2 Yu^$ & F SSW^S`Wa$gdB$ & F V^`Va$gdbT$ & F SSW^S`Wa$gd($ & F SSW^S`Wa$gdT$ & F SSW^S`Wa$gd$ & F SSW^S`Wa$gdnN$ & F SSW^S`Wa$gd_! ()+;JKLXYZį뚁hO:ĚĚ(h07hOOJPJQJ^JaJmH sH 1hZhOB* OJPJQJ^JaJmH ph `sH 1h07hwaB*OJPJQJ^JaJmH php0sH 1h07h6B*OJPJQJ^JaJmH php0sH (h07h6OJPJQJ^JaJmH sH (h07h(OJPJQJ^JaJmH sH (h07hwaOJPJQJ^JaJmH sH "hZOJPJQJ^JaJmH sH (h07hGOJPJQJ^JaJmH sH   ')@UXlm),ѼѼy``N"hGOJPJQJ^JaJmH sH 1hZh07B* OJPJQJ^JaJmH ph `sH 1h07hnNB*OJPJQJ^JaJmH php0sH (h07hnNOJPJQJ^JaJmH sH (h07h07OJPJQJ^JaJmH sH (h07h6OJPJQJ^JaJmH sH (h07hwaOJPJQJ^JaJmH sH 1hZhwaB* OJPJQJ^JaJmH ph `sH ,9QSUZgn~ʹ{f{Q{f?f{f{"h/OJPJQJ^JaJmH sH (h(hZOJPJQJ^JaJmH sH (h`hZOJPJQJ^JaJmH sH "hZOJPJQJ^JaJmH sH "hGOJPJQJ^JaJmH sH (h07hOJPJQJ^JaJmH sH 1hZhB* OJPJQJ^JaJmH ph `sH 1hZh07B* OJPJQJ^JaJmH ph `sH 1hZhnNB* OJPJQJ^JaJmH ph `sH *1KMs|/ֲ֙nYnYnYn@nY1hZhZB*OJPJQJ^JaJmH php0sH (h`hZOJPJQJ^JaJmH sH "hZOJPJQJ^JaJmH sH 1hZh07B* OJPJQJ^JaJmH ph `sH 1hZhnNB* OJPJQJ^JaJmH ph `sH "h07OJPJQJ^JaJmH sH "hGOJPJQJ^JaJmH sH (h07hOJPJQJ^JaJmH sH (h07hnNOJPJQJ^JaJmH sH /2E]}ռՎu\uGGGGGGG(hGhnNOJPJQJ^JaJmH sH 1hGhB* OJPJQJ^JaJmH ph `sH 1hGhnNB* OJPJQJ^JaJmH ph `sH 1hGh07B*OJPJQJ^JaJmH php0sH (hGh07OJPJQJ^JaJmH sH 1hGhnNB* OJPJQJ^JaJmH phsH 1hGh07B* OJPJQJ^JaJmH phsH "hZOJPJQJ^JaJmH sH  !14567Uv{|vv]H(hGhGOJPJQJ^JaJmH sH 1hGhB* OJPJQJ^JaJmH ph `sH 1hGhnNB* OJPJQJ^JaJmH ph `sH 1hGh07B* OJPJQJ^JaJmH ph `sH 1hGh07B*OJPJQJ^JaJmH php0sH (hGh07OJPJQJ^JaJmH sH (hGhnNOJPJQJ^JaJmH sH (hGhOJPJQJ^JaJmH sH  ѿgR91hThTB*OJPJQJ^JaJmH php0sH (h`hTOJPJQJ^JaJmH sH 1hThTB* OJPJQJ^JaJmH phsH (hGh6OJPJQJ^JaJmH sH (hGhOJPJQJ^JaJmH sH (hGhnNOJPJQJ^JaJmH sH "hGOJPJQJ^JaJmH sH (hGhGOJPJQJ^JaJmH sH 1hGhGB*OJPJQJ^JaJmH php0sH +,TUhikl ٮٮٮ~~h~~h~+htwB*OJPJQJ^JaJmH php0sH 1hThTB*OJPJQJ^JaJmH php0sH ,h`hT0JOJPJQJ^JaJmH sH 1jh`hTOJPJQJU^JaJmH sH "htwOJPJQJ^JaJmH sH (h`hTOJPJQJ^JaJmH sH "hTOJPJQJ^JaJmH sH ! &,-.1>UʹmT?**?*?T(h^ h(OJPJQJ^JaJmH sH (h^ hZOJPJQJ^JaJmH sH 1h^ hZB*OJPJQJ^JaJmH php0sH 1h^ hB*OJPJQJ^JaJmH php0sH (h^ hOJPJQJ^JaJmH sH 1h^ hB* OJPJQJ^JaJmH phsH 1h^ hIB* OJPJQJ^JaJmH phsH 1h^ h(B* OJPJQJ^JaJmH phsH 1h^ hTB* OJPJQJ^JaJmH phsH  !%&-;<OP\_e͸|cM+h\B* OJPJQJ^JaJmH ph `sH 1h^ hIB*OJPJQJ^JaJmH php0sH (h^ hIOJPJQJ^JaJmH sH "h\OJPJQJ^JaJmH sH (h^ h(OJPJQJ^JaJmH sH (h^ hZOJPJQJ^JaJmH sH 1h^ hZB*OJPJQJ^JaJmH php0sH 1h^ h(B*OJPJQJ^JaJmH php0sH )*:BѼqX?-"h^ OJPJQJ^JaJmH sH 1h^ h^ B* OJPJQJ^JaJmH ph `sH 1h^ hB* OJPJQJ^JaJmH ph `sH 1h^ h(B* OJPJQJ^JaJmH ph `sH 1h\hZB*OJPJQJ^JaJmH php0sH 1h\hIB*OJPJQJ^JaJmH php0sH (h^ h^ OJPJQJ^JaJmH sH (h^ hIOJPJQJ^JaJmH sH 1h^ hIB* OJPJQJ^JaJmH ph `sH  Bkm{| $BXY뮘fPPP+hbTB*OJPJQJ^JaJmH php0sH 1hbThbTB*OJPJQJ^JaJmH php0sH 1hbTh`B*OJPJQJ^JaJmH php0sH +hbTh`5OJPJQJ^JaJmH sH +hbThbT5OJPJQJ^JaJmH sH "h^ OJPJQJ^JaJmH sH (h^ h`OJPJQJ^JaJmH sH (h^ h(OJPJQJ^JaJmH sH  ,2<=>r6BPT*Vv оiii1hNmhBB*OJPJQJ^JaJmH php0sH (hNmhBOJPJQJ^JaJmH sH "hvqOJPJQJ^JaJmH sH (hBhBOJPJQJ^JaJmH sH "hBOJPJQJ^JaJmH sH +hBB* OJPJQJ^JaJmH phsH 1hNmhBB* OJPJQJ^JaJmH phsH " 6MP3Ccdѿѿѿ{b{P;(hGGAhvqOJPJQJ^JaJmH sH "hSOJPJQJ^JaJmH sH 1hhvqB*OJPJQJ^JaJmH php0sH 1hvqhvqB*OJPJQJ^JaJmH php0sH "hvqOJPJQJ^JaJmH sH 1hBhvqB* OJPJQJ^JaJmH phsH "hBOJPJQJ^JaJmH sH (hNmhBOJPJQJ^JaJmH sH 1hBhBB*OJPJQJ^JaJmH php0sH d" lu^$ & F SSW^S`Wa$gd>$ & F V^`Va$gd>$ & F SSW^S`Wa$gdsX$ & F SSW^S`Wa$gdI7$ & F SSW^S`Wa$gdr$ & F SSW^S`Wa$gd0$ & F SSW^S`Wa$gdvqd"$*NP8@tԻԩ}ԻԻԻhԻV=V1h0h0B*OJPJQJ^JaJmH php0sH "h0OJPJQJ^JaJmH sH (hI7hvqOJPJQJ^JaJmH sH +h)?TB*OJPJQJ^JaJmH phsH +h\B*OJPJQJ^JaJmH phsH "h\OJPJQJ^JaJmH sH 1hvqhvqB*OJPJQJ^JaJmH php0sH "hvqOJPJQJ^JaJmH sH 1hvqhvqB* OJPJQJ^JaJmH phsH  "Lbdf08FNP~íØfTT;;1hSh0B* OJPJQJ^JaJmH ph `sH "hsXOJPJQJ^JaJmH sH 1h0h0B* OJPJQJ^JaJmH ph `sH 1h0h0B*OJPJQJ^JaJmH php0sH (h0h0OJPJQJ^JaJmH sH +h0B* OJPJQJ^JaJmH phsH 1h0h0B* OJPJQJ^JaJmH phsH "hvqOJPJQJ^JaJmH sH "hSOJPJQJ^JaJmH sH JMU_~ٱiSi:1haC>hrB*OJPJQJ^JaJmH phsH +h/1UB*OJPJQJ^JaJmH php0sH +h0B*OJPJQJ^JaJmH php0sH 1hrhrB* OJPJQJ^JaJmH phsH 1h0hrUB* OJPJQJ^JaJmH phsH +h/1UB* OJPJQJ^JaJmH phsH "h0OJPJQJ^JaJmH sH (h0h0OJPJQJ^JaJmH sH "h)?TOJPJQJ^JaJmH sH  26Bprv|Ф麋uucNcN8+hh/1U6OJPJQJ^JaJmH sH (hh/1UOJPJQJ^JaJmH sH "h/1UOJPJQJ^JaJmH sH +h/1UB*OJPJQJ^JaJmH php0sH 1h/1Uh/1UB*OJPJQJ^JaJmH php0sH +hrB*OJPJQJ^JaJmH phsH +h/1UB*OJPJQJ^JaJmH phsH 1haC>hrB*OJPJQJ^JaJmH phsH +h0B*OJPJQJ^JaJmH phsH  bl (.0TV٪{fQQQhsXB* OJPJQJ^JaJmH ph `sH 1h}hsXB* OJPJQJ^JaJmH phsH "hsXOJPJQJ^JaJmH sH 1hY hsXB* OJPJQJ^JaJmH phsH +hsXB* OJPJQJ^JaJmH phsH "hI7OJPJQJ^JaJmH sH (h/1UhOJPJQJ^JaJmH sH (h/1UhI7OJPJQJ^JaJmH sH   OPкr\C*1h/1UhB* OJPJQJ^JaJmH phsH 1h/1Uh>B* OJPJQJ^JaJmH phsH +h>h 5OJPJQJ^JaJmH sH +h>B*OJPJQJ^JaJmH php0sH 1h>h>B*OJPJQJ^JaJmH php0sH 1h>h B*OJPJQJ^JaJmH php0sH +h>h>5OJPJQJ^JaJmH sH +hsXB*OJPJQJ^JaJmH phsH 1haC>hsXB*OJPJQJ^JaJmH phsH PQTVXlp|~Ҧx_F_4"h/1UOJPJQJ^JaJmH sH 1h'$hB* OJPJQJ^JaJmH ph `sH 1h'$h>B* OJPJQJ^JaJmH ph `sH 1h'$h/1UB* OJPJQJ^JaJmH ph `sH (hh>OJPJQJ^JaJmH sH +h/1UB*OJPJQJ^JaJmH php0sH +hhH*OJPJQJ^JaJmH sH 1h/1UhB*OJPJQJ^JaJmH php0sH (hhOJPJQJ^JaJmH sH 03RY^_clmqr{įįįįoV=V1hsXhB* OJPJQJ^JaJmH ph `sH 1hsXh>B* OJPJQJ^JaJmH ph `sH (hsXh>OJPJQJ^JaJmH sH 1hsXhsXB*OJPJQJ^JaJmH php0sH "hsXOJPJQJ^JaJmH sH (hhOJPJQJ^JaJmH sH (hh>OJPJQJ^JaJmH sH "h/1UOJPJQJ^JaJmH sH (hh/1UOJPJQJ^JaJmH sH dfjlprtz͸xbLb:xbxL"hsXOJPJQJ^JaJmH sH +hsXB*OJPJQJ^JaJmH php0sH +h'$B*OJPJQJ^JaJmH php0sH 1h'$hB*OJPJQJ^JaJmH php0sH "h'$OJPJQJ^JaJmH sH (hhOJPJQJ^JaJmH sH (hh>OJPJQJ^JaJmH sH 1hsXhsXB* OJPJQJ^JaJmH ph `sH 1hsXh'$B* OJPJQJ^JaJmH ph `sH "$&8Thjlԭ”~lZA,(h5hOJPJQJ^JaJmH sH 1h5hB* OJPJQJ^JaJmH phsH "hOJPJQJ^JaJmH sH "hsXOJPJQJ^JaJmH sH +hsXB*OJPJQJ^JaJmH php0sH 1h'$h'$B*OJPJQJ^JaJmH php0sH (hhOJPJQJ^JaJmH sH "h'$OJPJQJ^JaJmH sH (hh>OJPJQJ^JaJmH sH +h'$B*OJPJQJ^JaJmH php0sH ~>BDJѸѸѦэtѦ[E/+h'$B*OJPJQJ^JaJmH php0sH +hB*OJPJQJ^JaJmH php0sH 1hyhB* OJPJQJ^JaJmH ph `sH 1h'$hB* OJPJQJ^JaJmH ph `sH 1h'$h'$B* OJPJQJ^JaJmH ph `sH "hOJPJQJ^JaJmH sH 1h5hB* OJPJQJ^JaJmH ph `sH (h5hOJPJQJ^JaJmH sH 1h5hB*OJPJQJ^JaJmH php0sH JLN`r123:DLO^dѸѣu`u`uGu.u1h> h>B* OJPJQJ^JaJmH phsH 1h> hB* OJPJQJ^JaJmH phsH (h$ch>OJPJQJ^JaJmH sH (h$chOJPJQJ^JaJmH sH 1h5hB*OJPJQJ^JaJmH phsH (hsXhOJPJQJ^JaJmH sH 1hsXhB* OJPJQJ^JaJmH ph `sH (h5hOJPJQJ^JaJmH sH 1h5hB*OJPJQJ^JaJmH php0sH l2 x1*u^$ & F SSW^S`Wa$gd$$ & F SSW^S`Wa$gdU"$ & F SSW^S`Wa$gdu$ & F SSW^S`Wa$gd y$ & F V^`Va$gd y$ & F SSW^S`Wa$gd>$ & F SSW^S`Wa$gd &*,.D^`lprx|لkVVVD"h)?TOJPJQJ^JaJmH sH (h$ch>OJPJQJ^JaJmH sH 1h> hW{gB*OJPJQJ^JaJmH php0sH 1h> hB* OJPJQJ^JaJmH phsH (h$chW{gOJPJQJ^JaJmH sH "h> OJPJQJ^JaJmH sH (h$chj>`OJPJQJ^JaJmH sH (h$chOJPJQJ^JaJmH sH "hj>`OJPJQJ^JaJmH sH >DX`bydR@dd@ddRdd@d"h> OJPJQJ^JaJmH sH "hj>`OJPJQJ^JaJmH sH (h$ch>OJPJQJ^JaJmH sH 1h> h>B*OJPJQJ^JaJmH php0sH 1h> hW{gB*OJPJQJ^JaJmH php0sH (h$chW{gOJPJQJ^JaJmH sH 1h> hW{gB* OJPJQJ^JaJmH phsH "h)?TOJPJQJ^JaJmH sH (h$ch)?TOJPJQJ^JaJmH sH bv >ThydK٫٫٫1h> hW{gB* OJPJQJ^JaJmH ph `sH (h$ch>OJPJQJ^JaJmH sH 1h> h>B*OJPJQJ^JaJmH php0sH 1h> hW{gB*OJPJQJ^JaJmH php0sH (h$chW{gOJPJQJ^JaJmH sH 1h> hW{gB* OJPJQJ^JaJmH phsH "h> OJPJQJ^JaJmH sH (h$ch> OJPJQJ^JaJmH sH  $&*68XZfhIJIJIJIJIJIJIJr](h$chOJPJQJ^JaJmH sH 1h)?ThB* OJPJQJ^JaJmH phsH "h)?TOJPJQJ^JaJmH sH (h$ch> OJPJQJ^JaJmH sH "h> OJPJQJ^JaJmH sH (h$chW{gOJPJQJ^JaJmH sH "hj>`OJPJQJ^JaJmH sH (h$chj>`OJPJQJ^JaJmH sH  $(BDFvͷ͢xfxfM41h)?Th$cB*OJPJQJ^JaJmH php0sH 1h)?Th$cB* OJPJQJ^JaJmH phsH "h)?TOJPJQJ^JaJmH sH (h$ch>OJPJQJ^JaJmH sH (h$chOJPJQJ^JaJmH sH (h$chW{gOJPJQJ^JaJmH sH +h)?TB*OJPJQJ^JaJmH php0sH 1h)?ThW{gB*OJPJQJ^JaJmH php0sH 1h)?Th)?TB*OJPJQJ^JaJmH php0sH vxzBTVhjlnt|֝r]D]1h)?Th)?TB*OJPJQJ^JaJmH php0sH (h)?Th)?TOJPJQJ^JaJmH sH 1h)?Th)?TB* OJPJQJ^JaJmH phsH "h$cOJPJQJ^JaJmH sH "hj>`OJPJQJ^JaJmH sH (h$ch)?TOJPJQJ^JaJmH sH "h)?TOJPJQJ^JaJmH sH (h$ch>OJPJQJ^JaJmH sH (h$ch$cOJPJQJ^JaJmH sH .>NPbv©{bM;א"hj>`OJPJQJ^JaJmH sH (h)?Thj>`OJPJQJ^JaJmH sH 1h)?Th)?TB*OJPJQJ^JaJmH php0sH (h$ch)?TOJPJQJ^JaJmH sH 1hj>`h)?TB* OJPJQJ^JaJmH ph `sH 1hj>`h>B* OJPJQJ^JaJmH ph `sH (h)?Th>OJPJQJ^JaJmH sH "h)?TOJPJQJ^JaJmH sH +h)?Th)?TH*OJPJQJ^JaJmH sH efpwyкССЋr\rG(hvh yOJPJQJ^JaJmH sH +h yB* OJPJQJ^JaJmH phsH 1hvh yB* OJPJQJ^JaJmH phsH +h yh>5OJPJQJ^JaJmH sH 1h yh yB*OJPJQJ^JaJmH php0sH +h yB*OJPJQJ^JaJmH php0sH 1h yh>B*OJPJQJ^JaJmH php0sH +h yh y5OJPJQJ^JaJmH sH  N $%ѸѦѦѐ{bM(h yh yOJPJQJ^JaJmH sH 1h yh yB* OJPJQJ^JaJmH phsH (hoBh yOJPJQJ^JaJmH sH +h yB* OJPJQJ^JaJmH ph `sH "h yOJPJQJ^JaJmH sH 1hvh yB* OJPJQJ^JaJmH ph `sH (hvh yOJPJQJ^JaJmH sH 1hvh yB*OJPJQJ^JaJmH php0sH %()6:Mdhir@]rx{~ѸѣѸѸѸ{fTT"hU"OJPJQJ^JaJmH sH (h yh$OJPJQJ^JaJmH sH "h$OJPJQJ^JaJmH sH +h$B*OJPJQJ^JaJmH php0sH (h yh:OJPJQJ^JaJmH sH 1h yh yB* OJPJQJ^JaJmH ph `sH (h yh yOJPJQJ^JaJmH sH 1h yh yB*OJPJQJ^JaJmH php0sH @:t&(,-.ҽ|fM8(hyhuOJPJQJ^JaJmH sH 1hyhuB*OJPJQJ^JaJmH php0sH +huB*OJPJQJ^JaJmH php0sH "huOJPJQJ^JaJmH sH +huB* OJPJQJ^JaJmH ph `sH 1h yh yB* OJPJQJ^JaJmH ph `sH (h yh yOJPJQJ^JaJmH sH 1h yh yB*OJPJQJ^JaJmH php0sH (h yh yOJPJQJ^JaJmH sH .b^tvxѻѢvaL:"hU"OJPJQJ^JaJmH sH (hKhOJPJQJ^JaJmH sH (hKhuOJPJQJ^JaJmH sH +huB* OJPJQJ^JaJmH ph `sH +huB*OJPJQJ^JaJmH php0sH 1hyhuB*OJPJQJ^JaJmH php0sH +hyhu6OJPJQJ^JaJmH sH (hyhuOJPJQJ^JaJmH sH 1hyhuB* OJPJQJ^JaJmH ph `sH x6>@FP`渟pU<'(huhU"OJPJQJ^JaJmH sH 1huhU"B* OJPJQJ^JaJmH ph `sH 4huhU"6B* OJPJQJ^JaJmH ph `sH +huhU"6OJPJQJ^JaJmH sH 1huh$B* OJPJQJ^JaJmH ph `sH 1huh$B*OJPJQJ^JaJmH php0sH (huh$OJPJQJ^JaJmH sH 1huh$B* OJPJQJ^JaJmH phsH 1huh yB* OJPJQJ^JaJmH phsH 359:Hw{빤ҤydO:(hfhhuOJPJQJ^JaJmH sH (hKhuOJPJQJ^JaJmH sH (huhuOJPJQJ^JaJmH sH "huOJPJQJ^JaJmH sH 1huhU"B* OJPJQJ^JaJmH ph `sH (huhU"OJPJQJ^JaJmH sH 1huh$B* OJPJQJ^JaJmH ph `sH 1huh$B*OJPJQJ^JaJmH php0sH (huh$OJPJQJ^JaJmH sH   /01CmֽkV=1huh$B* OJPJQJ^JaJmH phsH (hfhhuOJPJQJ^JaJmH sH 1huhU"B* OJPJQJ^JaJmH ph `sH (h yhU"OJPJQJ^JaJmH sH "hKOJPJQJ^JaJmH sH "hU"OJPJQJ^JaJmH sH 1hU"hU"B* OJPJQJ^JaJmH phsH (huh$OJPJQJ^JaJmH sH (hfhhU"OJPJQJ^JaJmH sH m  FLbX뼧||c|N51h}h}B* OJPJQJ^JaJmH ph `sH (h}h}OJPJQJ^JaJmH sH 1h}h}B*OJPJQJ^JaJmH php0sH "h}OJPJQJ^JaJmH sH 1h}h$B* OJPJQJ^JaJmH ph `sH (huh$OJPJQJ^JaJmH sH +h}B*OJPJQJ^JaJmH php0sH 1huh$B* OJPJQJ^JaJmH phsH (huhuOJPJQJ^JaJmH sH )*CDîٙr]G.1hIh yB*OJPJQJ^JaJmH php0sH +hIh y5OJPJQJ^JaJmH sH (huh$OJPJQJ^JaJmH sH (hfhh$OJPJQJ^JaJmH sH "hKOJPJQJ^JaJmH sH (h}h$OJPJQJ^JaJmH sH (h}h}OJPJQJ^JaJmH sH +h}B* OJPJQJ^JaJmH phsH "h}OJPJQJ^JaJmH sH (huh}OJPJQJ^JaJmH sH  DTU_bз淡r`G`2`(hghZDOJPJQJ^JaJmH sH 1hV|hZDB*OJPJQJ^JaJmH php0sH "hZDOJPJQJ^JaJmH sH +hZDB* OJPJQJ^JaJmH phsH 1hghZDB* OJPJQJ^JaJmH phsH +hIh y5OJPJQJ^JaJmH sH 1hIh yB*OJPJQJ^JaJmH php0sH +hIB*OJPJQJ^JaJmH php0sH 1hIhIB*OJPJQJ^JaJmH php0sH * J~(` u$ & F SSW^S`Wa$gd($ & F SSW^S`Wa$gdP_$ & F SSW^S`Wa$gdI$ & F SSW^S`Wa$gd+W$ & F SSW^S`Wa$gdZD$ & F V^`Va$gdI      ' ( - 7 N O P Q W Z ^ _ e f g x  龬~iS~ii+hZDB*OJPJQJ^JaJmH php0sH (hYdhZDOJPJQJ^JaJmH sH 1hYdhZDB*OJPJQJ^JaJmH php0sH (hC9hZDOJPJQJ^JaJmH sH "hKOJPJQJ^JaJmH sH "hZDOJPJQJ^JaJmH sH 1h"hZDB* OJPJQJ^JaJmH ph `sH +hZDB* OJPJQJ^JaJmH ph `sH                * L V n r t x z 澥ЌоsZA1hC9hZDB*OJPJQJ^JaJmH php0sH 1hC9hZDB* OJPJQJ^JaJmH ph `sH 1h4hZDB* OJPJQJ^JaJmH ph `sH 1hQhZDB*OJPJQJ^JaJmH php0sH 1hPhZDB* OJPJQJ^JaJmH ph `sH "hZDOJPJQJ^JaJmH sH +hZDB*OJPJQJ^JaJmH php0sH 1hV|hZDB*OJPJQJ^JaJmH php0sH z  R T X Z \ ` r    4 6 X n x z   ѿwwewL6+hKB* OJPJQJ^JaJmH ph `sH 1hZhZDB*OJPJQJ^JaJmH php0sH "hiG+OJPJQJ^JaJmH sH 1hZDhZDB*OJPJQJ^JaJmH php0sH 1hPhZDB*OJPJQJ^JaJmH php0sH +hZDB*OJPJQJ^JaJmH php0sH "hZDOJPJQJ^JaJmH sH (hYdhZDOJPJQJ^JaJmH sH 1hYdhZDB*OJPJQJ^JaJmH php0sH     6HIJMNY[ѿfM7+h?B* OJPJQJ^JaJmH ph `sH 1h+Wh+WB* OJPJQJ^JaJmH ph `sH 1h+Wh+WB*OJPJQJ^JaJmH php0sH (h+Wh+WOJPJQJ^JaJmH sH "h+WOJPJQJ^JaJmH sH 1h+Wh+WB* OJPJQJ^JaJmH phsH "hZDOJPJQJ^JaJmH sH (h?hZDOJPJQJ^JaJmH sH 1hhZDB* OJPJQJ^JaJmH ph `sH   +`оwwbIb7bwwbIb"h+WOJPJQJ^JaJmH sH 1h+Wh+WB* OJPJQJ^JaJmH ph `sH (h+Wh+WOJPJQJ^JaJmH sH 1h+Wh+WB*OJPJQJ^JaJmH php0sH (h+Wh?OJPJQJ^JaJmH sH 1h+Wh?B* OJPJQJ^JaJmH ph `sH "h?OJPJQJ^JaJmH sH 1h+Wh?B*OJPJQJ^JaJmH php0sH +h?B*OJPJQJ^JaJmH php0sH `cdt(BpѸџэtџbP>t>"h+WOJPJQJ^JaJmH sH "hP_OJPJQJ^JaJmH sH "hiG+OJPJQJ^JaJmH sH 1hP_h+WB*OJPJQJ^JaJmH php0sH "hKOJPJQJ^JaJmH sH 1hP_h+WB* OJPJQJ^JaJmH ph `sH 1h+Wh+WB* OJPJQJ^JaJmH ph `sH (h+Wh+WOJPJQJ^JaJmH sH 1h+Wh+WB*OJPJQJ^JaJmH php0sH 0DFHPfltz|cJ5 5(h+WhZDOJPJQJ^JaJmH sH (h+WhIlOJPJQJ^JaJmH sH 1h+WhIlB*OJPJQJ^JaJmH php0sH 1h+Wh{B*OJPJQJ^JaJmH php0sH (h+Wh{OJPJQJ^JaJmH sH 1h+WhIB* OJPJQJ^JaJmH phsH +h?B* OJPJQJ^JaJmH phsH 1h+Wh{B* OJPJQJ^JaJmH phsH "h+WOJPJQJ^JaJmH sH (h?h+WOJPJQJ^JaJmH sH  zHJDFHJZѼёѪё|gR=(hP_hIlOJPJQJ^JaJmH sH (h+WhIOJPJQJ^JaJmH sH (h?h+WOJPJQJ^JaJmH sH (h?hIlOJPJQJ^JaJmH sH 1h+WhIlB*OJPJQJ^JaJmH php0sH "h+WOJPJQJ^JaJmH sH (h+Wh+WOJPJQJ^JaJmH sH (h+WhIlOJPJQJ^JaJmH sH 1hiG+hIlB* OJPJQJ^JaJmH ph `sH Zlt,BTVXZҹyy빠dK9"hP_OJPJQJ^JaJmH sH 1hiG+hIlB* OJPJQJ^JaJmH phsH (hP_hIlOJPJQJ^JaJmH sH (hP_hiG+OJPJQJ^JaJmH sH "hiG+OJPJQJ^JaJmH sH 1hiG+hiG+B* OJPJQJ^JaJmH phsH 1hiG+hIB* OJPJQJ^JaJmH phsH 1hP_hIlB* OJPJQJ^JaJmH phsH (hP_hIOJPJQJ^JaJmH sH Z`b$>t<ԿmXC-+hIhI5OJPJQJ^JaJmH sH (hP_h yOJPJQJ^JaJmH sH (hiG+hiG+OJPJQJ^JaJmH sH "hiG+OJPJQJ^JaJmH sH "h?OJPJQJ^JaJmH sH (hP_hZDOJPJQJ^JaJmH sH 1hiG+hIB* OJPJQJ^JaJmH ph `sH (hP_hIOJPJQJ^JaJmH sH "hP_OJPJQJ^JaJmH sH 1hP_hP_B*OJPJQJ^JaJmH php0sH <MP|}~(0OQ桏vvavaK5+hfhB*OJPJQJ^JaJmH php0sH +hP_B* OJPJQJ^JaJmH phsH (haqhP_OJPJQJ^JaJmH sH 1h%hP_B*OJPJQJ^JaJmH php0sH "hP_OJPJQJ^JaJmH sH 1h%hP_B* OJPJQJ^JaJmH phsH +hIhI5OJPJQJ^JaJmH sH +hIB*OJPJQJ^JaJmH php0sH 1hIhIB*OJPJQJ^JaJmH php0sH QR(>JLNRTdѸxbxI01hqhP_B* OJPJQJ^JaJmH ph `sH 1h%hP_B* OJPJQJ^JaJmH phsH +hfhB*OJPJQJ^JaJmH php0sH 1h%hP_B*OJPJQJ^JaJmH php0sH "hfhOJPJQJ^JaJmH sH (h(hfhOJPJQJ^JaJmH sH 1hqhfhB* OJPJQJ^JaJmH ph `sH (h%hfhOJPJQJ^JaJmH sH 1h%hfhB*OJPJQJ^JaJmH php0sH  dfp`bdjlpҹ맒|cN5N#"hP_OJPJQJ^JaJmH sH 1h%LhP_B*OJPJQJ^JaJmH php0sH (hk$XhP_OJPJQJ^JaJmH sH 1h%hP_B* OJPJQJ^JaJmH phsH +hP_B* OJPJQJ^JaJmH phsH (h(hNOJPJQJ^JaJmH sH "hNOJPJQJ^JaJmH sH 1hqhP_B* OJPJQJ^JaJmH ph `sH 1h^JhP_B*OJPJQJ^JaJmH php0sH (h%hP_OJPJQJ^JaJmH sH  p"6@Z\`bfh~Dzًًr\rًJJ"hiG+OJPJQJ^JaJmH sH +hP_B*OJPJQJ^JaJmH php0sH 1h%LhP_B*OJPJQJ^JaJmH php0sH "hP_OJPJQJ^JaJmH sH (h9h9OJPJQJ^JaJmH sH (hmh(OJPJQJ^JaJmH sH "h(OJPJQJ^JaJmH sH (hk$XhP_OJPJQJ^JaJmH sH "h9OJPJQJ^JaJmH sH :>l&*ٵٵu`G1h%LhP_B*OJPJQJ^JaJmH php0sH (hk$XhP_OJPJQJ^JaJmH sH 1hqhP_B*OJPJQJ^JaJmH php0sH "hP_OJPJQJ^JaJmH sH (hIhDOJPJQJ^JaJmH sH "hDOJPJQJ^JaJmH sH "hmOJPJQJ^JaJmH sH "hiG+OJPJQJ^JaJmH sH (hBQhiG+OJPJQJ^JaJmH sH *,.02^drxлл~iT?(hmh(OJPJQJ^JaJmH sH (h<h9OJPJQJ^JaJmH sH (hmh9OJPJQJ^JaJmH sH 1h9h9B*OJPJQJ^JaJmH php0sH "h9OJPJQJ^JaJmH sH "hP_OJPJQJ^JaJmH sH (hk$XhP_OJPJQJ^JaJmH sH 1h%LhP_B*OJPJQJ^JaJmH php0sH +hP_B*OJPJQJ^JaJmH php0sH 47=DEOU\c楓lS:1h9h9B* OJPJQJ^JaJmH phsH 1h(hIB* OJPJQJ^JaJmH phsH (h<h9OJPJQJ^JaJmH sH "h(OJPJQJ^JaJmH sH "h<OJPJQJ^JaJmH sH (hmh(OJPJQJ^JaJmH sH +h9B* OJPJQJ^JaJmH phsH +h(B* OJPJQJ^JaJmH phsH 1h(h(B* OJPJQJ^JaJmH phsH  #      D ^ ` b   ռ|cQ81h9hIB* OJPJQJ^JaJmH phsH "hDOJPJQJ^JaJmH sH 1h(hIB* OJPJQJ^JaJmH ph `sH 1h(h(B* OJPJQJ^JaJmH phsH (hDhIOJPJQJ^JaJmH sH "h(OJPJQJ^JaJmH sH 1h9h9B* OJPJQJ^JaJmH phsH 1h(h9B* OJPJQJ^JaJmH phsH "h9OJPJQJ^JaJmH sH     !!!!!n!p!iN0;h5khF5>*B* CJOJPJQJ^JaJmH phsH 5hF5>*B* CJOJPJQJ^JaJmH phsH 5h^^5>*B* CJOJPJQJ^JaJmH phsH (hS1hv<OJPJQJ^JaJmH sH (hmh yOJPJQJ^JaJmH sH "hewOJPJQJ^JaJmH sH "h9OJPJQJ^JaJmH sH 1h9h9B* OJPJQJ^JaJmH ph `sH (hmhIOJPJQJ^JaJmH sH  ` !!p!#,$()*.x1kk$ & F SSW^S`Wa$gdn^$ & F V^`Va$gdIH$ & F SSW^S`Wa$gdo-$ & F SSW^S`Wa$gdT=$ & F V^`Va$gd8qgdgd\H$ & F SSW^S`Wa$gdm p!F"G"H""""""""""####εpWA,(h8qh7 IOJPJQJ^JaJmH sH +h8qh7 I5OJPJQJ^JaJmH sH 1h8qhiB*OJPJQJ^JaJmH php0sH +h7cB*OJPJQJ^JaJmH php0sH +h8qB*OJPJQJ^JaJmH php0sH 1h8qh8qB*OJPJQJ^JaJmH php0sH 1h8qh7 IB*OJPJQJ^JaJmH php0sH 4h8qhW>W>W,W"heOJPJQJ^JaJmH sH 1hLhT=B*OJPJQJ^JaJmH php0sH (hLhT=OJPJQJ^JaJmH sH 1hLhT=B* OJPJQJ^JaJmH phsH 4hLhT=6B* OJPJQJ^JaJmH phsH (hQGhT=OJPJQJ^JaJmH sH "hfOJPJQJ^JaJmH sH "ho-OJPJQJ^JaJmH sH "hfhOJPJQJ^JaJmH sH (h){hfOJPJQJ^JaJmH sH '<'z''%(?(@(A(I(((((((((ѿѪtbMtM41hIHh8qB* OJPJQJ^JaJmH phsH (h){h){OJPJQJ^JaJmH sH "hfOJPJQJ^JaJmH sH "hIHOJPJQJ^JaJmH sH "hfhOJPJQJ^JaJmH sH "h){OJPJQJ^JaJmH sH (h8qh){OJPJQJ^JaJmH sH "ho-OJPJQJ^JaJmH sH (hLhT=OJPJQJ^JaJmH sH 1hLhT=B*OJPJQJ^JaJmH php0sH (())))!)&)')2)3)=)A)O)V)`)c)n)o)p)w)}))))))͸mmmX(ho-h8qOJPJQJ^JaJmH sH "hOJPJQJ^JaJmH sH (h){h){OJPJQJ^JaJmH sH "hIHOJPJQJ^JaJmH sH "hfOJPJQJ^JaJmH sH (h){h8qOJPJQJ^JaJmH sH 1hIHh8qB* OJPJQJ^JaJmH phsH 1hIHh){B* OJPJQJ^JaJmH phsH )* * *{*~***********εpZE,1hmhn^B* OJPJQJ^JaJmH phsH (hIHh,OJPJQJ^JaJmH sH +hIHh,5OJPJQJ^JaJmH sH +h~B*OJPJQJ^JaJmH php0sH +hIHB*OJPJQJ^JaJmH php0sH 1hIHhIHB*OJPJQJ^JaJmH php0sH 1hIHh,B*OJPJQJ^JaJmH php0sH 4hIHhIH5B*OJPJQJ^JaJmH php0sH +hIHhIH5OJPJQJ^JaJmH sH ******* ,,P,R,T,^,,,,,,-лwawHH1hChn^B* OJPJQJ^JaJmH ph `sH +hn^B* OJPJQJ^JaJmH ph `sH 1h\zhn^B* OJPJQJ^JaJmH ph `sH "hn^OJPJQJ^JaJmH sH 1hChn^B*OJPJQJ^JaJmH php0sH (hmhn^OJPJQJ^JaJmH sH 1hmhn^B* OJPJQJ^JaJmH phsH +hn^B* OJPJQJ^JaJmH phsH - -(-6---. ...R.\..... //,/./澥оwbbL3L1h5hn^B* OJPJQJ^JaJmH phsH +hn^B* OJPJQJ^JaJmH phsH (hChn^OJPJQJ^JaJmH sH (hhn^OJPJQJ^JaJmH sH 1hhn^B* OJPJQJ^JaJmH ph `sH 1hChn^B*OJPJQJ^JaJmH php0sH "hn^OJPJQJ^JaJmH sH +hn^B* OJPJQJ^JaJmH ph `sH 1hmhn^B* OJPJQJ^JaJmH ph `sH ./\//////0 0L0N0P0\0r0t0v0~000111@1B1b1x1ҽҫҫҫ|cN(hhn^OJPJQJ^JaJmH sH 1hhn^B* OJPJQJ^JaJmH ph `sH 1hChn^B*OJPJQJ^JaJmH php0sH +hn^B* OJPJQJ^JaJmH ph `sH "hn^OJPJQJ^JaJmH sH (h5hn^OJPJQJ^JaJmH sH 1hChn^B* OJPJQJ^JaJmH ph `sH (hChn^OJPJQJ^JaJmH sH x111111120212@2A2B2Q2g2h2j2͸mXXC*C1hn^hn^B*OJPJQJ^JaJmH php0sH (hn^hn^OJPJQJ^JaJmH sH (hn^hXOJPJQJ^JaJmH sH 1hn^hXB* OJPJQJ^JaJmH ph `sH 1hn^hGTB* OJPJQJ^JaJmH ph `sH 1hn^hGTB*OJPJQJ^JaJmH php0sH (hn^hGTOJPJQJ^JaJmH sH 1hn^hGTB* OJPJQJ^JaJmH phsH 1hn^hXB* OJPJQJ^JaJmH phsH j2k2x22222222>3V3\3^3_3`3a3f3n3~344@4B4H44445͸͸͸͸t_J_J__J(hn^hXOJPJQJ^JaJmH sH (hn^hn^OJPJQJ^JaJmH sH 1hn^hXB* OJPJQJ^JaJmH ph `sH 1hn^hGTB* OJPJQJ^JaJmH ph `sH "hzOJPJQJ^JaJmH sH (hn^hGTOJPJQJ^JaJmH sH 1hn^hGTB*OJPJQJ^JaJmH php0sH 1hn^hn^B*OJPJQJ^JaJmH php0sH 555$5,5R55555555556367696뽢֐{֐fMf;"h;OJPJQJ^JaJmH sH 1h;h;B* OJPJQJ^JaJmH phsH (h;h;OJPJQJ^JaJmH sH (hn^hzOJPJQJ^JaJmH sH "hn^OJPJQJ^JaJmH sH 4h;hn^6B* OJPJQJ^JaJmH ph `sH 1hn^hn^B* OJPJQJ^JaJmH ph `sH (hn^hXOJPJQJ^JaJmH sH (hn^hn^OJPJQJ^JaJmH sH x15677V8699K;;=?u$ & F SSW^S`Wa$gd!X$ & F SSW^S`Wa$gdO}$ & F SSW^S`Wa$gd'$ & F V^`Va$gd*$ & F SSW^S`Wa$gd;$ & F SSW^S`Wa$gdX 96<6@6F6Q6h6i6j6n6o6s6|6}666666666ѶыѝycJ1hn^hn^B* OJPJQJ^JaJmH phsH +h)B* OJPJQJ^JaJmH ph `sH "h;OJPJQJ^JaJmH sH "h)OJPJQJ^JaJmH sH 1h;h;B* OJPJQJ^JaJmH ph `sH 4h;h;6B* OJPJQJ^JaJmH ph `sH (h;h;OJPJQJ^JaJmH sH 1h;h;B*OJPJQJ^JaJmH php0sH 666667727677787H7I7P7[7^7i7p7л~iTiT;TT1h;hXB* OJPJQJ^JaJmH ph `sH (h;hXOJPJQJ^JaJmH sH (h;hn^OJPJQJ^JaJmH sH 1h;h;B*OJPJQJ^JaJmH php0sH "h)OJPJQJ^JaJmH sH "h;OJPJQJ^JaJmH sH (h;h;OJPJQJ^JaJmH sH 1h;h;B* OJPJQJ^JaJmH ph `sH +h;B* OJPJQJ^JaJmH phsH p7x7y7777777777777뮓zaKz5zKz+h~B*OJPJQJ^JaJmH php0sH +hO}B*OJPJQJ^JaJmH php0sH 1hO}hO}B*OJPJQJ^JaJmH php0sH 1hIHh*B*OJPJQJ^JaJmH php0sH 4hIHh*5B*OJPJQJ^JaJmH php0sH +hChO}5OJPJQJ^JaJmH sH (h;h;OJPJQJ^JaJmH sH "hn^OJPJQJ^JaJmH sH (hn^hXOJPJQJ^JaJmH sH 7777788!888<8=8T8U8V8[8^8ԿmT;1h*h*B*OJPJQJ^JaJmH php0sH 1h*h*B* OJPJQJ^JaJmH phsH (h gh'OJPJQJ^JaJmH sH 1h'h'B* OJPJQJ^JaJmH phsH "hOJPJQJ^JaJmH sH "h'OJPJQJ^JaJmH sH (hh'OJPJQJ^JaJmH sH (hIHh*OJPJQJ^JaJmH sH +hTh*5OJPJQJ^JaJmH sH ^8f8g8u8v888888888888888שה{bI0I1h'hB* OJPJQJ^JaJmH ph `sH 1h'hO}B* OJPJQJ^JaJmH ph `sH 1hh'B* OJPJQJ^JaJmH ph `sH 1hhO}B* OJPJQJ^JaJmH ph `sH (hhO}OJPJQJ^JaJmH sH 1hh*B*OJPJQJ^JaJmH php0sH (h*h*OJPJQJ^JaJmH sH "h*OJPJQJ^JaJmH sH +h*B*OJPJQJ^JaJmH php0sH 8888.9/9495969R9S9V9j9n99кlS>%>%>1h'h'B*OJPJQJ^JaJmH php0sH (h'h'OJPJQJ^JaJmH sH 1h'h'B* OJPJQJ^JaJmH phsH (hThO}OJPJQJ^JaJmH sH (hTh'OJPJQJ^JaJmH sH "h'OJPJQJ^JaJmH sH "hOJPJQJ^JaJmH sH +h!XB* OJPJQJ^JaJmH ph `sH 1h'hO}B* OJPJQJ^JaJmH ph `sH +h gB* OJPJQJ^JaJmH ph `sH 9999999999999ֽ֨~iT;&(hqch'OJPJQJ^JaJmH sH 1hqch'B* OJPJQJ^JaJmH phsH (h gh'OJPJQJ^JaJmH sH (h gh YOJPJQJ^JaJmH sH (h ghO}OJPJQJ^JaJmH sH (hThO}OJPJQJ^JaJmH sH (hTh'OJPJQJ^JaJmH sH 1h'h'B*OJPJQJ^JaJmH php0sH (h'h'OJPJQJ^JaJmH sH (h'hO}OJPJQJ^JaJmH sH  999 :::;:<:=:>:?:A:L:M:a:лwwbI01h!XhO}B* OJPJQJ^JaJmH ph `sH 1h!Xh'B* OJPJQJ^JaJmH ph `sH (hqch'OJPJQJ^JaJmH sH 1hqch'B*OJPJQJ^JaJmH php0sH 1h!Xh!XB* OJPJQJ^JaJmH ph `sH "h!XOJPJQJ^JaJmH sH (hqch!XOJPJQJ^JaJmH sH 1hqch!XB*OJPJQJ^JaJmH php0sH +h!XB*OJPJQJ^JaJmH php0sH a:i:j:::::::::::::: ;֨ygN<"h*OJPJQJ^JaJmH sH 1h!XhqcB* OJPJQJ^JaJmH ph `sH "hqcOJPJQJ^JaJmH sH +h!XB*OJPJQJ^JaJmH php0sH 1hqchqcB*OJPJQJ^JaJmH php0sH (hqchqcOJPJQJ^JaJmH sH 1h!XhO}B* OJPJQJ^JaJmH ph `sH (hqch YOJPJQJ^JaJmH sH (hqchO}OJPJQJ^JaJmH sH  ; ;&;=;B;I;J;K;];w;x;y;;Ի~eOe=+"hTOJPJQJ^JaJmH sH "h!XOJPJQJ^JaJmH sH +h!XB* OJPJQJ^JaJmH phsH 1h'h!XB* OJPJQJ^JaJmH phsH "hqcOJPJQJ^JaJmH sH (h0!h*OJPJQJ^JaJmH sH +h*B* OJPJQJ^JaJmH ph `sH 1h*h*B* OJPJQJ^JaJmH ph `sH "h*OJPJQJ^JaJmH sH 1h*h*B*OJPJQJ^JaJmH php0sH  ;;;;;;;;;;;;;<<@<F<H<J<ǮgQg8Q1hS_hS_B*OJPJQJ^JaJmH php0sH +hS_B* OJPJQJ^JaJmH phsH 1h!Xh!XB* OJPJQJ^JaJmH phsH (h0!h!XOJPJQJ^JaJmH sH 1h!Xh!XB* OJPJQJ^JaJmH ph `sH 1hTh!XB* OJPJQJ^JaJmH ph `sH "h!XOJPJQJ^JaJmH sH "hTOJPJQJ^JaJmH sH (h!Xh!XOJPJQJ^JaJmH sH J<f<h<|<<<<<<<<D=F=J=R=\=t=z=ٯ}kRk=k(hO}hS_OJPJQJ^JaJmH sH 1h*hS_B*OJPJQJ^JaJmH php0sH "hS_OJPJQJ^JaJmH sH 1h0!h!XB* OJPJQJ^JaJmH ph `sH 1h0!hO}B* OJPJQJ^JaJmH ph `sH (h!XhO}OJPJQJ^JaJmH sH (h!Xh!XOJPJQJ^JaJmH sH "h!XOJPJQJ^JaJmH sH (hO}h!XOJPJQJ^JaJmH sH z======>>> >F>v>z>>>>>>ԿjQ?j?jQ?j-"h/YOJPJQJ^JaJmH sH "h*OJPJQJ^JaJmH sH 1h*h*B*OJPJQJ^JaJmH php0sH (hS_hS_OJPJQJ^JaJmH sH 1hS_hS_B* OJPJQJ^JaJmH phsH "h!XOJPJQJ^JaJmH sH (h0!h*OJPJQJ^JaJmH sH (hThS_OJPJQJ^JaJmH sH "hS_OJPJQJ^JaJmH sH 1h0!hS_B* OJPJQJ^JaJmH ph `sH >>???????f@i@įeL3+h;B*OJPJQJ^JaJmH php0sH 1h;h;B*OJPJQJ^JaJmH php0sH 1h;h*B*OJPJQJ^JaJmH php0sH 4h;hyF5B*OJPJQJ^JaJmH php0sH +h;hyF5OJPJQJ^JaJmH sH 1hS_hS_B* OJPJQJ^JaJmH phsH (h0!h*OJPJQJ^JaJmH sH (h0!hS_OJPJQJ^JaJmH sH (hS_hS_OJPJQJ^JaJmH sH "hS_OJPJQJ^JaJmH sH  i@@@@@@@@@@@@@@@@溡v`G`,`4h;hyF6B* OJPJQJ^JaJmH phsH 1h;h;B* OJPJQJ^JaJmH phsH +h;B* OJPJQJ^JaJmH phsH (h;h*OJPJQJ^JaJmH sH +h;h*5OJPJQJ^JaJmH sH 1h;hLs,B*OJPJQJ^JaJmH php0sH +hLs,B*OJPJQJ^JaJmH php0sH +h~B*OJPJQJ^JaJmH php0sH 1h;h*B*OJPJQJ^JaJmH php0sH ?@>DGDIvNQVRHWu^$ & F SSW^S`Wa$gd\!$ & F SSW^S`Wa$gde)$ & F SSW^S`Wa$gd3[$ & F V^`Va$gdLs,$ & F SSW^S`Wa$gdLs,$ & F SSW^S`Wa$gd;$ & F V^`Va$gd;@@@@@@A A"A&A'A9A:AAAAAAAAABBB&BtBxBBBBBBB(CѸџџѸѸъѸxxъxxѸъx_1h;h;B* OJPJQJ^JaJmH ph `sH "h;OJPJQJ^JaJmH sH (h;h;OJPJQJ^JaJmH sH 1h;hyFB* OJPJQJ^JaJmH ph `sH 1h;hyFB*OJPJQJ^JaJmH php0sH (h;hyFOJPJQJ^JaJmH sH 1h;hyFB* OJPJQJ^JaJmH phsH !(C4CD`DD©Ԕ{fQ81hLs,hyFB* OJPJQJ^JaJmH phsH (hLs,hyFOJPJQJ^JaJmH sH (h/YhyFOJPJQJ^JaJmH sH 1h;hyFB* OJPJQJ^JaJmH ph `sH (h;hyFOJPJQJ^JaJmH sH 1h;h;B*OJPJQJ^JaJmH php0sH "h;OJPJQJ^JaJmH sH (h;h;OJPJQJ^JaJmH sH +h;h;6OJPJQJ^JaJmH sH  DDEEDEJEEE*F,G.GVGXGGGGGH͸͸摣xcN8+h3[hLs,5OJPJQJ^JaJmH sH (hLs,h*OJPJQJ^JaJmH sH (h!hyFOJPJQJ^JaJmH sH 1hLs,hyFB* OJPJQJ^JaJmH phsH "hLs,OJPJQJ^JaJmH sH (hLs,hyFOJPJQJ^JaJmH sH (hLs,hLs,OJPJQJ^JaJmH sH 1hLs,hLs,B*OJPJQJ^JaJmH php0sH 1hLs,hLs,B* OJPJQJ^JaJmH phsH HHHHHHHHHHHHHHHHHHHHHHHII III7I8IBICIֻs]+h~B*OJPJQJ^JaJmH php0sH +h3[B*OJPJQJ^JaJmH php0sH 1h3[h3[B*OJPJQJ^JaJmH php0sH 1h3[hLs,B*OJPJQJ^JaJmH php0sH 4h3[hLs,5B*OJPJQJ^JaJmH php0sH +h3[hLs,5OJPJQJ^JaJmH sH %h)5OJPJQJ^JaJmH sH CIDIIIJIKI_IsItIIIIIIJJJҼqqX=X((hxh3[OJPJQJ^JaJmH sH 4h6h3[6B*OJPJQJ^JaJmH php0sH 1hxh3[B*OJPJQJ^JaJmH php0sH "hGOJPJQJ^JaJmH sH (hGhGOJPJQJ^JaJmH sH "he)OJPJQJ^JaJmH sH "h3[OJPJQJ^JaJmH sH +he)B* OJPJQJ^JaJmH phsH 1hxh3[B* OJPJQJ^JaJmH phsH (h3[hLs,OJPJQJ^JaJmH sH JJJJ"K&KFKRKfKvKKK,L.L0LJLpLtLLLLLLLLLlMMMMMNN~iSS~S+h3[B*OJPJQJ^JaJmH php0sH (he)he)OJPJQJ^JaJmH sH (hxh3[OJPJQJ^JaJmH sH 4h6h3[6B*OJPJQJ^JaJmH php0sH 1h6h3[B*OJPJQJ^JaJmH php0sH "he)OJPJQJ^JaJmH sH (hh3[OJPJQJ^JaJmH sH "h3[OJPJQJ^JaJmH sH  NJNrNtNvN|N~NNNNNNNNNzbI44(hh3[OJPJQJ^JaJmH sH 1hech3[B* OJPJQJ^JaJmH phsH .h3[6B* OJPJQJ^JaJmH phsH 4h6h3[6B* OJPJQJ^JaJmH phsH 1hth3[B* OJPJQJ^JaJmH phsH +h3[B* OJPJQJ^JaJmH phsH (hh3[OJPJQJ^JaJmH sH (htRh3[OJPJQJ^JaJmH sH "h3[OJPJQJ^JaJmH sH NNNNNOOO:O>OpOOOOOOO\\\\\\\\\\\\\\\кССЋv]D]D/(hhfoOJPJQJ^JaJmH sH 1hhfoB* OJPJQJ^JaJmH phsH 1hh B* OJPJQJ^JaJmH phsH (h hOJPJQJ^JaJmH sH +h h5OJPJQJ^JaJmH sH 1h h8IB*OJPJQJ^JaJmH php0sH +h~B*OJPJQJ^JaJmH php0sH 1h hB*OJPJQJ^JaJmH php0sH +h B*OJPJQJ^JaJmH php0sH \\\ ].]2]<]>]@]D]L]r]]]]]] ^R^T^t^v^ԿԕԕԕjX?X1h98h98B*OJPJQJ^JaJmH php0sH "h98OJPJQJ^JaJmH sH 1h98h98B* OJPJQJ^JaJmH phsH "hjOJPJQJ^JaJmH sH (hhOJPJQJ^JaJmH sH (hh OJPJQJ^JaJmH sH (hhfoOJPJQJ^JaJmH sH "hOJPJQJ^JaJmH sH 1hhB*OJPJQJ^JaJmH php0sH v^F_H_\_^_f_n_________:`>``JaNajataaaaaaa٫٫٫ْ}}}hVhh"hjOJPJQJ^JaJmH sH (h98h OJPJQJ^JaJmH sH (h98hOJPJQJ^JaJmH sH 1h98h98B* OJPJQJ^JaJmH phsH (hh98OJPJQJ^JaJmH sH 1h98h98B*OJPJQJ^JaJmH php0sH "h98OJPJQJ^JaJmH sH (h98h98OJPJQJ^JaJmH sH aaaaab(b0b2b8bA in the IKBKB gene encoding the IKK protein, leading to a premature stop codon p.Y107X (parents were heterozygous carriers) ! clinical course: insufficient response to therapy, patient died at 25 months of age ! HSCT should be considered in other patients with similar disease. IKBKB gene mutations may also present as SCID with agammaglobulinemia (recently reported abstract). OCCURRENCE OF B-CELL LYMPHOMAS IN PATIENTS WITH ACTIVATED PHOSPHOINOSITIDE 3-KINASE  SYNDROME (Kracker S, Curtis J, Ibrahim MAA, Sediva A, Salisbury J, Campr V, Debr M, Edgar JDM, Imai K, Picard C, Casanova J-L, Fischer A, Nejentsev S, Durandy A. J Allergy Clin Immunol 2014; 134: 233-236): Activated phosphoinositide 3-kinase  syndrome (APDS): (i) novel autosomal-dominant primary immunodeficiency; (ii) etiology: heterozygous gain-of-function mutation in the PIK3CD gene encoding the p110 protein, the catalytic subunit of phosphoinositide 3-kinase  (PI3K); (iii) the c.3061G>A mutation (E1021K) is a frequent one; (iv) clinical features: recurrent respiratory infections, bronchiectasis, progressive lymphopenia, ! T-cell apoptosis, ! T-cell cytokine production, immunoglobulin class switch recombination defect (! IgM, normal or ! IgG and IgA); (v) variable clinical presentation: from an isolated antibody deficiency (well controlled by IgG substitution) to a combined immunodeficiency requiring HSCT. Authors screened 139 patients with an immunoglobulin class switch recombination defect for the c.3061G>A mutation in PIK3CD gene ! (i) 8 patients with APDS were detected; (ii) 2 of them developed B-cell lymphomas. Author s commentaries: (i) APDS must be considered in patients with an immunoglobulin class switch recombination defect; (ii) APDS patients might have ! risk of malignancies (hypothesis: ! T-cell mediated immune surveillance, uncontrolled B-cell proliferation). Selective p110 inhibitors: (i) molecules: IC87114 and GS-1101 (CAL-101 or Idelalisib); (ii) effect: ! activity of the mutant p110 in cells of APDS patients ex vivo; (iii) potential therapy for patients with APDS; (iv) GS-1101 has been used in clinical trials to treat chronic lymphocytic leukemia (good safety profile). PRESENCE OF HYPOGAMMAGLOBULINEMIA AND ABNORMAL ANTIBODY RESPONSES IN GATA2 DEFICIENCY (Chou J, Lutskiy M, Tsitsikov E, Notarangelo LD, Geha RS, Dioun A. J Allergy Clin Immunol 2014; 134: 223-226): GATA2 gene encodes a transcription factor that regulates stem cell homeostasis. GATA2 mutations: (i) diverse clinical phenotypes: myelodysplastic syndrome/acute myeloid leukemia; multilineage cytopenias; ! monocyte, B-cell and NK-cell counts; recurrent infections, including opportunistic (bacterial, mycobacterial, viral); lymphedema; (ii) the same mutation can result in varied phenotypes (hypothesis: modifier genes, environment, epigenetic factors). Authors report 2 patients with hypogammaglobulinemia and defective antibody responses associated with a GATA2 mutation (c.C1061T; T354M; dominant negative effect) detected by whole-exome sequencing (patient 1: recurrent sinopulmonary infections; patient 2: asymptomatic into mid-adulthood; both patients had multilineage cytopenias). Author s commentary: consider GATA2 mutations in patients with hypogammaglobulinemia, particularly in the setting of abnormal lymphocyte subsets and monocytopenia. PROGRESS IN HIV-1 VACCINE DEVELOPMENT (Haynes BF, Moody MA, Alam M, Bonsignori M, Verkoczy L, Ferrari G, Gao F, Tomaras GD, Liao H-X, Kelsoe G. J Allergy Clin Immunol 2014; 134: 3-10): Advances in HIV-vaccine development: (i) discovery of novel HIV-envelope targets for protective antibodies, (ii) demonstration that CD8+ T cells can control HIV-1 infection, (iii) development of immunogens to overcome diversity of T-cell epitopes, (iv) defining pathways to develop broad-neutralizing antibodies. A safe and effective HIV-1 vaccine is a global priority but still appears years away. RECENT DEVELOPMENTS IN THE SEARCH FOR A CURE FOR HIV-1 INFECTION: TARGETING THE LATENT RESERVOIR FOR HIV-1 (Siliciano JD, Siliciano RF. J Allergy Clin Immunol 2014; 134: 12-19): Antiretroviral therapy can control HIV-1 infection but does not cure it ! main problem: latent HIV-1 reservoir in resting CD4+ T cells. Authors discuss several strategies to eradicate the latent HIV-1 reservoir and provide a cure for HIV-1 infection. There have been reports of patients cured from HIV (e.g. an adult with HIV and acute myeloid leukemia was cured after transplantation with CCR5-deficient hematopoietic stem cells). THE EDITORS CHOICE (Leung DYM, Szefler SJ. J Allergy Clin Immunol 2014; 134: 23-24): Common variable immunodeficiency (CVID): (i) heterogeneous group of immunodeficiencies (diverse etiology and clinical presentation; involve B- or T-cell defects; only 15% of cases have confirmed genetic defects); (ii) prevalence: up to 1:25,000 subjects; (iii) clinical features: defective antibody responses; susceptibility to infections, autoimmunity and neoplasms. Gathmann et al studied retrospectively 2212 patients with CVID ! (i) symptom onset was very early (<10 yrs of age) in >1/3rd of patients; (ii) male subjects with early-onset CVID were more prone to pneumonia and less prone to other complications; (iii) diagnostic delay was high especially in early-onset patients; (iv) diagnostic delay was strongly related to ! patient survival; (v) higher doses of immunoglobulin therapy were associated with ! serious bacterial infections. Human rhinovirus (HRV): (i) frequently cause of asthma exacerbations in children; (ii) HRV-C species is associated with more severe attacks than HRV-A and HRV-B. Asthma patients had higher antibody responses to HRV-A and HRV-B, but a less efficacious immune response to HRV-C. Many patients with seasonal allergic rhinitis are sensitized to multiple pollens, including cross-reacting panallergens ! correct prescription of allergen immunotherapy (AIT) is not easy. In patients allergic to multiple pollens, component-resolved diagnosis (CRD) can refine the diagnosis made with extract-based SPT or IgE assays and the consequent AIT prescription. Gene defects in the IFN-/IL-12 and NF-B signaling pathways ! primary immunodeficiencies in which mycobacterial susceptibility is a strong phenotypic feature. Burns et al describe a patient with a novel homozygous loss-of-function mutation in the gene encoding the subunit  of IB kinase (IKK) ! severe infections by mycobacteria and other bacteria, conical teeth, abnormal immunologic studies. IKK deficiency has also been reported in a patient with SCID. Bone marrow transplantation should be considered in patients with complete IKK deficiency. Sialic acid binding immunoglobulin-like lectin 7 (Siglec-7): (i) novel inhibitory receptor on allergy effector cells (mast cells and basophils); (ii) therapeutic target for allergic diseases. Chou et al report an autosomal dominant mutation in GATA2 causing hypogammaglobulinemia, defective antibody responses and abnormal B-cell phenotyping (! naive B cells, ! marginal zone like B cells [skewed differentiation of transitional B cells toward marginal zone like B cells?]) in 2 patients (patient 1: recurrent sinopulmonary infections; patient 2: asymptomatic into mid-adulthood; both patients had multilineage cytopenias). GATA2 deficiency can present with diverse phenotypes. PEDIATRIC ALLERGY AND IMMUNOLOGY: COMMON COLIC, GASTROESOPHAGEAL REFLUX AND CONSTIPATION IN INFANTS UNDER 6 MONTHS OF AGE DO NOT NECESSITATE AN ALLERGY WORK-UP (Bergmann MM, Caubet JC, McLin V, Belli DC, Schppi MG, Eigenmann PA. Pediatr Allergy Immunol 2014; 25: 410 412): Infantile colic, constipation, gastroesophageal reflux (GER): (i) common in infants <6 months of age; (ii) usually mild and transient at this age; (iii) cow s milk (CM)-free diets are frequently prescribed, although pathogenic role of CM is debated (most evidence exists for constipation). Wessel s criteria for colic: crying/fussing >3 hrs/day, >3 days/wk for >3 consecutive wks. Rome III criteria for constipation: <1 bowel movement every third day and/or crying/pain during defecation and/or palpable stool in left colic quadrant. NASPGHAN/ESPGHAN criteria for GER: recurrent episodes of regurgitations and/or vomiting, irritability, rumination, hematemesis, wheezing or stridor in relation with GER. Risk of avoidance diets: (i) malnutrition; (ii) ! QoL; (iii) ! medical costs; (iv) development of IgE-mediated allergy after food reintroduction. Author s commentaries: (i) CM allergy seems not to play a role in most young infants with transient colic, constipation or GER ! restricting CM is not recommended; (ii) some infants with persistent and severe symptoms might need allergy testing and a diagnostic CM-free diet. CM allergy (IgE- and non-IgE-mediated) rarely occurs through exclusive breastfeeding, except for allergic proctocolitis (benign non-IgE-mediated allergy characterized by isolated bloody stool during the 1st yr of life). DRUG-INDUCED ENTEROCOLITIS SYNDROME (DIES) (Novembre E, Mori F, Barni S, Pucci N. Pediatr Allergy Immunol 2014; 25: 415 416): Food protein-induced enterocolitis syndrome (FPIES): (i) non-IgE-mediated allergy to food proteins; (ii) usually starts in the 1st yr of life (has also been described in adults); (iii) clinical history: vomiting, diarrhea, dehydration, hypotension, shock, acidemia, methemoglobinemia (2-6 hrs after eating the culprit food); (iv) frequent culprits: cow s milk, soy, grains (potentially any food may trigger an FPIES reaction); (v) diagnosis: clinical history, OFC; (vi) differential diagnosis: sepsis, metabolic diseases; (vii) acute treatment: fluid resuscitation, parenteral corticosteroids; (viii) long-term treatment: allergen avoidance; (ix) prognosis: typically resolves by 3-5 yrs of age (OFCs are usually performed to confirm resolution). Authors report the case of a 6-yr-old girl with an adverse reaction to amoxicillin (vomiting 1-2 h after ingesting AMX syrup, morbilliform rash the next day) ! allergy testing: negative serum specific IgE to cefaclor, penicillin, ampicillin and AMX; negative SPT and intradermal tests to AMX and penicillin ! open oral challenge with AMX: vomiting, diarrhoea, pallor, lethargy, hypotension, tachycardia, tachypnea, leukocytosis, neutrophilia, acidemia and methemoglobinemia starting 2 hrs after the 350 mg dose; successful treatment with intravenous fluids and hydrocortisone ! final diagnosis:  drug-induced enterocolitis syndrome (DIES) . Author s commentaries: (i) 1st report of DIES provoked by AMX (based on clinical history and drug challenge); (ii) enterocolitis syndrome can rarely be drug-induced. GENERALIZED FIXED DRUG ERUPTION IN A CHILD DUE TO TRIMETHOPRIM/SULFAMETHOXAZOLE (Can C, Akkelle E, Bay B, Ar1can , Yalc1n , Yazicioglu M. Pediatr Allergy Immunol 2014; 25: 413 415): Fixed drug eruption (FDE): (i) common skin allergic reaction; (ii) pathogenic mechanism: type IVc CD8+ T-cell-mediated delayed hypersensitivity reaction; (iii) clinical features: recurrent red-brown round skin lesions appearing in the same location 30 min to 8 hrs after exposure to the culprit drug, usually a single lesion (multiple lesions can occur), frequent residual hyperpigmentation; (iv) most common affected sites: hands, lips, oral mucosa, genitalia; (v) >100 culprit drugs have been reported; (vi) most common culprit drugs: penicillins, sulfonamides, tetracyclines, pyrazolones, barbiturates, phenolphthalein; (vii) diagnosis: clinical history, skin biopsy, patch testing, drug challenge (gold standard). Authors report the case of a 3-yr-old boy with generalized FDE after taking TMP/SMX (diagnostic features: characteristics of the skin lesions, relationship between drug intake and reaction onset, disease remission after drug withdrawal, histopathologic findings) ! successful treatment: hydroxyzine, topical methylprednisolone aceponate ! patch testing (~2 months after the reaction): doubtful reaction to TMP/SMX ! drug challenge was not performed due to the risk of a more severe allergic reaction. MANAGING A CHILD WITH POSSIBLE ALLERGY TO VACCINE (Caubet J-C, Rudzeviciene O, Gomes E, Terreehorst I, Brockow K, Eigenmann PA. Pediatr Allergy Immunol 2014; 25: 394 403): Vaccines: (i) one of the most cost-effective methods of all health interventions; (ii) ! morbidity and mortality of many infectious diseases (eg. smallpox eradication); (iii) ~20 vaccines are currently in use; (iv) each year billions of doses are administered worldwide. Adverse events to vaccines (3 to 83 per 100,000 doses of the most frequently used vaccines): (i) immediate allergy (minutes to hours): IgE-mediated (e.g. urticaria, angioedema, wheezing, GI symptoms, hypotension); (ii) delayed allergy (hours to days): usually non IgE-mediated (e.g. serum sickness, polyarthritis, erythema nodosum, maculopapular rash, delayed onset urticaria, erythema multiforme); (iii) non immunologic reactions (e.g. local reactions due to the injection itself or a foreign body; subcutaneous nodules after the injection of vaccines containing aluminum salts; nonspecific fever, irritability, drowsiness or rash; vasovagal reactions). Local reactions: (i) can be treated with cool packs and analgesic drugs (these drugs may ! immune response to vaccination and should not be administered prophylactically); (ii) may be difficult to distinguish from infectious cellulitis (monitoring is recommended). Importance of accurate diagnosis of vaccine allergy: (i) to prevent serious reactions; (ii) to avoid unnecessary vaccine restriction. Hypersensitivity reactions to vaccines can be classified according to the extent (local, systemic), timing of the reaction (immediate, non-immediate) and severity (minor, moderate, major). Immediate hypersensitivity to vaccines range from 1 per 50,000 doses for DTP to about 1 per 500,000 1,000,000 doses for most other vaccines. Anaphylaxis to vaccines: (i) rare but possible (reported for nearly every vaccine); (ii) most often due to vaccine constituents (e.g. gelatin, egg, milk, chicken, preservatives, antibiotics, yeast, latex) rather than the microbial components; (iii) in many cases a specific culprit is not detected. Important considerations regarding adverse reactions to vaccines: (i) confirm the adverse reaction (fever and local reactions are very common, generally self-limited, and usually do not contraindicate further doses); (ii) evaluate if the patient needs further doses of the culprit vaccine or similar vaccines (some patients mount adequate immune responses after fewer than the recommended vaccine doses; antibody measurements can be useful); (iii) if the clinical history and laboratory testing (e.g. serum tryptase) suggests an IgE-mediated reaction, perform in vivo and in vitro tests to detect specific IgE (sIgE) against the vaccine or its components (no single investigation alone is sufficiently predictive for vaccine allergy); (iv) patients with negative vaccine skin tests will usually tolerate the vaccine; (v) patients with positive vaccine skin tests might tolerate the vaccine (if benefits outweigh risk the vaccine should be administered gradually); (vi) it is prudent to observe the patient 30 min after vaccination; (vii) it is prudent to be prepared for anaphylaxis; (viii) if an IgE-mediated reaction to the vaccine is confirmed, try to detect the specific culprit allergen because other vaccines could contain the same allergen (eg. a patient with gelatin allergy may react to MMR, varicella or influenza vaccines); (ix) in most cases, patients with suspected allergy to vaccines can receive subsequent vaccinations safely; (x) some vaccines might be more important that others (e.g. measles is a potential fatal disease; influenza infection is usually less life-threatening). How to confirm an IgE-mediated allergy to a vaccine? (i) Suggestive clinical history: manifestations of mast cell degranulation within 4 hrs after immunization; (ii) specific IgE detection by skin testing (use the same vaccine brand that caused the reaction; falsely positive results may occur;  normal delayed responses are common [most likely represent prior immunity]): SPT (usually with undiluted vaccine, consider using dilutions when there is a history of severe reaction), intradermal test with 1/100 diluted vaccine (nonirritating concentration). How to confirm an IgE-mediated allergy to a vaccine component? (i) Suggestive clinical history: signs of mast cell degranulation within 4 hrs after exposure to a vaccine component (eg. egg, gelatin, yeast, latex, chicken, antibiotics); (ii) specific IgE detection to the vaccine component: SPT, in vitro testing; (iii) allergen challenge. Gelatin: (i) stabilizer (g to mg quantities) of many vaccines (e.g. MMR, varicella, influenza, Japanese encephalitis, rabies); (ii) bovine or porcine origin (extensively cross-reactive; patients sensitized to pork or beef are at higher risk of gelatin allergy); (iii) most frequent culprit allergen in vaccines; (iv) strong association between gelatin allergy and HLA-DR9 (particularly prevalent in Japan); (v) common ingredient in processed foods, particularly candies and desserts. How to diagnose gelatin allergy? (i) Clinical history: ask for reactions after gelatin ingestion, a negative history does not exclude gelatin allergy; (ii) sIgE detection in vitro; (iii) SPT with an office-made extract (not approved by the FDA): dissolve 1 teaspoon of sugared gelatin powder (any flavor) in 5 mL of normal saline (unsugared gelatin tends to gel at room temperature). How to approach a patient with IgE-mediated gelatin allergy? Perform skin testing with gelatin-containing vaccines ! (i) negative results ! vaccinate the patient, observe 30 min afterward, be prepared for anaphylaxis; (ii) positive results ! consider alternative approach to vaccination or vaccination in graded doses (take informed consent, be prepared for anaphylaxis). Egg protein (ovalbumin): (i) very low amounts in influenza, MMR and rabies vaccines (usually no risk for egg-allergic patients); (ii) higher amounts in yellow fever vaccine (be careful with egg-allergic patients). How to diagnose egg allergy? (i) Clinical history: ask for reactions after egg ingestion; (ii) sIgE detection by skin and serum tests; (iii) oral food challenge. How to approach a patient with IgE-mediated egg allergy who needs influenza vaccine? (i) Administer an entire dose without previous skin tests, even in patients with anaphylaxis to egg (allergy tests are recommended in patients with a history of allergic reaction to the influenza vaccine itself); (ii) observe 30 min after vaccination; (iii) be prepared to manage anaphylaxis; (iv) injectable trivalent vaccine is preferred over nasal live attenuated vaccine because its safety in egg-allergic patients has been studied more extensively; (v) 2 egg-free influenza vaccines were recently approved for patients e"18 yrs of age (Optaflu [Flucelvax] and Flublok). How to approach a patient with IgE-mediated egg allergy who needs yellow fever vaccine? Perform skin tests with the vaccine ! (i) negative results ! vaccinate the patient, observe 30 min afterward, be prepared for anaphylaxis; (ii) positive results ! consider alternative approach to vaccination or vaccination in graded doses (take informed consent, be prepared for anaphylaxis). Yellow fever vaccine may contain chicken proteins ! follow the same approach (see last paragraph) when vaccinating chicken-allergic patients. Yeast protein (Saccharomyces cerevisiae; common baker s or brewer s yeast): (i) present in hepatitis B vaccines (up to 25 mg per dose) and quadrivalent human papillomavirus vaccine (<7 g per dose); (ii) yeast allergy is rare. How to diagnose yeast allergy? (i) Clinical history: ask for reactions after yeast ingestion; (ii) sIgE detection by skin and serum tests to Saccharomyces cerevisiae. How to approach a patient with IgE-mediated yeast allergy? Perform skin testing with yeast-containing vaccines ! (i) negative results ! vaccinate the patient, observe 30 min afterward, be prepared for anaphylaxis; (ii) positive results ! consider alternative approach to vaccination or vaccination in graded doses (take informed consent, be prepared for anaphylaxis). Natural rubber latex: (i) present in latex gloves and in the packaging of many vaccines (vial stopper, syringe plunger); (ii) risk of vaccine contamination with latex is very low ! minimal risk of allergic reactions in patients with IgE-mediated latex allergy. How to diagnose latex allergy? (i) Clinical history: ask for immediate reactions after exposure to latex; (ii) sIgE detection by skin and serum tests. How to approach a patient with IgE-mediated latex allergy? (i) Use a vaccine without latex stopper; (ii) if not possible, remove the stopper and take the vaccine directly from the vial; (iii) if latex packaging cannot be avoided (eg. a prefilled syringe), vaccinate and observe the patient 30 min afterward, be prepared to treat anaphylaxis; (iv) do not use latex gloves. Contact allergy to latex ! no contraindication for latex-containing vaccines.  HYPERLINK "http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/latex-table.pdf" http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/latex-table.pdf (information on latex and vaccine packaging). Pertussis vaccines (DTaP or Tdap) and Sabin vaccine may contain trace amounts of casein ! be careful when vaccinating milk-allergic children (the vast majority of patients, even those with severe milk allergy, will tolerate these vaccines well). Some vaccines (e.g. polio, MMR, influenza) may contain traces of antibiotics (e.g. neomycin, gentamicin, streptomycin, polymyxin B) ! be careful when vaccinating patients with allergy to these compounds (not including contact dermatitis). Vaccines commonly contain aluminum (adjuvant), which may cause delayed-type allergic reactions (including localized or generalized contact dermatitis and granulomatous reactions). Vaccines commonly contain preservatives (e.g. thimerosal, phenoxyethanol, formaldehyde), which may cause delayed-type hypersensitivity reactions (including contact dermatitis and generalized maculopapular rash). BCG, some MMR vaccines and some rotavirus vaccines contain dextran, which may cause immediate reactions (by complement-activating IgG antibodies?) and delayed reactions (e.g. maculopapular exanthema, erythema nodosum, urticarial vasculitis, neutrophilic dermatoses). Approaching a patient with nonsevere nonimmediate allergy to vaccine components: (i) patch tests can help to detect a specific culprit but they usually cannot predict the response to the vaccine; (ii) it is recommended to use vaccines not containing the culprit agent (if not possible, vaccination can usually be performed after evaluating risk vs benefit); (iii) intramuscular administration of aluminum-containing vaccines may prevent the formation of granulomas in aluminum-sensitized patients; (iv) delayed urticarial reactions often result from non-specific mast cell degranulation and do not contraindicate revaccination (premedication with antihistamines from 48 hrs before vaccination can be considered); (v) a previous Arthus reaction is not an absolute contraindication for revaccination.  HYPERLINK "http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table.pdf" http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table.pdf or  HYPERLINK "http://www.vaccinesafety.edu" www.vaccinesafety.edu (information of potential allergens in vaccines). MODERN MANAGEMENT OF PRIMARY T-CELL IMMUNODEFICIENCIES (Pachlopnik Schmid J, Gngr T, Seger R. Pediatr Allergy Immunol 2014; 25: 300 313): Primary immunodeficiencies (PIDs): (i) inherited disorders of the immune system; (ii) prevalence: 1:10,000 subjects; (iii) impact: severe complications (infections, autoimmunity, neoplasms), ! mortality, ! QoL, high costs; (iv) early diagnosis and treatment can be lifesaving; (v) genetic diagnosis is usually important for therapy, prognosis and genetic counseling; (vi) when indicated, definite therapy of severe PIDs (e.g. HSCT) should not be delayed while waiting for genetic diagnosis. Severe combined immunodeficiency (SCID): genetic defects causing complete lack of T-cell development ( other cell lineages) ! lack of cellular and humoral immunity ! early-life severe infections (including opportunistic), fatal course if not treated (HSCT, gene therapy, enzyme replacement therapy). Combined immunodeficiency: genetic defects causing reduced T-cell function ! ! cellular and humoral immunity ! severe infections (including opportunistic), immune dysregulation, usually fatal course if not treated (HSCT, gene therapy, enzyme replacement therapy). RHINITIS AS A RISK FACTOR FOR DEPRESSIVE MOOD IN PREADOLESCENTS: A NEW APPROACH TO THIS RELATIONSHIP (Audino P, La Grutta S, Cibella F, La Grutta S, Melis MR, Bucchieri S, Alfano P, Marcantonio S, Cuttitta G. Pediatr Allergy Immunol 2014; 25: 360 365): Allergic rhinitis (AR): (i) definition: IgE-mediated inflammation of the nasal mucosa; (ii) prevalence: up to 40% of the population; (iii) impact: ! physical, psychological, economical and social well-being, ! school and work productivity, ! QoL, ! risk of asthma and comorbidities. Authors performed a cross-sectional study in 1283 subjects (10 13 yrs old) to evaluate the relationships between allergic respiratory diseases and depressive/anxious mood using the partial directed acyclic graph ! (i) AR increased the likelihood of depression; (ii) anxious condition and low socioeconomic status contributed to depressive mood. Author s commentary: treatment of AR can ! psychologic wellness and ! disease burden. SUCCESSFUL RIFAMPIN DESENSITIZATION IN A PEDIATRIC PATIENT WITH LATENT TUBERCULOSIS (Logsdon S, Ramirez-Avila L, Castells M, Dioun A. Pediatr Allergy Immunol 2014; 25: 404 405): Severe allergic reactions to antituberculosis drugs represent a therapeutic challenge, especially in patients with multidrug-resistant infections [reasons: (i) patients require prompt therapy; (ii) patients need a combination of several drugs; (iii) therapy lasts months to years; (iv) in some cases it is difficult to find alternative drug regimens; (v) diagnostic tests are not standardized] ! drug desensitization should be considered. Author s report a 10-yr-old boy with latent tuberculosis (positive PPD and QuantiFERON test), G6PD deficiency (risk of hemolysis to isoniazid) and hypersensitivity to rifampicin and isoniazid (non-blistering urticarial skin rash responsive to antihistamines) ! allergy testing: negative SPT to rifampin at 2 mg/ml, positive intradermal reaction (wheal=9 mm, flare=15 mm) to rifampin at 0.002 mg/ml (highest non-irritating concentration) ! diagnosis: probable IgE-mediated rifampin hypersensitivity ! successful treatment: 13-step, 390-min, oral desensitization to rifampin (maintenance dose was scheduled to 600 mg in the morning and 300 mg at night to prevent resensitization due to short rifampin half-life [3 hrs]). SYSTEMIC TREATMENT WITH ISOTRETINOIN SUPPRESSES ITRACONAZOLE BLOOD LEVEL IN CHRONIC GRANULOMATOUS DISEASE (von Bernuth H, Wahn V. Pediatr Allergy Immunol 2014; 25: 405 407): Chronic granulomatous disease (CGD): (i) immunodeficiency caused by an inborn defect of the oxygen burst reaction; (ii) clinical features: severe bacterial and fungal infections, granuloma formation, inflammatory manifestations (e.g. colitis, interstitial pneumonitis, nodular pneumonia, neutrophilic dermatosis, granulomatous hepatitis, cystitis); (iii) high early mortality if untreated. Forms of CGD: (i) X-linked CGD (the most frequent): mutations of the CYBB gene encoding for the gp91phox subunit of the NADPH oxidase complex; (ii) autosomal recessive CGD: mutations of the genes that encode for the p22phox, p47phox, p67phox, and p40phox subunits. Treatment of CGD: (i) curative treatment: HSCT, gene therapy; (ii) supportive treatment to prevent infections: antibacterial prophylaxis (e.g. cotrimoxazole), antifungal prophylaxis (e.g. itraconazole), IFN-; (iii) supportive treatment for granulomas and inflammatory manifestations: immunosuppressive agents (corticosteroids, azathioprine, anti-TNF-, thalidomide). Itraconazole therapy: (i) reduces incidence of invasive aspergillosis; (ii) improves long-term outcomes in CGD patients; (iii) drug interactions must be considered (e.g. itraconazole raises levels of calcineurin inhibitors; rifampicin lowers itraconazole levels). Acne vulgaris: (i) common skin disease (~3 9% of the population); (ii) systemic isotretinoin is used for moderate-severe acne, usually for 3 6 months. Authors report the case of a 21-yr-old boy with X-linked CGD and acne vulgaris ! systemic isotretinoin reduced blood itraconazole levels ! Aspergillus disease was aggravated. Author s commentary: (i) systemic isotretinoin treatment may reduce itraconazole levels, thus increasing the risk of fungal disease in CGD patients; (ii) hypothesis: systemic isotretinoin ! induction of cytochrome P450 ! ! itraconazole metabolism ! ! itraconazole levels. THE EDITOR RECOMMENDS THIS ISSUE S ARTICLES TO THE READER (von Bernuth H, Wahn V. Pediatr Allergy Immunol 2014; 25: 299): Hoyos-Bachiloglu et al: ! latitude ! ! sun exposure ! ! vit D levels ! ! IgE-mediated food-induced anaphylaxis. Hovland V et al.: in adolescents with asthma, concomitant allergic rhinitis was associated with ! bronchial responsiveness and airways inflammation. Abelius et al.: allergic children had ! Th2-like chemokine levels (CCL17, CCL18, CCL22), which were influenced by maternal chemokine levels. VERNAL KERATOCONJUNCTIVITIS: A SEVERE ALLERGIC EYE DISEASE WITH REMODELING CHANGES (Vichyanond P, Pacharn P, Pleyer U, Leonardi A. Pediatr Allergy Immunol 2014; 25: 314 322): Vernal keratoconjunctivitis (VKC): (i) severe sight-threatening ocular allergy; (ii) more frequent in warm weather; (iii) usually starts <10 yrs of age; (iv) pathogenesis is not well understood; (v) clinical features: itching, redness, swelling, discharge, photofobia, giant papillae on the upper tarsal conjunctiva (cobblestoning appearance), Horner-Trantas dots (eosinophil collections), corneal damage (ulcers, scars); (vi) therapy: conventional therapy for allergic conjunctivitis is usually insufficient, immunosuppressive therapy is generally required (topical corticosteroids, cyclosporine A, tacrolimus), surgery is reserved for complications.     Juan Carlos Aldave Becerra, MD Allergy and Clinical Immunology Rebagliati Martins National Hospital, Lima-Peru The purpose of this summary is exclusively educational, to provide practical updated knowledge for Allergy/Immunology Physicians. It does not intend to replace the clinical criteria of the physician. PEARLS IN ALLERGY AND IMMUNOLOGY July 2014  But knowledge puffs up while love builds up 1 Corinthians 8:1 July 2014 =============>>> >">6>:>p>v>>>>>>>>? ?ѸѦёѦѦjjjjjjjX"h?(OJPJQJ^JaJmH sH (h<h OJPJQJ^JaJmH sH "hOJPJQJ^JaJmH sH (h<hOJPJQJ^JaJmH sH "hNOJPJQJ^JaJmH sH 1h<h\XjB*OJPJQJ^JaJmH php0sH (h<h\XjOJPJQJ^JaJmH sH 1h<h\XjB* OJPJQJ^JaJmH phsH  ???:?"hOJPJQJ^JaJmH sH "h{bOJPJQJ^JaJmH sH 1h<h<B*OJPJQJ^JaJmH php0sH +h<B*OJPJQJ^JaJmH php0sH 1h<h<B* OJPJQJ^JaJmH phsH (h<h<OJPJQJ^JaJmH sH (h h<OJPJQJ^JaJmH sH "h<OJPJQJ^JaJmH sH 1hhh<B* OJPJQJ^JaJmH phsH BBBBBCCCCC&C(C0CDCnC­mR9m9'"hhOJPJQJ^JaJmH sH 1hhhhB* OJPJQJ^JaJmH phsH 4hhh 6B* OJPJQJ^JaJmH phsH 1hhh B* OJPJQJ^JaJmH phsH "h<OJPJQJ^JaJmH sH (h{bhOJPJQJ^JaJmH sH (h{bh{bOJPJQJ^JaJmH sH "h{bOJPJQJ^JaJmH sH "hOJPJQJ^JaJmH sH 1hhB* OJPJQJ^JaJmH phsH nCCCCCDDD:EEԿy`G.1hS|hS|B*OJPJQJ^JaJmH php0sH 1hS|hoB*OJPJQJ^JaJmH php0sH 1hS|hB*OJPJQJ^JaJmH php0sH 4hS|ho5B*OJPJQJ^JaJmH php0sH +hS|ho5OJPJQJ^JaJmH sH (hh OJPJQJ^JaJmH sH (h{bhhOJPJQJ^JaJmH sH "hhOJPJQJ^JaJmH sH 1hhhhB* OJPJQJ^JaJmH ph `sH  EEFFF F$F(F*F,F.FvFFFкССЋv]D/(hChCOJPJQJ^JaJmH sH 1hLYhCB* OJPJQJ^JaJmH phsH 1hLYhS|B* OJPJQJ^JaJmH phsH (hS|hOJPJQJ^JaJmH sH +hS|h5OJPJQJ^JaJmH sH 1hS|hoB*OJPJQJ^JaJmH php0sH +h~B*OJPJQJ^JaJmH php0sH 1hS|hB*OJPJQJ^JaJmH php0sH +hS|B*OJPJQJ^JaJmH php0sH  FFFG G&G(GGGGGGGGGGH:HOXOOOѸџџqџ\G\G\2(h~!#h:^OJPJQJ^JaJmH sH (hAhS|OJPJQJ^JaJmH sH (hAh~!#OJPJQJ^JaJmH sH 1hk(h~!#B*OJPJQJ^JaJmH php0sH (h1Th~!#OJPJQJ^JaJmH sH 1hk(h~!#B* OJPJQJ^JaJmH ph `sH 1h~!#h~!#B*OJPJQJ^JaJmH php0sH (h~!#h~!#OJPJQJ^JaJmH sH 1h~!#h~!#B* OJPJQJ^JaJmH phsH OOOOOOOOOO2P6P>P@PLPPPʹ柆p^I^p3p+h1TB*OJPJQJ^JaJmH php0sH (h+yhS|OJPJQJ^JaJmH sH "h+yOJPJQJ^JaJmH sH +h+yB*OJPJQJ^JaJmH php0sH 1h+yh+yB*OJPJQJ^JaJmH php0sH (h+yh:^OJPJQJ^JaJmH sH 1h+yh:^B* OJPJQJ^JaJmH phsH 1h+yhS|B* OJPJQJ^JaJmH phsH 1h+yh+yB* OJPJQJ^JaJmH phsH PPRPTPdPfPPPPPPPPPPPPPDzDzǝLJrYCYr+h+yB*OJPJQJ^JaJmH php0sH 1h+yhk(B*OJPJQJ^JaJmH php0sH (h+yhk(OJPJQJ^JaJmH sH +h+yhs 6OJPJQJ^JaJmH sH (h+yh1TOJPJQJ^JaJmH sH (h+yhs OJPJQJ^JaJmH sH (h+yhS|OJPJQJ^JaJmH sH "h+yOJPJQJ^JaJmH sH "h1TOJPJQJ^JaJmH sH PPQ&Q(Q0Q4QQQQQQQR R͸xcccN9(h+yhOJPJQJ^JaJmH sH (h1Th+yOJPJQJ^JaJmH sH (h+yh+yOJPJQJ^JaJmH sH 1h+yh+yB*OJPJQJ^JaJmH php0sH "h+yOJPJQJ^JaJmH sH (h+yhs OJPJQJ^JaJmH sH (h+yhS|OJPJQJ^JaJmH sH 1h+yhS|B* OJPJQJ^JaJmH ph `sH 1h+yh+yB* OJPJQJ^JaJmH ph `sH  RRR4S8SzS|SSSSSSSεtY>%1hLAh7OB* OJPJQJ^JaJmH phsH 4hLAhs 6B* OJPJQJ^JaJmH phsH 4hLAh#\6B* OJPJQJ^JaJmH phsH (hs hs OJPJQJ^JaJmH sH +h~B*OJPJQJ^JaJmH php0sH +hs B*OJPJQJ^JaJmH php0sH 1hs hs B*OJPJQJ^JaJmH php0sH 4hs hs 5B*OJPJQJ^JaJmH php0sH +hs hs 5OJPJQJ^JaJmH sH  SSSTT4T>TRTTTVTԿ}dK21h5h7OB* OJPJQJ^JaJmH phsH 1h5h5B* OJPJQJ^JaJmH phsH 1h5hp~B* OJPJQJ^JaJmH phsH 4hLAhs 6B* OJPJQJ^JaJmH phsH (hLAh7OOJPJQJ^JaJmH sH "h7OOJPJQJ^JaJmH sH (h7Ohs OJPJQJ^JaJmH sH "hLAOJPJQJ^JaJmH sH 1hLAhLAB* OJPJQJ^JaJmH phsH  VT`T~TTTTTT,U.UPURU^U`UjUtUzUUUUUUU VVV4VV@VFVʹʹucNNcNcuNucuNNcN(h5h5OJPJQJ^JaJmH sH "h5OJPJQJ^JaJmH sH (h5hp6OJPJQJ^JaJmH sH (h5hs OJPJQJ^JaJmH sH (h5h7OOJPJQJ^JaJmH sH 1h5h7OB*OJPJQJ^JaJmH php0sH 1h5hs B*OJPJQJ^JaJmH php0sH 1h5h5B*OJPJQJ^JaJmH php0sH FV`V~VVVVVVWW W.W>WRWTW^WWWWѿѿѿрkkR=R(hVhs OJPJQJ^JaJmH sH 1hp6hs B* OJPJQJ^JaJmH phsH (hp6hs OJPJQJ^JaJmH sH (hp6hp~OJPJQJ^JaJmH sH (hS&h5OJPJQJ^JaJmH sH (hLAh5OJPJQJ^JaJmH sH "h5OJPJQJ^JaJmH sH (h5h5OJPJQJ^JaJmH sH 1h5h5B* OJPJQJ^JaJmH ph `sH WWWWWWW XXX X$X͸kR@+@(hp6hp6OJPJQJ^JaJmH sH "hp6OJPJQJ^JaJmH sH 1h hs B*OJPJQJ^JaJmH php0sH 1h hS&B*OJPJQJ^JaJmH php0sH 4h hS&6B*OJPJQJ^JaJmH php0sH 1hp6hs B* OJPJQJ^JaJmH ph `sH (hp6hs OJPJQJ^JaJmH sH 1hp6hs B* OJPJQJ^JaJmH phsH 1hp6hp~B* OJPJQJ^JaJmH phsH  $X.X2XbX~XXXXXXXXY Y Y"Y`YdYYYYYٯsZsZssA1h5h5B* OJPJQJ^JaJmH phsH 1h^R^`^b^f^n^p^t^^^뽤뽤vddR@R"h8yOJPJQJ^JaJmH sH "hmDmNmPmXmbmpmrmtmmmmmmmmmѼѼѣxfxQ<(h3(ph3(pOJPJQJ^JaJmH sH (h^oh% UOJPJQJ^JaJmH sH "h3(pOJPJQJ^JaJmH sH 1h3(ph% UB* OJPJQJ^JaJmH ph `sH "h% UOJPJQJ^JaJmH sH 1h3(ph#\B* OJPJQJ^JaJmH ph `sH (h% Uh#\OJPJQJ^JaJmH sH (h% Uh% UOJPJQJ^JaJmH sH 1h3(ph% UB* OJPJQJ^JaJmH phsH mm"n*n,nHnZnhn~nnnnnnnnno o$o>o뤋vaHa6"h3(pOJPJQJ^JaJmH sH 1hUr^h3(pB* OJPJQJ^JaJmH phsH (h3(ph3(pOJPJQJ^JaJmH sH (h^oh3(pOJPJQJ^JaJmH sH 1hUr^h#\B* OJPJQJ^JaJmH ph `sH 1hUr^h3(pB* OJPJQJ^JaJmH ph `sH (h3(phAOJPJQJ^JaJmH sH 1hUr^h#\B* OJPJQJ^JaJmH phsH (h3(ph#\OJPJQJ^JaJmH sH >o@oBoooooooo pnppppppppv]vK9K"h^oOJPJQJ^JaJmH sH "hAOJPJQJ^JaJmH sH 1hUr^hAB* OJPJQJ^JaJmH ph `sH 1hUr^h#\B* OJPJQJ^JaJmH ph `sH 1hUr^h#\B* OJPJQJ^JaJmH phsH 1hUr^h3(pB* OJPJQJ^JaJmH phsH (hAh#\OJPJQJ^JaJmH sH (hAhAOJPJQJ^JaJmH sH (h3(phAOJPJQJ^JaJmH sH ppppppp"q$q&q(q6q8qVq^qpqqqr4rxrzrr͸͸xx_M;x"h" OJPJQJ^JaJmH sH "hAOJPJQJ^JaJmH sH 1hUr^h#\B* OJPJQJ^JaJmH ph `sH "hUr^OJPJQJ^JaJmH sH (hAhAOJPJQJ^JaJmH sH 1hUr^hUr^B* OJPJQJ^JaJmH phsH (hAh#\OJPJQJ^JaJmH sH 1hUr^h#\B* OJPJQJ^JaJmH phsH 1hUr^hAB* OJPJQJ^JaJmH phsH rrrrrrrrrrJsLsu\uF1(hAh#\OJPJQJ^JaJmH sH +hUr^B* OJPJQJ^JaJmH phsH 1hUr^hAB* OJPJQJ^JaJmH phsH 1hUr^h#\B* OJPJQJ^JaJmH phsH 1h" h#\B* OJPJQJ^JaJmH phsH 1h" hAB* OJPJQJ^JaJmH phsH 1h" h" B* OJPJQJ^JaJmH phsH "h" OJPJQJ^JaJmH sH (hAhAOJPJQJ^JaJmH sH  LsRshsjslsssssss8t@tBtDtHtzttʵʣq\Cܣq.(hAh#\OJPJQJ^JaJmH sH 1h" hAB* OJPJQJ^JaJmH ph `sH (h#\h#\OJPJQJ^JaJmH sH 1h" hAB* OJPJQJ^JaJmH phsH 1h" h#\B* OJPJQJ^JaJmH phsH "hAOJPJQJ^JaJmH sH (hAhAOJPJQJ^JaJmH sH "h OJPJQJ^JaJmH sH "h" OJPJQJ^JaJmH sH "hOJPJQJ^JaJmH sH qsDtt|vyHzJzzp|~j~~~$ & F SSW^S`Wa$gd"$ & F SSW^S`Wa$gd-|$ & F V^`Va$gd" SgdVVgd*B* CJOJPJQJ^JaJmH phsH 5hVV5>*B* CJOJPJQJ^JaJmH phsH +h*B* CJOJPJQJ^JaJmH phsH ||||||||}}*}.}0}8}з枌w^E/E+hmB* OJPJQJ^JaJmH ph `sH 1h"h"B* OJPJQJ^JaJmH ph `sH 1h"h-|B* OJPJQJ^JaJmH ph `sH (h-|h-|OJPJQJ^JaJmH sH "h"OJPJQJ^JaJmH sH 1h"h-|B*OJPJQJ^JaJmH php0sH 1h"h"B* OJPJQJ^JaJmH phsH +hmB* OJPJQJ^JaJmH phsH 1h"h-|B* OJPJQJ^JaJmH phsH  8}<}D}J}V}z}}}}}}}} ~>~J~d~n~ҽҽygUgUC"hqOJPJQJ^JaJmH sH "h1 OJPJQJ^JaJmH sH "hHOJPJQJ^JaJmH sH 1h"h-|B* OJPJQJ^JaJmH ph `sH 1h"h"B* OJPJQJ^JaJmH ph `sH "h"OJPJQJ^JaJmH sH (h-|h-|OJPJQJ^JaJmH sH 1h"h-|B*OJPJQJ^JaJmH php0sH (h1 h-|OJPJQJ^JaJmH sH n~~~~~~~ $&246DFbfj@DzrrrrrrrrrrZr.h"h"56OJPJQJ^JaJmH sH (h?h"OJPJQJ^JaJmH sH "h"OJPJQJ^JaJmH sH 1h"h"B* OJPJQJ^JaJmH phsH (h-|h-|OJPJQJ^JaJmH sH "h1 OJPJQJ^JaJmH sH "hHOJPJQJ^JaJmH sH (h?h1 OJPJQJ^JaJmH sH @Lz|Jj~ "(FNӖӯӄӄӄkRk991h"h"B*OJPJQJ^JaJmH php0sH 1h"h-|B* OJPJQJ^JaJmH phsH 1h"h"B* OJPJQJ^JaJmH phsH "h1 OJPJQJ^JaJmH sH 1h"h"B* OJPJQJ^JaJmH phsH "h"OJPJQJ^JaJmH sH "h"OJPJQJ^JaJmH sH (h?h"OJPJQJ^JaJmH sH .h h"56OJPJQJ^JaJmH sH N^hl "$@êÕgNg51hqh1 B* OJPJQJ^JaJmH phsH 1hqhqB* OJPJQJ^JaJmH phsH 1hqh?B* OJPJQJ^JaJmH phsH (h-|h-|OJPJQJ^JaJmH sH (h1h1 OJPJQJ^JaJmH sH 1hqh1 B*OJPJQJ^JaJmH php0sH "h1 OJPJQJ^JaJmH sH 1h"h"B*OJPJQJ^JaJmH php0sH "h"OJPJQJ^JaJmH sH  @BHJN^`nȃ܃2X\dpҽvvdRdvdRRd9d1hqhqB*OJPJQJ^JaJmH php0sH "hB!OJPJQJ^JaJmH sH "hqOJPJQJ^JaJmH sH (hqh-|OJPJQJ^JaJmH sH 1hqh-|B* OJPJQJ^JaJmH ph `sH 1hqhqB* OJPJQJ^JaJmH ph `sH (hqh?OJPJQJ^JaJmH sH 1hqh1 B*OJPJQJ^JaJmH php0sH (hqh1 OJPJQJ^JaJmH sH pƄ&:<PTZ\tv뤒}}}hS:1h1 h-|B* OJPJQJ^JaJmH ph `sH (h?h?OJPJQJ^JaJmH sH (h?h-|OJPJQJ^JaJmH sH (h?h1 OJPJQJ^JaJmH sH "h1 OJPJQJ^JaJmH sH 1h1 h-|B* OJPJQJ^JaJmH phsH (h1hqOJPJQJ^JaJmH sH 1hqhqB* OJPJQJ^JaJmH ph `sH (hqhqOJPJQJ^JaJmH sH <ƍȒ u^$ & F SSW^S`Wa$gdl$ & F V^`Va$gdkf$ & F SSW^S`Wa$gdh$ & F SSW^S`Wa$gdkf$ & F V^`Va$gd?$ & F SSW^S`Wa$gd-|$ & F SSW^S`Wa$gdq*,.<\^pȆʆԆ؆HJîîÃn\J3,h?h?5B*OJPJQJ^JaJphp0#h?h?5OJPJQJ^JaJ"h?OJPJQJ^JaJmH sH (h1h1 OJPJQJ^JaJmH sH +h1 h1 H*OJPJQJ^JaJmH sH (h?h?OJPJQJ^JaJmH sH (h?h-|OJPJQJ^JaJmH sH "h1 OJPJQJ^JaJmH sH 1hqh-|B* OJPJQJ^JaJmH ph `sH "hqOJPJQJ^JaJmH sH J\blr~XZ`bˆ ƵnUnU:U4h$!hkfB* H*OJPJQJ^JaJmH ph `sH 1h$!hkfB* OJPJQJ^JaJmH ph `sH 1h$!hkfB*OJPJQJ^JaJmH php0sH (h$!hkfOJPJQJ^JaJmH sH 1h$!hkfB* OJPJQJ^JaJmH phsH  h?h?OJPJQJ^JaJ#h?h?5OJPJQJ^JaJ#h?B*OJPJQJ^JaJphp0)h?h?B*OJPJQJ^JaJphp0 RVz؊BFbʋ2ʌ̌čƍֽֽֽֽֽ֤vdֽN+h$!B*OJPJQJ^JaJmH php0sH "h$!OJPJQJ^JaJmH sH (h$!h$!OJPJQJ^JaJmH sH 1h$!h$!B*OJPJQJ^JaJmH php0sH 1h$!hkfB* OJPJQJ^JaJmH ph `sH 1h$!hkfB*OJPJQJ^JaJmH php0sH (h$!hkfOJPJQJ^JaJmH sH (h$!h5]OJPJQJ^JaJmH sH ƍ(<NTVj&:FHX̏ҏڏ܏,.0jljj1hB!hhqB*OJPJQJ^JaJmH php0sH "hqOJPJQJ^JaJmH sH +h1B* OJPJQJ^JaJmH phsH (hB!hhqOJPJQJ^JaJmH sH "hB!OJPJQJ^JaJmH sH 1hB!hhqB* OJPJQJ^JaJmH phsH (hG hhqOJPJQJ^JaJmH sH #lDTx‘đFHJlĒƒDzDzDzٲLJrY@r1hB!hhqB* OJPJQJ^JaJmH ph `sH 1hB!hhqB*OJPJQJ^JaJmH php0sH (hG hhqOJPJQJ^JaJmH sH 1hB!hhqB* OJPJQJ^JaJmH phsH "h4OJPJQJ^JaJmH sH (hG hB!OJPJQJ^JaJmH sH "hB!OJPJQJ^JaJmH sH "hqOJPJQJ^JaJmH sH (hG hG OJPJQJ^JaJmH sH ƒȒ:ҹucN51hc?hhB* OJPJQJ^JaJmH ph `sH (h$!hhOJPJQJ^JaJmH sH "hB!OJPJQJ^JaJmH sH +h$!h$!H*OJPJQJ^JaJmH sH 1hB!h$!B*OJPJQJ^JaJmH php0sH (h$!h$!OJPJQJ^JaJmH sH 1hB!h$!B* OJPJQJ^JaJmH phsH 1hB!hB!B* OJPJQJ^JaJmH phsH (hG hhOJPJQJ^JaJmH sH  :<BXȓړ͸{i{i{iPi;(h$!hhOJPJQJ^JaJmH sH 1hc?hqB* OJPJQJ^JaJmH ph `sH "hqOJPJQJ^JaJmH sH "hB!OJPJQJ^JaJmH sH 1hB!h$!B*OJPJQJ^JaJmH php0sH "hc?OJPJQJ^JaJmH sH (h$!h$!OJPJQJ^JaJmH sH 1hc?hhB* OJPJQJ^JaJmH ph `sH 1hc?h$!B* OJPJQJ^JaJmH ph `sH  (tv|~εpZE,1hqh7%B* OJPJQJ^JaJmH phsH (hkfhhOJPJQJ^JaJmH sH +hkfhh5OJPJQJ^JaJmH sH +hlB*OJPJQJ^JaJmH php0sH +hkfB*OJPJQJ^JaJmH php0sH 1hkfhkfB*OJPJQJ^JaJmH php0sH 1hkfhhB*OJPJQJ^JaJmH php0sH 4hkfhkf5B*OJPJQJ^JaJmH php0sH +hkfhkf5OJPJQJ^JaJmH sH ؕڕ66JtvgNҀҫ1hqh LNB*OJPJQJ^JaJmH php0sH 1h LNh LNB*OJPJQJ^JaJmH php0sH +h LNB*OJPJQJ^JaJmH php0sH (hqhqOJPJQJ^JaJmH sH (hqhlOJPJQJ^JaJmH sH "h LNOJPJQJ^JaJmH sH 1hqhqB*OJPJQJ^JaJmH php0sH (hqh7%OJPJQJ^JaJmH sH vܗޗ DFHԘ֘  &(IJٲٲIJjUCj"ht?OJPJQJ^JaJmH sH (hqhlOJPJQJ^JaJmH sH 1h LNh LNB*OJPJQJ^JaJmH php0sH +h LNB*OJPJQJ^JaJmH php0sH 1h LNhqB*OJPJQJ^JaJmH php0sH "hqOJPJQJ^JaJmH sH (hqhqOJPJQJ^JaJmH sH "h LNOJPJQJ^JaJmH sH (hT}{h LNOJPJQJ^JaJmH sH (*0@HLN`rvz|ΙЙʹ͛tt[E[t0(hqh7%OJPJQJ^JaJmH sH +h LNB*OJPJQJ^JaJmH php0sH 1h LNh LNB*OJPJQJ^JaJmH php0sH "h LNOJPJQJ^JaJmH sH (hqhlOJPJQJ^JaJmH sH 1h LNhlB* OJPJQJ^JaJmH ph `sH 1hmh LNB* OJPJQJ^JaJmH ph `sH 1hmhlB* OJPJQJ^JaJmH ph `sH 1hmhqB* OJPJQJ^JaJmH ph `sH Й>@\^b Z\l֬lS:1hmhlB* OJPJQJ^JaJmH phsH 1hmh7%B* OJPJQJ^JaJmH phsH (hmh7%OJPJQJ^JaJmH sH 1hmhmB*OJPJQJ^JaJmH php0sH "hmOJPJQJ^JaJmH sH (h LNhlOJPJQJ^JaJmH sH (hqh7%OJPJQJ^JaJmH sH (hqhlOJPJQJ^JaJmH sH (hqht?OJPJQJ^JaJmH sH  lrt~ƛțʛ,.02\Ѽ掼uccJ5(hmhT}{OJPJQJ^JaJmH sH 1hmhT}{B*OJPJQJ^JaJmH php0sH "hmOJPJQJ^JaJmH sH 1hmhmB* OJPJQJ^JaJmH ph `sH (hmhmOJPJQJ^JaJmH sH 1hmh7%B* OJPJQJ^JaJmH phsH (hmh7%OJPJQJ^JaJmH sH (hmhlOJPJQJ^JaJmH sH 1hmhmB* OJPJQJ^JaJmH phsH ĝƝН JL\^`Ѹq_M4M1hmhmB* OJPJQJ^JaJmH phsH "hmOJPJQJ^JaJmH sH "hrOJPJQJ^JaJmH sH 1h( {h7%B*OJPJQJ^JaJmH php0sH (hmh7%OJPJQJ^JaJmH sH 1hmh7%B*OJPJQJ^JaJmH php0sH 1hmhT}{B*OJPJQJ^JaJmH php0sH (hmhT}{OJPJQJ^JaJmH sH 1hmhT}{B* OJPJQJ^JaJmH phsH  `| lnpԿgN51hHhHB*OJPJQJ^JaJmH php0sH 1hHhlB*OJPJQJ^JaJmH php0sH 4hHhl5B*OJPJQJ^JaJmH php0sH +hHhH5OJPJQJ^JaJmH sH "hrOJPJQJ^JaJmH sH (hmhT}{OJPJQJ^JaJmH sH (hmhlOJPJQJ^JaJmH sH "hmOJPJQJ^JaJmH sH 1hmhmB*OJPJQJ^JaJmH php0sH   b6Puu^^^$ & F SSW^S`Wa$gdH$ & F SSW^S`Wa$gdX$ & F SSW^S`Wa$gd*$ & F SSW^S`Wa$gdr+$ & F SSW^S`Wa$gdg$ & F V^`Va$gdH$ & F SSW^S`Wa$gdm TX\^`brv|кsZE,EZ1hghgB* OJPJQJ^JaJmH ph `sH (hghgOJPJQJ^JaJmH sH 1hghgB*OJPJQJ^JaJmH php0sH 1hghgB* OJPJQJ^JaJmH phsH 1hghHB* OJPJQJ^JaJmH phsH (hHhlOJPJQJ^JaJmH sH +hHhl5OJPJQJ^JaJmH sH 1hHhlB*OJPJQJ^JaJmH php0sH +hHB*OJPJQJ^JaJmH php0sH Tzء$Fh빤rgNr51hHghgB* OJPJQJ^JaJmH ph `sH 1h#jhgB* OJPJQJ^JaJmH ph `sH hghgmH sH 1hghgB*OJPJQJ^JaJmH php0sH 1hghgB*OJPJQJ^JaJmH phsH (hgh(9OJPJQJ^JaJmH sH 1hgh(9B*OJPJQJ^JaJmH phsH 1hghHB* OJPJQJ^JaJmH ph `sH (hghHOJPJQJ^JaJmH sH hz~¢΢68:dnv׾wewץP7PePeP1hghHB*OJPJQJ^JaJmH php0sH (hghHOJPJQJ^JaJmH sH "h#jOJPJQJ^JaJmH sH (hghgOJPJQJ^JaJmH sH 1hghgB* OJPJQJ^JaJmH phsH 1hghHB* OJPJQJ^JaJmH phsH 1hghHB*OJPJQJ^JaJmH phsH "hgOJPJQJ^JaJmH sH +hgB*OJPJQJ^JaJmH phsH (,T`prȥܥ@FdhٮoYG5G5"hr+OJPJQJ^JaJmH sH "h8cOJPJQJ^JaJmH sH +h#jB*OJPJQJ^JaJmH php0sH (hBhHOJPJQJ^JaJmH sH (hBh OJPJQJ^JaJmH sH (h h OJPJQJ^JaJmH sH "h#jOJPJQJ^JaJmH sH 1hghHB*OJPJQJ^JaJmH php0sH (hghHOJPJQJ^JaJmH sH "h OJPJQJ^JaJmH sH hnƧ,<DJt֯hOO=h=O"h*OJPJQJ^JaJmH sH 1h1h*B* OJPJQJ^JaJmH ph `sH 1h1h*B*OJPJQJ^JaJmH php0sH (h1h*OJPJQJ^JaJmH sH 1h1h*B* OJPJQJ^JaJmH phsH "hr+OJPJQJ^JaJmH sH (hBh1OJPJQJ^JaJmH sH (hBhr+OJPJQJ^JaJmH sH (hr+hr+OJPJQJ^JaJmH sH  $H^fP\46зОзЅlSlSllSl:1h8hHB* OJPJQJ^JaJmH phsH 1h hXB* OJPJQJ^JaJmH ph `sH 1h#jhXB*OJPJQJ^JaJmH phsH 1h hXB* OJPJQJ^JaJmH phsH 1hghXB*OJPJQJ^JaJmH phsH 1hghXB*OJPJQJ^JaJmH php0sH +hXB*OJPJQJ^JaJmH phsH 1hghXB* OJPJQJ^JaJmH phsH $&LNPȭʭ&Nê|jQj|ٕ81h#jhHB* OJPJQJ^JaJmH ph `sH 1hFhHB* OJPJQJ^JaJmH ph `sH "h#jOJPJQJ^JaJmH sH 1h#jh#jB*OJPJQJ^JaJmH php0sH (hFhHOJPJQJ^JaJmH sH 1hFhHB* OJPJQJ^JaJmH phsH +hHB*OJPJQJ^JaJmH phsH "hHOJPJQJ^JaJmH sH (h8hHOJPJQJ^JaJmH sH NPR\ʮ 26@B\­­˜˜jQ?-"h OJPJQJ^JaJmH sH "h#jOJPJQJ^JaJmH sH 1h#jh#jB*OJPJQJ^JaJmH php0sH (h#jhHOJPJQJ^JaJmH sH 1h#jhHB* OJPJQJ^JaJmH ph `sH (hFhHOJPJQJ^JaJmH sH (hUUhHOJPJQJ^JaJmH sH "hHOJPJQJ^JaJmH sH (h8hHOJPJQJ^JaJmH sH +hHB*OJPJQJ^JaJmH php0sH \`b(*02jʱiP:!1hA_hHB* OJPJQJ^JaJmH ph `sH +hHB*OJPJQJ^JaJmH phsH 1h8hHB*OJPJQJ^JaJmH php0sH 1hNThHB*OJPJQJ^JaJmH phsH 1hNThHB* OJPJQJ^JaJmH phsH +hHB* OJPJQJ^JaJmH phsH 1hghHB*OJPJQJ^JaJmH phsH "hHOJPJQJ^JaJmH sH "h OJPJQJ^JaJmH sH "hHgOJPJQJ^JaJmH sH  jln TX`ʲ$4TV^׬zhדO9+h1B*OJPJQJ^JaJmH phsH 1hA_hHB* OJPJQJ^JaJmH ph `sH "h1OJPJQJ^JaJmH sH 1h8hHB* OJPJQJ^JaJmH ph `sH 1h8hHB*OJPJQJ^JaJmH php0sH +hHB*OJPJQJ^JaJmH phsH (h!hHOJPJQJ^JaJmH sH "hHOJPJQJ^JaJmH sH +hHB* OJPJQJ^JaJmH ph `sH ^.0:Ph´ƴȴкw^H6"h*OJPJQJ^JaJmH sH +h*B*OJPJQJ^JaJmH phsH 1hA_hHB* OJPJQJ^JaJmH ph `sH (h?%hHOJPJQJ^JaJmH sH %hH6OJPJQJ^JaJmH sH 4h-.hH6B*OJPJQJ^JaJmH phsH +hHB*OJPJQJ^JaJmH phsH +h1B*OJPJQJ^JaJmH phsH 1h1h1B* OJPJQJ^JaJmH ph `sH  ȴ6`dl,b.6Zh*8b¸êÑêxÑ_êÑêÑêFF1h{hHB* OJPJQJ^JaJmH ph `sH 1hhHB*OJPJQJ^JaJmH phsH 1hBnhHB*OJPJQJ^JaJmH phsH 1hA_hHB* OJPJQJ^JaJmH ph `sH 1h8hHB*OJPJQJ^JaJmH php0sH +hHB*OJPJQJ^JaJmH phsH "h*OJPJQJ^JaJmH sH (h#jh*OJPJQJ^JaJmH sH n Xܺdrֻ鞅lZAZAZ1h~(hHB* OJPJQJ^JaJmH ph `sH "hHOJPJQJ^JaJmH sH 1hVHhHB*OJPJQJ^JaJmH php0sH 1hhHB* OJPJQJ^JaJmH ph `sH 1hshhHB*OJPJQJ^JaJmH phsH 1h8hHB*OJPJQJ^JaJmH php0sH 1hDhHB*OJPJQJ^JaJmH phsH +hHB*OJPJQJ^JaJmH phsH ȼʼ`j|$FHhҾ pШо~~~eeO+hHB* OJPJQJ^JaJmH ph `sH 1hVHhHB* OJPJQJ^JaJmH ph `sH (h~(hHOJPJQJ^JaJmH sH (hNhHOJPJQJ^JaJmH sH +hHB*OJPJQJ^JaJmH php0sH "hHOJPJQJ^JaJmH sH 1hVHhHB*OJPJQJ^JaJmH php0sH +hHB* OJPJQJ^JaJmH phsH vz&jV4$ & F SSW^S`Wa$gd9#W$ & F SSW^S`Wa$gd*$ & F SSW^S`Wa$gdHpv46N,ռռգxxbxxI01h{hHB* OJPJQJ^JaJmH phsH 1hNThHB*OJPJQJ^JaJmH phsH +hZ'hH6OJPJQJ^JaJmH sH "hHOJPJQJ^JaJmH sH 1h^hHB* OJPJQJ^JaJmH ph `sH 1h[#hHB*OJPJQJ^JaJmH php0sH 1h-.hHB* OJPJQJ^JaJmH phsH +hHB* OJPJQJ^JaJmH phsH (h1hHOJPJQJ^JaJmH sH ,.46J$&V$*4Rr枈sasaHsa1he(rhe(rB*OJPJQJ^JaJmH php0sH "he(rOJPJQJ^JaJmH sH (he(rhe(rOJPJQJ^JaJmH sH +he(rB*OJPJQJ^JaJmH phsH +hHB*OJPJQJ^JaJmH phsH 1h hHB* OJPJQJ^JaJmH ph `sH 1h[#hHB*OJPJQJ^JaJmH php0sH 1h{hHB*OJPJQJ^JaJmH phsH FLRT~&(RҒ|cJ11h[#hHB*OJPJQJ^JaJmH php0sH 1h{hHB* OJPJQJ^JaJmH ph `sH 1h6MhHB* OJPJQJ^JaJmH phsH +hHB*OJPJQJ^JaJmH phsH (h he(rOJPJQJ^JaJmH sH 1he(rhe(rB*OJPJQJ^JaJmH php0sH "he(rOJPJQJ^JaJmH sH 1h he(rB* OJPJQJ^JaJmH ph `sH (he(rhe(rOJPJQJ^JaJmH sH RT:<LP,6DJ"©zdzK1h92hHB* OJPJQJ^JaJmH phsH +hhhH6OJPJQJ^JaJmH sH 1h[#hHB*OJPJQJ^JaJmH php0sH +hHB*OJPJQJ^JaJmH phsH 1h{hHB*OJPJQJ^JaJmH phsH "hHOJPJQJ^JaJmH sH (h6MhHOJPJQJ^JaJmH sH +hHB* OJPJQJ^JaJmH ph `sH "<^pJ\Bb0кoooV=1hnAhHB*OJPJQJ^JaJmH php0sH 1hhHB* OJPJQJ^JaJmH phsH 1h{hHB*OJPJQJ^JaJmH phsH 1h hHB*OJPJQJ^JaJmH php0sH 1h[#hHB*OJPJQJ^JaJmH php0sH +hHB*OJPJQJ^JaJmH phsH 1h92hHB* OJPJQJ^JaJmH phsH +hHB* OJPJQJ^JaJmH phsH 0BDFNTVt&zзЅoVoo=o1hhHB* OJPJQJ^JaJmH phsH 1hnAhHB*OJPJQJ^JaJmH php0sH +hHB*OJPJQJ^JaJmH phsH 1hnAhHB* OJPJQJ^JaJmH ph `sH 1h"hHB* OJPJQJ^JaJmH ph `sH 1h>hHB*OJPJQJ^JaJmH phsH +hHB* OJPJQJ^JaJmH ph `sH 1hhhHB* OJPJQJ^JaJmH ph `sH .Thnp.4NТsZsD/(h*h*OJPJQJ^JaJmH sH +h*B*OJPJQJ^JaJmH phsH 1h*nhHB* OJPJQJ^JaJmH ph `sH 1h*nhHB*OJPJQJ^JaJmH phsH +hHB* OJPJQJ^JaJmH phsH 1h*nhHB* OJPJQJ^JaJmH phsH (hevhHOJPJQJ^JaJmH sH +hHB*OJPJQJ^JaJmH phsH 1hNhHB*OJPJQJ^JaJmH php0sH Np 8`jl8:"yyyyy`1h*nhHB* OJPJQJ^JaJmH phsH (h*hHOJPJQJ^JaJmH sH 1h*hHB* OJPJQJ^JaJmH ph `sH 1h*hHB*OJPJQJ^JaJmH php0sH 1h*hHB*OJPJQJ^JaJmH phsH (h*h*OJPJQJ^JaJmH sH "h*OJPJQJ^JaJmH sH "8hZlRr麡oooVA(hnAhHOJPJQJ^JaJmH sH 1h-`hHB* OJPJQJ^JaJmH phsH 1h{hHB*OJPJQJ^JaJmH phsH 1h hHB*OJPJQJ^JaJmH php0sH 1hp[hHB*OJPJQJ^JaJmH php0sH +hHB*OJPJQJ^JaJmH phsH 1h*nhHB* OJPJQJ^JaJmH phsH +hHB* OJPJQJ^JaJmH phsH  @BDզՑ|cJ4+hHB*OJPJQJ^JaJmH phsH 1hshhHB*OJPJQJ^JaJmH phsH 1hhhHB* OJPJQJ^JaJmH phsH (hnAhHOJPJQJ^JaJmH sH (h hHOJPJQJ^JaJmH sH +hHB* OJPJQJ^JaJmH ph `sH 1h hHB* OJPJQJ^JaJmH phsH 1h-`hHB* OJPJQJ^JaJmH ph `sH "hHOJPJQJ^JaJmH sH  bfh(|к溈rY@1hWhHB*OJPJQJ^JaJmH php0sH 1hhHB* OJPJQJ^JaJmH phsH +hHB* OJPJQJ^JaJmH phsH 1hhhHB* OJPJQJ^JaJmH ph `sH 1hshhHB*OJPJQJ^JaJmH phsH +hHB*OJPJQJ^JaJmH phsH +h9#WB*OJPJQJ^JaJmH phsH 1h9#Wh9#WB*OJPJQJ^JaJmH php0sH |  Hpj|bзОЅoV==1h{hHB*OJPJQJ^JaJmH phsH 1hnhHB*OJPJQJ^JaJmH php0sH +hHB* OJPJQJ^JaJmH phsH 1h92hHB* OJPJQJ^JaJmH phsH 1hshhHB*OJPJQJ^JaJmH phsH 1hhhHB*OJPJQJ^JaJmH phsH +hHB*OJPJQJ^JaJmH phsH 1hWhHB*OJPJQJ^JaJmH php0sH  "68P^hz:RXʹ͞lWB0B"h9#WOJPJQJ^JaJmH sH (h)khHOJPJQJ^JaJmH sH (h9#WhHOJPJQJ^JaJmH sH 1h`hHB* OJPJQJ^JaJmH ph `sH 1h9#Wh9#WB* OJPJQJ^JaJmH ph `sH +h9#WB*OJPJQJ^JaJmH phsH 1h9#Wh9#WB*OJPJQJ^JaJmH php0sH 1h`hHB*OJPJQJ^JaJmH phsH 1h`hHB* OJPJQJ^JaJmH phsH X"46`&ѻssZA(1h9#WhHB*OJPJQJ^JaJmH php0sH 1hhHB* OJPJQJ^JaJmH phsH 1h`hHB* OJPJQJ^JaJmH phsH 1h]hHB*OJPJQJ^JaJmH php0sH 1hhHB* OJPJQJ^JaJmH phsH +hHB* OJPJQJ^JaJmH phsH +hHB*OJPJQJ^JaJmH phsH (h)khHOJPJQJ^JaJmH sH 1h)khHB* OJPJQJ^JaJmH ph `sH &@t "&x BзззззззСo]H(h9#Wh9#WOJPJQJ^JaJmH sH "h9#WOJPJQJ^JaJmH sH 1h9#Wh9#WB* OJPJQJ^JaJmH phsH 1h9#Wh9#WB*OJPJQJ^JaJmH php0sH +h9#WB*OJPJQJ^JaJmH phsH 1h`hHB*OJPJQJ^JaJmH phsH +hHB*OJPJQJ^JaJmH phsH 1h9#WhHB*OJPJQJ^JaJmH php0sH dhj  &dj϶ϝmXF0X+h B* OJPJQJ^JaJmH phsH "h OJPJQJ^JaJmH sH (h1hHOJPJQJ^JaJmH sH 1h1hHB* OJPJQJ^JaJmH phsH ,hyfwhH0JOJPJQJ^JaJmH sH 1h`hHB*OJPJQJ^JaJmH phsH 1h$hHB*OJPJQJ^JaJmH phsH +hHB*OJPJQJ^JaJmH phsH 4jhHB*OJPJQJU^JaJmH phsH  PTV`FVpvxzfT?T?T?(h h OJPJQJ^JaJmH sH "h OJPJQJ^JaJmH sH 1h h B* OJPJQJ^JaJmH phsH "hYSOJPJQJ^JaJmH sH 1h1hHB* OJPJQJ^JaJmH ph `sH +h*B* OJPJQJ^JaJmH ph `sH (h1hHOJPJQJ^JaJmH sH 1h hHB* OJPJQJ^JaJmH phsH "hHOJPJQJ^JaJmH sH $@D^`4hxѿёxfQ81h hHB* OJPJQJ^JaJmH phsH (h9#WhHOJPJQJ^JaJmH sH "hHOJPJQJ^JaJmH sH 1h*hHB* OJPJQJ^JaJmH ph `sH 1h#jhHB* OJPJQJ^JaJmH phsH (hfhnOJPJQJ^JaJmH sH "h OJPJQJ^JaJmH sH (hfhHOJPJQJ^JaJmH sH 1h h B* OJPJQJ^JaJmH phsH  xz8^,0ѼѼѼxcJcxcxcx1h1h9#WB* OJPJQJ^JaJmH phsH (h1h9#WOJPJQJ^JaJmH sH "h9#WOJPJQJ^JaJmH sH 1h9#Wh9#WB* OJPJQJ^JaJmH ph `sH 1h9#WhHB* OJPJQJ^JaJmH ph `sH (h9#WhHOJPJQJ^JaJmH sH (h9#Wh9#WOJPJQJ^JaJmH sH 1h h9#WB* OJPJQJ^JaJmH phsH 4DZDTNu$ & F V^`Va$gd(p$ & F SSW^S`Wa$gdA/e$ & F V^`Va$gd*$ & F SSW^S`Wa$gd*$ & F SSW^S`Wa$gd9#W$ & F SSW^S`Wa$gd#j 0HZn46BDīĖٖلoV=o1h h#jB* OJPJQJ^JaJmH phsH 1h h B* OJPJQJ^JaJmH phsH (h h OJPJQJ^JaJmH sH "h OJPJQJ^JaJmH sH (h9#Wh9#WOJPJQJ^JaJmH sH 1h1h9#WB* OJPJQJ^JaJmH ph `sH (h1h9#WOJPJQJ^JaJmH sH "h9#WOJPJQJ^JaJmH sH (h#jh9#WOJPJQJ^JaJmH sH r &(TZjlpҹҤycyJcJ1hXh*B* OJPJQJ^JaJmH phsH +hXB* OJPJQJ^JaJmH phsH 1hXhXB* OJPJQJ^JaJmH phsH "h OJPJQJ^JaJmH sH (h h OJPJQJ^JaJmH sH 1h}h B* OJPJQJ^JaJmH ph `sH 1h}h#jB* OJPJQJ^JaJmH ph `sH (h h#jOJPJQJ^JaJmH sH p&02:>FHZ͸qqXq?q?qX1hXhEgB*OJPJQJ^JaJmH php0sH 1hXhEgB* OJPJQJ^JaJmH ph `sH (hXhEgOJPJQJ^JaJmH sH 1hXh*B* OJPJQJ^JaJmH ph `sH 1hXh*B*OJPJQJ^JaJmH php0sH (hXh*OJPJQJ^JaJmH sH 1hXh*B* OJPJQJ^JaJmH phsH 1hXhEgB* OJPJQJ^JaJmH phsH Z$h (:<ѼѼѼѧ|c|E:jhUUh*B*OJPJQJU^JaJmH phsH 1hXhXB* OJPJQJ^JaJmH ph `sH "hXOJPJQJ^JaJmH sH 1hXhXB*OJPJQJ^JaJmH php0sH (hXhXOJPJQJ^JaJmH sH (hXhEgOJPJQJ^JaJmH sH (hXh#jOJPJQJ^JaJmH sH 1hXh#jB* OJPJQJ^JaJmH ph `sH ^` hjhȱ昃qXB+hA/ehA/e5OJPJQJ^JaJmH sH 1h*h*B*OJPJQJ^JaJmH phsH "h*OJPJQJ^JaJmH sH (hUUh*OJPJQJ^JaJmH sH 1jhUUh*OJPJQJU^JaJmH sH ,hUUh*0JOJPJQJ^JaJmH sH :jhUUh*B*OJPJQJU^JaJmH phsH 1hUUh*B*OJPJQJ^JaJmH phsH hjlẊ̳̝q\C1hVChA/eB* OJPJQJ^JaJmH phsH (hHh*OJPJQJ^JaJmH sH +hHh*5OJPJQJ^JaJmH sH +h*B*OJPJQJ^JaJmH php0sH +hA/eB*OJPJQJ^JaJmH php0sH 1hA/ehA/eB*OJPJQJ^JaJmH php0sH 1hHh*B*OJPJQJ^JaJmH php0sH 4hHhA/e5B*OJPJQJ^JaJmH php0sH XZ` :>DFjBZtxx_x1hhA/eB* OJPJQJ^JaJmH ph `sH +hA/eB* OJPJQJ^JaJmH ph `sH 1hShA/eB*OJPJQJ^JaJmH php0sH 1hVChA/eB* OJPJQJ^JaJmH ph `sH "hA/eOJPJQJ^JaJmH sH 1hVChA/eB*OJPJQJ^JaJmH php0sH (hVChA/eOJPJQJ^JaJmH sH (*:l,2468LNZ\pԻweLԐԐLe7e(hmhk~OJPJQJ^JaJmH sH 1hChA/eB* OJPJQJ^JaJmH ph `sH "hk~OJPJQJ^JaJmH sH 1hk~hk~B* OJPJQJ^JaJmH ph `sH (hmhA/eOJPJQJ^JaJmH sH +hA/eB* OJPJQJ^JaJmH phsH 1hmhA/eB* OJPJQJ^JaJmH phsH "hA/eOJPJQJ^JaJmH sH 1hShA/eB* OJPJQJ^JaJmH ph `sH p>BDFtvxտ~~iS:~1h\zhA/eB* OJPJQJ^JaJmH ph `sH +hMB* OJPJQJ^JaJmH ph `sH (hmhA/eOJPJQJ^JaJmH sH 1hmhA/eB* OJPJQJ^JaJmH phsH +hA/eB* OJPJQJ^JaJmH phsH "hk~OJPJQJ^JaJmH sH +hA/eB* OJPJQJ^JaJmH ph `sH 1hmhA/eB* OJPJQJ^JaJmH ph `sH "hA/eOJPJQJ^JaJmH sH  DzTԿԪԘԂiiS84h(ph(p5B*OJPJQJ^JaJmH php0sH +h(ph(p5OJPJQJ^JaJmH sH 1hmhA/eB* OJPJQJ^JaJmH ph `sH +hA/eB* OJPJQJ^JaJmH ph `sH "hk~OJPJQJ^JaJmH sH (hmhA/eOJPJQJ^JaJmH sH (hkhA/eOJPJQJ^JaJmH sH "hA/eOJPJQJ^JaJmH sH 1hChA/eB* OJPJQJ^JaJmH ph `sH  .0HJLN|~Xrͷ桌s^E^E^E^3"h&OJPJQJ^JaJmH sH 1h3|hXB*OJPJQJ^JaJmH php0sH (h3|hXOJPJQJ^JaJmH sH 1h3|hXB* OJPJQJ^JaJmH phsH (h(phk~OJPJQJ^JaJmH sH +h(phk~5OJPJQJ^JaJmH sH +h(pB*OJPJQJ^JaJmH php0sH 1h(ph(pB*OJPJQJ^JaJmH php0sH 1h(phk~B*OJPJQJ^JaJmH php0sH ,.8:<:fٲDzǝٲDŽoZoZoE(h&hagOJPJQJ^JaJmH sH (h&hOJPJQJ^JaJmH sH (h&hXOJPJQJ^JaJmH sH 1hhB* OJPJQJ^JaJmH phsH (h3|hOJPJQJ^JaJmH sH (h3|hXOJPJQJ^JaJmH sH "hOJPJQJ^JaJmH sH "h&OJPJQJ^JaJmH sH (h&h&OJPJQJ^JaJmH sH N6  F Ruuu$ & F SSW^S`Wa$gd$ & F V^`Va$gdY$ & F SSW^S`Wa$gdz$ & F V^`Va$gdz$ & F SSW^S`Wa$gd&$ & F SSW^S`Wa$gdX f,.068<Rvѣq\Gq\.\q1h&h&B*OJPJQJ^JaJmH php0sH (h&h(pOJPJQJ^JaJmH sH (h&h&OJPJQJ^JaJmH sH 1h&h&B* OJPJQJ^JaJmH ph `sH 1h&hXB*OJPJQJ^JaJmH php0sH 1h&hXB* OJPJQJ^JaJmH phsH (h&hXOJPJQJ^JaJmH sH (h&hagOJPJQJ^JaJmH sH 1h&hagB* OJPJQJ^JaJmH phsH 2 6 ^ ` p r x z        ͣxbIbI7"hjOJPJQJ^JaJmH sH 1h&h@B* OJPJQJ^JaJmH ph `sH +h@B* OJPJQJ^JaJmH ph `sH 1h&h&B* OJPJQJ^JaJmH phsH "h&OJPJQJ^JaJmH sH (h&h&OJPJQJ^JaJmH sH (h&h(pOJPJQJ^JaJmH sH 1h&h&B* OJPJQJ^JaJmH ph `sH 1h&h(pB* OJPJQJ^JaJmH ph `sH          0 8 : > B D F T պrr\G.1h%/h B* OJPJQJ^JaJmH phsH (hzh(pOJPJQJ^JaJmH sH +hzh(p5OJPJQJ^JaJmH sH +hzB*OJPJQJ^JaJmH php0sH 1hzhzB*OJPJQJ^JaJmH php0sH 1hzh(pB*OJPJQJ^JaJmH php0sH 4hzhz5B*OJPJQJ^JaJmH php0sH +hzhz5OJPJQJ^JaJmH sH (h&h(pOJPJQJ^JaJmH sH T f  h l | ~    . 8 x   VXZ\^jлwwwwwbbIbI1h%/h%/B* OJPJQJ^JaJmH phsH (h%/h%/OJPJQJ^JaJmH sH 1h%/h B*OJPJQJ^JaJmH php0sH 1h2h%/B*OJPJQJ^JaJmH php0sH "h%/OJPJQJ^JaJmH sH (h%/h OJPJQJ^JaJmH sH 1h%/h B* OJPJQJ^JaJmH phsH +h%/B* OJPJQJ^JaJmH phsH j$lpѼgR9g'"h2OJPJQJ^JaJmH sH 1h2hzB* OJPJQJ^JaJmH phsH (h2hzOJPJQJ^JaJmH sH 1h2h%/B* OJPJQJ^JaJmH phsH (hsthzOJPJQJ^JaJmH sH (hsth%/OJPJQJ^JaJmH sH "h%/OJPJQJ^JaJmH sH (h4Jh%/OJPJQJ^JaJmH sH (h%/h%/OJPJQJ^JaJmH sH 1h%/hzB* OJPJQJ^JaJmH phsH p4|*dѿѦєѿ{fMff4f1h2hstB* OJPJQJ^JaJmH ph `sH 1h2hstB*OJPJQJ^JaJmH php0sH (hsthstOJPJQJ^JaJmH sH 1h2hstB* OJPJQJ^JaJmH phsH "hstOJPJQJ^JaJmH sH 1h2h2B* OJPJQJ^JaJmH phsH "h2OJPJQJ^JaJmH sH (hsth%/OJPJQJ^JaJmH sH 1h2h%/B* OJPJQJ^JaJmH phsH  "6d͸t^tI7It"hstOJPJQJ^JaJmH sH (hzhstOJPJQJ^JaJmH sH +h@B*OJPJQJ^JaJmH php0sH "h2OJPJQJ^JaJmH sH 1h2hstB*OJPJQJ^JaJmH php0sH 1h2hstB* OJPJQJ^JaJmH phsH (hsthstOJPJQJ^JaJmH sH 1h2hstB* OJPJQJ^JaJmH ph `sH 1h2h2B* OJPJQJ^JaJmH ph `sH ,0HPrt@JLR$&(pU<1hYhzB*OJPJQJ^JaJmH php0sH 4hYhY5B*OJPJQJ^JaJmH php0sH %hY5OJPJQJ^JaJmH sH +hYhY5OJPJQJ^JaJmH sH (hsthzOJPJQJ^JaJmH sH "h2OJPJQJ^JaJmH sH "hstOJPJQJ^JaJmH sH 1h2hstB* OJPJQJ^JaJmH ph `sH (hsthstOJPJQJ^JaJmH sH (>FNRзззsZE,E1h^6hB*OJPJQJ^JaJmH php0sH (h^6hOJPJQJ^JaJmH sH 1h^6hB* OJPJQJ^JaJmH phsH 1h^6hYB* OJPJQJ^JaJmH phsH (hYhzOJPJQJ^JaJmH sH +hYhz5OJPJQJ^JaJmH sH 1hYhzB*OJPJQJ^JaJmH php0sH +hYB*OJPJQJ^JaJmH php0sH 1hYhYB*OJPJQJ^JaJmH php0sH <dfdhrtҹҤv]G.G1h^6h^6B*OJPJQJ^JaJmH php0sH +h^6B*OJPJQJ^JaJmH phsH 1h^6hB*OJPJQJ^JaJmH phsH (h^6h^6OJPJQJ^JaJmH sH 1h^6hB*OJPJQJ^JaJmH php0sH (h^6hOJPJQJ^JaJmH sH 1h,hB* OJPJQJ^JaJmH ph `sH 1h,hYB* OJPJQJ^JaJmH ph `sH (h^6hYOJPJQJ^JaJmH sH  t "ѿѦw^H/w1h5~hB*OJPJQJ^JaJmH php0sH +hB*OJPJQJ^JaJmH php0sH 1h\ hB*OJPJQJ^JaJmH php0sH +hB*OJPJQJ^JaJmH phsH 1h\ hB* OJPJQJ^JaJmH phsH 1h^6hB*OJPJQJ^JaJmH phsH "h^6OJPJQJ^JaJmH sH (h^6hOJPJQJ^JaJmH sH 1h^6hB* OJPJQJ^JaJmH ph `sH  "DLzXZjx|몑{eL1hhB* OJPJQJ^JaJmH phsH +hB*OJPJQJ^JaJmH phsH +hB*OJPJQJ^JaJmH php0sH 1h\ hB*OJPJQJ^JaJmH php0sH "hOJPJQJ^JaJmH sH 1hhB* OJPJQJ^JaJmH ph `sH +h,h6OJPJQJ^JaJmH sH (h\ hOJPJQJ^JaJmH sH H| 6^p:\tͷ͡zzaHa1h^6hYB* OJPJQJ^JaJmH phsH 1h^6h^6B* OJPJQJ^JaJmH phsH "h^6OJPJQJ^JaJmH sH (hbwhOJPJQJ^JaJmH sH +hB*OJPJQJ^JaJmH phsH +hB*OJPJQJ^JaJmH php0sH 1hhB*OJPJQJ^JaJmH php0sH 1hhB*OJPJQJ^JaJmH phsH  6:BDTVxz&(*lz|gU"h^6OJPJQJ^JaJmH sH (hhOJPJQJ^JaJmH sH +hB* OJPJQJ^JaJmH ph `sH (h^6hYOJPJQJ^JaJmH sH 1hhYB* OJPJQJ^JaJmH ph `sH "hOJPJQJ^JaJmH sH 1h^6h^6B*OJPJQJ^JaJmH php0sH (h^6h^6OJPJQJ^JaJmH sH @ H J t      ī}}dR=R=R(hsRhsROJPJQJ^JaJmH sH "hsROJPJQJ^JaJmH sH 1hsRhsRB* OJPJQJ^JaJmH ph `sH 1hhsRB*OJPJQJ^JaJmH php0sH (hhsROJPJQJ^JaJmH sH 1hhsRB* OJPJQJ^JaJmH phsH "hOJPJQJ^JaJmH sH (h^6hYOJPJQJ^JaJmH sH (h^6hOJPJQJ^JaJmH sH  H"h$\%<&f'()..ul Sgd=\$ & F SSW^S`Wa$gda$ & F V^`Va$gd3R$ & F SSW^S`Wa$gdG$ & F V^`Va$gdY$ & F SSW^S`Wa$gdsR$ & F SSW^S`Wa$gdY $!8!>!J!b!d!l!!!!!!!!!!!!!("ҹҤ다y``N5N1h Uh UB* OJPJQJ^JaJmH phsH "h UOJPJQJ^JaJmH sH 1hhB* OJPJQJ^JaJmH ph `sH "hOJPJQJ^JaJmH sH 1hhYB* OJPJQJ^JaJmH ph `sH (hhYOJPJQJ^JaJmH sH 1hhB* OJPJQJ^JaJmH phsH 1hhYB* OJPJQJ^JaJmH phsH (hhOJPJQJ^JaJmH sH ("0"F"H"p"r"x"z""# #r#z######$ $4$f$h$$ʱܘܘiTTT>+hGhG5OJPJQJ^JaJmH sH (hsRh UOJPJQJ^JaJmH sH +h UB*OJPJQJ^JaJmH php0sH 1h h UB* OJPJQJ^JaJmH ph `sH 1h Uh UB*OJPJQJ^JaJmH php0sH 1h Uh UB* OJPJQJ^JaJmH phsH "hOJPJQJ^JaJmH sH "h UOJPJQJ^JaJmH sH "h OJPJQJ^JaJmH sH $$$$%%P%V%X%Z%\%%%%̶̶̠̊u\C-+h3RB*OJPJQJ^JaJmH php0sH 1h3Rh3RB* OJPJQJ^JaJmH phsH 1h3Rh1\HB* OJPJQJ^JaJmH phsH (hYhYOJPJQJ^JaJmH sH +hYhY5OJPJQJ^JaJmH sH +h~xB*OJPJQJ^JaJmH php0sH +hYB*OJPJQJ^JaJmH php0sH 1hYhYB*OJPJQJ^JaJmH php0sH 4hYhG5B*OJPJQJ^JaJmH php0sH  %%%%%&"&.&8&:&<&\&^&b&ygN5#"hs>?OJPJQJ^JaJmH sH 1h3Rh3RB* OJPJQJ^JaJmH phsH 1h3Rhs>?B* OJPJQJ^JaJmH phsH "hGOJPJQJ^JaJmH sH (hc2lh1\HOJPJQJ^JaJmH sH 1hc2lhGB* OJPJQJ^JaJmH ph `sH 1hc2lhA4B* OJPJQJ^JaJmH ph `sH 1hc2lh1\HB* OJPJQJ^JaJmH ph `sH "h1\HOJPJQJ^JaJmH sH (h1\Hh1\HOJPJQJ^JaJmH sH  b&f&|&&&&&&&&0'2'b'd'f''''īրրgN9(heheOJPJQJ^JaJmH sH 1h3Rh3RB* OJPJQJ^JaJmH phsH 1h3RheB* OJPJQJ^JaJmH phsH "hs>?OJPJQJ^JaJmH sH 1h3RhGB* OJPJQJ^JaJmH ph `sH 1h3Rhs>?B* OJPJQJ^JaJmH ph `sH "hUOJPJQJ^JaJmH sH (hUhUOJPJQJ^JaJmH sH (hUhGOJPJQJ^JaJmH sH ''''''(0(\(|(~(($)ê|gR='+h3Rh3R5OJPJQJ^JaJmH sH (h3RheOJPJQJ^JaJmH sH (h3Rh3ROJPJQJ^JaJmH sH (hehGOJPJQJ^JaJmH sH (heheOJPJQJ^JaJmH sH 1h3RhGB* OJPJQJ^JaJmH ph `sH 1h3Rh3RB* OJPJQJ^JaJmH ph `sH +h3RB* OJPJQJ^JaJmH ph `sH "h3ROJPJQJ^JaJmH sH (heh3ROJPJQJ^JaJmH sH  $)&)()))))))))"*$***,*̳̇rYD+D1h,h 5B*OJPJQJ^JaJmH php0sH (h,h 5OJPJQJ^JaJmH sH 1h,h 5B* OJPJQJ^JaJmH phsH (h3RhGOJPJQJ^JaJmH sH +h3RhG5OJPJQJ^JaJmH sH +h3RB*OJPJQJ^JaJmH php0sH 1h3Rh3RB*OJPJQJ^JaJmH php0sH 1h3RhGB*OJPJQJ^JaJmH php0sH 4h3RhG5B*OJPJQJ^JaJmH php0sH ,*:*D*\*~********* + +++++ҹucJ1u1hF4qh 5B* OJPJQJ^JaJmH ph `sH 1hF4qh@B* OJPJQJ^JaJmH ph `sH "h@OJPJQJ^JaJmH sH +h,B*OJPJQJ^JaJmH php0sH 1h,h 5B*OJPJQJ^JaJmH php0sH (h,h 5OJPJQJ^JaJmH sH 1h,h 5B* OJPJQJ^JaJmH ph `sH 1h,haB* OJPJQJ^JaJmH ph `sH (h,haOJPJQJ^JaJmH sH ++2+d+j+l++,,,,,-&-*-.-0-4-yydydK5K+h8B*OJPJQJ^JaJmH php0sH 1h,haB*OJPJQJ^JaJmH php0sH (h,haOJPJQJ^JaJmH sH (h,h,OJPJQJ^JaJmH sH 1h,h 5B*OJPJQJ^JaJmH php0sH 1h8h8B*OJPJQJ^JaJmH php0sH "h8OJPJQJ^JaJmH sH 1hF4qh8B* OJPJQJ^JaJmH ph `sH (h,h 5OJPJQJ^JaJmH sH 4-D-F-------. .<.j.n.t..........///// / ///ѼѼјѼѼѼѼshdshdshdshdh"6hrbh"6CJaJjhrbh"6CJUaJ+h"B*OJPJQJ^JaJmH phsH "h8OJPJQJ^JaJmH sH "h,OJPJQJ^JaJmH sH (h,haOJPJQJ^JaJmH sH (h,h,OJPJQJ^JaJmH sH 1h,h,B*OJPJQJ^JaJmH php0sH  .../// ///N////1111\2^2r2t2v2x2 $ B#a$gd:H  B#9!gd4=$a$gd~JOgd4=$ B#9!a$gd4= dgd_b2/L/N////00|1~11111111Ǵzo`T`2Bh:HhQB* CJOJQJ^JaJfHmH ph q sH hQOJQJmH sH h4=hQOJQJmH sH hrbhQCJaJ$h4=hQCJOJQJaJmH sH hQCJOJQJaJmH sH $hrbhQCJOJQJaJmH sH hQ$h4=hQCJOJQJaJmH sH $h#DZhQCJOJQJaJmH sH !hIu5CJOJQJaJmH sH 'h^hQ5CJOJQJaJmH sH 1426282Z2\2^2f2n2p2r2t2v2~njZGZ4)%h"6hrbhQCJaJ$h>,hQCJ@OJQJaJ@mH (sH ($h>,hQCJ@OJQJaJ@mH sH hQCJ@OJQJaJ@mH sH hQh:HhQ5OJQJmH sH Eh:HhQ5B* CJOJQJ^JaJfHmH ph q sH <hQB* CJOJQJ^JaJfHmH ph q sH Bh:HhQB* CJOJQJ^JaJfHmH ph q sH :h:HhQB* CJOJQJ^JaJfHph q x2z2|2~2 Sgd=\v2z2|2~2+h"B*OJPJQJ^JaJmH phsH hgShV}CJaJhgShQCJaJ5 01h:p4=. A!"#$% f! 666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~OJQJ_HmH nH sH tH J`J 4HbNormal dCJ_HaJmH sH tH ``` !Ttulo 1$<@&&5CJ KH OJQJ\aJ mHsHtHXX fpTtulo 3$<@&5CJOJPJQJ\^JaJT T WTtulo 4$<@&5CJ\aJmHsHtHNA N Fuente de prrafo predeter.RiR 0 Tabla normal4 l4a ,k , 0 Sin lista ^ ^ d0Texto de globo dCJOJQJaJmHsHtHP/P d0Texto de globo CarCJOJQJ^JaJb/b hDefault 7$8$H$-B*CJOJ QJ ^J _HaJmH phsH tH 2/!2 h0A1B*CJ ^J aJ ph66 W0Pa1d B*^JphR/AR ! Ttulo 1 Car"5CJ KH OJPJQJ\^JaJ H`RH _b20 Encabezado  B# mHsHtH</a< _b20Encabezado CarCJaJN `rN _b20 Pie de pgina  B# mHsHtHB/B _b20Pie de pgina CarCJaJN/N W Ttulo 4 Car5CJOJPJQJ\^JaJ:U`: W0 Hipervnculo >*phN N m Sin espaciadoCJ_HaJmH sH tH R)R ^0Nmero de pginaPJ\]^JaJmH sH NN fp Ttulo 3 Car5CJOJPJQJ\^JaJ>3> fp0Lista 3Q^Q`m$H0H fp0Lista con vietas  & Fm$L6L fp0Lista con vietas 2 & Fm$PK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!&lTRtheme/theme/theme1.xmlYMoE#F{oc'vGuرHF[xw;jf7q7J\ʯ AxgfwIFPA}H1^3tH6r=2%@3'M 5BNe tYI?C K/^|Kx=#bjmo>]F,"BFVzn^3`ե̳_wr%:ϻ[k.eNVi2],S_sjcs7f W+Ն7`g ȘJj|l(KD-ʵ dXiJ؇kZov[fDNc@M!͐,a'4Y_wp >*D8i&X\,Wxҕ=6.^ۄ Z *lJ~auԙՍj9 !bM@-U8kp0vbp!971 bn w*byx$پ,@\7R(=Q,)'KQk5qpq Qz,!_ Y4[an}`B-,#U,ђMpE`35XYd״?%1U9إ;R>QD DcNU'&LGpm^9+ugVh^n<*u7ƝSdJ9gn V.rF^*Ѕ҈}-p !:P5gyڧ!# B-;Y=ۻ,K12URWV9$l{=An;sVAP9zszH'[`ۇ@PbW<{ˆ1W+m_SsncY̕([ @}`g >V?4hf6՗t#M&ʺ6'B gks:\qN-^3;k ] =Y42&0GN|tI&MI`=DCPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!&lTRtheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] __ h  |Er3  *P+1q4W5799:|<>BC0IJLMN\OOP?QRRTIZZ[\Q^^bbc"dexfgJhikm o-p8qrNstuvx~4IɈ{(8t2l޳~$[  ,/ B dPJbv%.xmD z  `zZZ<Qdp* p!##'()*-./x1j25966p77^8899a: ;;J<z=>i@@(CDHCIJNN|PQRTVHW,X8Y(\\v^abrdeg= ?@ABnCEF\HTI$KLzMOPPP RSVTFVW$XYN[\L]^_j`aVdTeghjklm>oprLsttuzvwyz|8}n~@N@pJ ƍlƒ:v(Йl`hhN\j^ȴp,R"0N"|Xx0ZhXpf T jp(t" ("$%b&'$),*+4-/1v2~2      !"$%&'()*+,-./013456789:;<=>?ABCDEFGHIJKLMNOPQRTUVWXYZ[\]^_`abcdefhijklmnopqrsuvwxyz{|}~ !"#$&'()*+,-./012345689:;<=>?@ABCDEGHIJKLMNOPQRSUVWXYZ[\]^_`abcefghijklmnopqrtuvwxyz{|}~ jP+Rkql*` x1?HW.F^q 4N.x2~2#2@Sgt%7FTds,D89T9A~AAABB_XXXXX)  ,"$j8[;Ru{6|# 0 @, (    H3 @ #" `?   ZBw `$>? PEARLS IN ALLERGY AND IMMUNOLOGYArial Black#" `?B S  ?H0(  _49;t@ -8t@gnu|"59>JNUblp{u|GMQVZbmsw # ( - 4 ? R b j n u y ~  ^ f k o H O S X \ c k q i n >CL[_f{chlrv!59=A(6uxELPWho[_cmqyDMR[lrw|9?EQx  \cgkisw~ &=)A)T)X)])i)m)t)))))))))))))))555555555666#6)6A6D6E6J6N6T6`6f6DDDDDDDE EEEE!E'EKKqgwg{gggggggggggggghhh$h)h9hMhRhWh^hih|hhhhhhhhh}tttt}||||$ &/"(HN |!*9=DY^tx׿ݿ7<@FZ^bf ,37>OV!(CIZ_ch3:>G[_diu }       18CIMSWaBBBBBBBB_GeGlGrGvG}GGGGGGGGGGGGG1K9K=KBKgPnPrPvPBXIXMXQXXXXXYYcZmZqZxZ|ZZZZK]M]N]P]Q]S]T]V]W]^^^^^^^^^^^^ _ __|((@@5>jl%88?8JJK]M]N]P]Q]S]T]V]W] _ __3333333333)E@j`N CȪɺI  K]M]N]P]Q]S]T]V]W]]^_ _ __L@ l[Xh]&f{挿YSjwL8h(Dd)Y/ " 0>;8/DfC)@eGɪBrTVKj88LRvQ@/]Wjr_z4X0:%l[ [*f!\&)<v.`&MQb޸SJ djp1,lfvELvtP\j~U ^`OJQJo( hh^h`OJQJo(" " " " B*CJaJphsH " " " " " " " " " " " " " " " " " " " " " h^`B*OJQJo(phhHh^`OJ QJ ^J o(hHohq^q`OJ QJ o(hHhA ^A `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohQ^Q`OJ QJ o(hHYS 0(,lfvLv{!\DXz4X8LL8J dQb [rTVK)Y/%l[RvQ)@eGv.`]W>;]j~YSPu Ѡ~^4        1Y =@lhJX!l'\3s4Qn: vCk`Qn[R5bd35hyit|-ku=/oEmsm|y5@?< cwRp`!""')))B*,+.w0035Q8c<>d>@ACFFGGKNPQXSXXYY\]`u``QfEg[lInXppuXxyH||P y+t'$&'~./135558:i;L>BI$ILTULVX\] ^`^S__waGbcenostCuuuv w%z({m||[}}~#N1 <   4 $.&S&&&'()9,9229`;?aDkE>GbGGdKKfQTUZZJ\]_`Qgmooqr>yq{|^||x~ P@ E F   #DT+F  l$x$$$6%h'*+-.5e7?;?uCC[G~GHK[QQ%T+W[W`WBYZ|[\_]^^u__ddkf;hth/qr{{|(~m~.v   "E/Ke  %-~..00d1d3<O=='@@HEfFF GHJLLLOOPQUYVVMXTY\?_`uaac6d]eikltn qmqGrLrruu-ygy~78,   :x O"#$I%&9(G)r)*'+/+<+,,o-.0M23B668:7>@BC+EENN,QRZ[z\r^4aaa b$bSb.cecdefilnoqtuyz){}Ij lO7;!@%K%&O'+/11 4m5+669<dBCDgEFHIJ(KpKLRSTT*UoUyWXYYYZn[\_`aybdef6nnpst'uxyy|(on q  .YPC&'*-J...36N7q9;b<=?n@BEiGMMNNNRSTcglgk`mmonnpq rrUssttzo|~E a    gY  $(//233A5f5i779<<<=hCCoFFPJKqLSNlODTN\]i^*ddghiVjnq8r{t xx?y{{|}ahO  Z +  " ^ ,    D K U r  t   U! " $ % F& @' ) v, - - ,. 0 0 1 L3 9 v< ZB LG I M 8M M O Q ?R W W X Y [ \ \ \ ] c e f f k n [o +q t av w {z z n    g        ! @% & l& ' ) Z+ F, 5 N9 :< < < "= > D@ ~B GD oD PL L R S V W YW (Z gZ ~Z h] ` a g k ?r 's u u | ? ?         e , 3 r4 w4 8 I< > > *@ C C C E %F .H ?J J K N O O 2P P `Q UY [ \ _ ` (b d =e e n n n z { ~ \ x  -    p p  Y    B  " X# ( ( * * + + 30 3 4 95 I6 9 F9 9 {= > A G K M N O Q =R DT U oV W 7Z [ [ [ \ b e h i j !k km on n ip {s s 9t rt u x Zz  e  y 3 X   Z     n! # $ & ( ( * , (0 /2 X2 M5 d7 7 8 : < = = xA C hD }D D J J WM Q XS S T V I^ ze Dk +q `r t t { } 1~ `M A   P>*j ""'(f)*Q,-/2?yAbBB[CILNMRR5STUUUGY["\eejllUogooqrz {|{| }y # } <B!!!.?01336466=789;<==!>BCC DlEFHGGHHGIKM OQRRU)WW`YRZ[a.bbdd&h`j&mmnkopqru3ux{|~$6 %     uxe !x"%+<0457:<=oBBBC&HuMdNfNxNOYRS1T&YY[&`b#dXhjk`mmopKqeyz"D K.cQOaK'O'(*/ 1 1B125o8799M:9=@ABzCCNDDGK*NANNOQBS?ThTQW\X]m^^S_a=bbfkmnJsUsz|z||~S? ( 7!3$%(#)!*.%/3@5<O?BCoDD]GGHXI$JQJMNTQ$RSAT6VX Z[[[\,]] bKb&ccfxm!oqq0wYx{{||cHP{I    3Of"$"&'+,,/23t444?DSErEGILdMPPQQQRjUW\?]"`cdd-jblmepsuZwww!xxuy}}R"s {   QE5t;T&&&/W//T339</GIIjj[kk}nqtvv%||c})vq  (x}  ""+#a%v'x)*+g,^37;;?x@@CBGjGHIU>VJ[[]gth4ilm/qsv{_i{/r"% &'++C--..15E668Y;?A}FGM{OOPQUQUUUZ_]`FewhZkmnoVq v}vBTCCwIhJ#MMM7OJO)PlSSdTuT0[C\r\>fhjk|}F       s}$'u'E-X-..s3M48%@JKKKTVZ_`bPccGdjlmoxy z|TG" @ I   !7!V#1 "d).2}3456Z:;??ASCDDEBHgJKLOPPVW[u[d\Qc g1hl^nrHuvvyy{}~"Wm l   D!R"""p-Y.B3 56H7L<1=?B*EFxFGHJJLMNKPAQTRRTtUX|Z[G^^cdje|ijklq2rvwy6|}=U, "#%'+I--633)8X9:>A BC9DHD#E0FIPK OQtTWWY\`^#_6_` bjbxcejjklUllTr"tuw{~k_  &Y!h!S"M#Q%%''x*F,.*//0o1256}7}99;=CDFJuKBLaLMNO PSiTUWWXXZ^*dpgjWmsoqvrsGvvz||6KZw    *   i~FzL#%*r+t,-/0!1r114-5K8Z8u88Z9<T=?h?AG%IJJ'K/OQTXCYB[S[[__cee2ggiq0r#tLwk  td ]vl2b;l *$D$&&&'^(W++.@/e1135H6@@BDEFRHI$PeQR TTUY [q\%^_`~b8cfRgWjlotwBy zz{|m} $ I   # * (   x   / O &  1 $ % ) + c, <- ^/ "1 1 2 =3 R6 m6 [< e= > F /J L M P dS )T wY B[ &\ A\ \ M` b yc d Oe i ~k k Bp ;q q w x z /{ \} b  B!x!!! !& !$!/!-!l!!@!!!j!!!g!#!$!;%!$&!'!n(!3*!(,!-!0!2!b3!4!z7!9!B!qE!E!oF!G!zH!YI!J!J!L!$M!N!N!R!~S!X!X!\!\!]!_!_!a!Bb!b!e![g!g! i!.j!j!hl!mp!fs!w!Ry!y!m{!!""""t" " "B"D""_""""""""""#"("x)"*"+"E-"0"5">"o@"F"KH"K"M"JP"P"S"U"U"Y"p^"_"d"Ee"yf"f"bg"Lj"9m":m"jm"Qp"q"Ys"u"w"|"&"##M#Q## # # # #o######~!#P"#(#7,#.#`/#d/#W2#3#o4#6#7# 9#f;#M<#=# ?#B#YC#C#D#)D#DD#F#%G#G#dK#S#T#Z#[#I^#^#&`#a#gb#d#6g#m#8n#q#Nq#z# ~#$$$$7 $s$$$}$$$$%$$$$&$($U)$.$3$}4$c8$:$F=$N=$=$6A$ C$\F$XI$K$O$O$R$NU$U$8Z$$[$\$_$_$`$a$b$Tc$ d$Nd$d$0e$ f$ih$m$or$s$t$u$,{${$$%%?%%B%%%#%%q % % %%%%7%%%[%>%'%'%-%-%/%00%f0%)1%83%3%6%7%W8%;%t>%@%eE%}H%I%I%/J%-K%M%SO%O%P%_Q%Q%lW%Y%a%c%c%d%e%}f%}n%n%Bo%r%s%$s%ct%t%v%w%y%X|%}%~%(&&&c&&&& &M &&&&&&!&Z#&$&\(&+&4-&2&2&5&5&5&<&|>&?&@&B&B&B&E&F&G&5I&P&\R&V&\&5]&R]&,^&_&f&f&?g&i&j&k&}m&o&\r&s&s&t&u&u& v&x&9x& y&wy&1z&J''e' ' ''' ' ''''''7'#'N$'%'-''(')'*'#,';-'`-'1'3'5'#5'5'9';';'HB'C'PF'oH'H'J'K'!L'hM'Q'Q'/R'S'V'NW'X'G]'^'B`'Ka'Qb'c'oc'ld'e'g'=i'j'"o'o'Uq'q'mx'y'y'K}'(y((n (c(1(-(X((((((%(Z*(,(,(-(w.(o4(7(8(79(>(M?(?(#@(A(YB(E( F(G(H(J(J(K(M(Q(R(S(~Z(c(Ld(d(e(f(3h(j(k(.m(=m(p('{(^~(~((q)))')))()q ) ) )l )1)))G#)U$)$):%)%)M')+)A0)2)3)5)9);) @)C) F)F)kF)qF)-H)J)YO)P)P)P)S)S)T)U)V)W)W)X)X)[)`)4b)^b)tc)]d)d)e)8i)j)j)k)k)k)k)4m)n)r)s)t)t)Hu)Ju)_v)v)z){)})v** * *w * *X * * ******V*****!*#*'*G+*G-*//*f/*/*1*2*H3*5*6*8*:*:*:*:* ;*';*P;*;*M=*=*\@*A*B*B*B*D*D*:F*F*H*H*J*!L*O*V*V*Y*Z*[*\*V^*_*A_*"`*la*d*e*(f*@h*^h*lk*k*m*?o*r*r*Rw* z*z*z*0*b**#++ + +u+z++y+l++++++ +"+(#+$+@&+(+,+,+2+3+u4+5+8+9+?+E+iG+`J+K+UN+N+Q+Q+!S+~U+,X@,A, G,J,$N,O,YQ,R,S,eT,W,W,W,X,X,X,[,_,_,_,]e,e,e,g,h,o,p,~q,q,Ls,s,s,u,w,x, y,{,~,,,,---- -q -` - - ---2-f----"-#-$-m%-+---0-g2-54-;6-9-p;-<->-?-@-B-F-cI-J-aM-N-O-QP-S-XT-W-W-Z-^-`->a-La-c-Ue-f-*f-j-cl-m-s-}v-}-... ..'. ..;..6.D...... .".#.$.C$.G$.).-.0.K0.G1.3.a3.^6.6.8.a<.=.>.y?.?..A.jC.E.jG.wG.G.M.N.N.Q.R.6R.U.U.[.].Vb.~b.d.e.bk.o.cu.!v.Xx.z.}.~.s.c//// / ///?//9/////@/5B/iB/>H/J/0K/K/kL/M/:N/N/tP/R/]T/U/MV/\/5g/h/k/Un/o/]q/tr/v/w/x/x/~/o0n000 000 0> 0 0 00O0v0000h00000 0$09&0W,0/0F00B10 20k2020X@0iC0D0lE0 G09G0I0I0L0P0YQ0W0Z0J^0a0h0i0@j0n0bo0p0u0x02y011d13111 1K 1 1+ 1 1 1 1111111 1#1 '1D'1)1+1+1+1,13151N91S;1<1=1?1E13]>3?3@3OB3C3F3cG344O4;444\ 4 4e44P444Q4q4"4$4%4%4#&4I(4(4)4+404w24454Q8494:48>4>4@4A4DC4C4C42D4D4E4E4tF4F4fH4 J45J4J4K4 L45M4R4R4S4T4oX4Z4=[4\4&a4a4c4i4p4q4s4:u4'w4+w4^x4x4{455#55p55555 555h5"5(5u1525d8595:5,=5 >55>5A5)G50I5:L5M5M55O5O5S5^U5W5[5\5s\5'^5b54c5c5j5*j5j5l5m5q56s5w5y5 6666666"666666b66i!6 "6#6(6,636466666{9696;6?6JD6F61H6oH6J6K6O6Q6R6R6%V6W6Y6*[6W[6\6\6f6fg6Rh6i6i6#k6k6 l6m6q6s6t6x6.z6{64~6i67717O 7 7[7M777 77 7"7(7)7*7+7,7-707j27+57 87<7<7?7xD7 G7>H7H7nI7I7{J7L7R7T7\W7tW7Y7_7_79`7ra7Cb7c7c7"d7e7Lf7n7p7s7u7v7My7y7K{7\{7:|7}77O8{888y8888 8w 8h8F8u8888 8{"8 %8j%8x%8&8&8)8`)8d-808,58Q5878V8888{@8A8JB8C89D8GD8D8D8F8CI8M8M8N8O8O8iS8hT8 X8_8_8`89b8b8c8He87f8xk8sp8yt8 v8w8b{8{8}8~89199+99 99j9o9a9999n9?9y!9"9q$9X%9%9 (9(9Z)9)9"+9+,9/93939[3989J:9;9;9>9fB9!C9uC9G9H9_I9yI9RN9N9O9R9T9{U9\9k]9Ba9c9d9Ie9e9f9`g9i9o9p9Wq9u9w9{9T|9`}9m}9:I::'::::: :o :@ : :%:[:W:::: :D!:!:!:':R):*:V+:)-:F/:)0:[0:2:3:Q6:7:8::::::1>:?:z?:}@:@:"C:VD:D:E:DG: K:9N:N:N:S:T:T:;?;cB;C;C;E;G;L;M;P; P;P;V;V;eW;Z;[;[;5\;_;b;Bc;Zd;h;i;j;So;|r;r;r;Os;s;t;t;t;x;T{;;<< <5 <w <L < <<<<!<z<<<< <"<<0<<< <a<<<b< <M"<"<"<#<r$<$<5%<&<!*<z+<+<.<L/<=0<%1<.3<4<H6<k6<r6<-8<9<;<<<><><B<LE<E<G<iI<I<K<L<M<N<-S<W<Z<[<]<e<e<f<f<f<li<+j<j<Bl<l<lm<o<r<s<u<0u<u<v<w<z<>{<\<]==/ =' = =======e==e=U=i%=,=C-=.=.=0=3=3=4=5= 9=_9===R?=?=?=A=zA=aC=lC=F=H=O=O=Q=nR=HS=sW=Y=Z=\=ua=}b=b=i=o=So=q=as=|=R}=~=>> > >>>>3>@>L>>>>B>}>>>E">#>%>#*>",>Y.>0>5>k7>$9>9> :>?>C>aC>E>jJ>6Q> R>1R>S>jU>W>Y>Z\>a>g>Ri>i>&k>k>5l>Kn>o>Qp>@r>t>y>y>D{>l{>L~>????; ? ? ? ???Q?n???S????I ?_ ? ?C$?h%?(?7+?,?-?z.?0?k1?1?1?4?5?7?E9?:?G;?;??>?m?? A?C?K??L??Q?T?V?2W?W?UX?bX?[? `?a?Yb?b?c? f?ag?h?)h?h?h? i?n?Bo?yq?t?w??x?z?z?~?@o@`@g@@@8@ @ @E@@$@@~@8@@@@T@@@`@@@_ @>!@k"@"@L%@k'@'@8*@*@ ,@/@1@1@3@_4@f8@g:@r<@<@V@@@@@@A@B@C@PE@F@G@eH@I@L@L@N@aP@U@X@;]@c@e@`h@i@j@k@l@xn@{p@ s@Qv@uv@|v@w@x@AAAAA"Ar A A AAeA,ALAAA$A'A*A-A..Ar.AO3A 6AD=Ar?A@ADAEAFAGGAJA:KALA2OAOABRATAmVAVAZA[A\AO`AhaAcA!jAnjAkA oA+qAqAvtA9wAxAyA{A|A4~AABBBcBB B, B B BYBB`BBLB;BBB"Bx'B'B.B&/B0B2B<3B5B6B:B:B;B>Bd?BIBXJB OBOBOBjUB)WBv]B^B_BbBbBAeBhBelB5mBoB:pBHpBYpBpBqBtBzBzBP|B~BCCCCVCCCZ C{ Cr C C CCCC#C!CR"C#CZ#C$Cw*CC.C0C:C;C;C=C@CXBCDCEC!FCICJCJCKCMCZNCOCISCSCWTCCVCXCXCj\C\C]C]CT^C_C`CqbCdCfChCkCkCmCpCcrCsCtCtCzC{CD6DvDDDn D$ D D D DD_DDD"DDDD#%D &DS&D'DN(Da(D3+D},DM-D/D1D6D8D:D,DgADxADBDDDWEDEDGDID-JDXJDJDKDNDODPD/PD QDQDTDZDS]D]DM`DaDdD'eDeDeDmDmDrDzD~DZ~DEJEEEEEhEE`EEXEEP EEEEEE$E)'EE(ER*E*EU+E+EY.Ef.E70EG?GBGBGEGFGHGnJGKG~LG@MGTMGqQGRGUGUGJVG?WGbWG_`GRbGcGgGbkGlGBmG"|G|G~GHIH\H0HNHyH) H H_ H HHH:HHHwHFH?H"H"H#H;#H%H(HQ+H[+H,HT/H/H 0H0Hl5HL8H8H9Hf;H9K3AKSCK\DKEKEK)FK7FKHKIK NKIOKRK0SK/ZK]K^K_K_KfKhKhKiKkKlKpKvKgwKxKLyK|K|K|KL:LCLLLDL L6 L=LL0L8LLzLLLyLLI L!L%Lq%LN+L|-L-L`.LS0L0L3L4L4L{9L-=L:>L?L?L@LrBLBLELSGLHLuIL:JLJL&KLqPL`[L_LaLRbLgLhLkLpLqLqLrL1rLvLQwLyLzLzL~LMM Mn M M M M%MM6MMqMMM/Mc"M0'M>'M'M2M3M4M95M.8MMoBMIMKMNM.QMQMSMUMVMVMRXMZM[M[Mb\M]MWdMAfMvfMjM[lMpMiqM[tM(xMfyMyM}M~MkMN[NNNN<NNNN{N1NN!N)N ,N5,N2N3N-4N5Ny6N6N>:N:N:Nb;N[=N CNEN7FNgHN~JN LNdLNLNMNONPNyUNtVNYNIZN[N[N_No_N`NdNSmNtNtNuNwN1{N|Nq~NYOqOOO;OO O O OOONO^OOOO Oa'O*O+O,OY.O/O1O2O2O3O(9OE:O=O?OBOCOCOEODFO~JOMKOMO/TOQTO0VOYXOcYOZO+[Ow[O^O._O_OWcOncOgOiOBlOlOpOqOqOPtOd{O#}O}O}Oy~OP P1 P^ PdPWPePPbPP P P!P1+P}+P",P,Pv-Pf.P.P2PP4P5P87P7PZ;P;PR?RCR@GRGRIR JRJRORJQRQRYSRdSRXRZRucR dRdR8fRgR[hRkRkRqRqRsRtRwR zRT{RC|Rt|R|R}RS~SSS/ShS$ S S S<S4SAS SSSSS-SSS S!S#S%'S0'S(Sp(S(SW)S,S/S0S1S1Si6S7S8S9S>S9>S%@S ASPAS,DSESHS@NSNSQSSSTSVSYSYSZS(^S^SbSgdS#fSLgSgShSRiSiS*jS@lSoSpSvSvSxS}S~STTTTAT T TU T TTjTTTTTTTT!T%T}*T*T-T-Th.TW0T0T1T1T3T5TG7T99T9T:TE;Tz;T'Xk?XDXEXFEXbEXzEXFX9JXLXLX3NXNXQXQXSXTXPVXWXx]X^X'_X_XGbXeXgXhXiX'mXmXqXqXsXsX_tXuXyX{X|X|X_}X+YYY YYYEYY Y$YV%Y+&YV&Yn*Y-Y=0YA0YL6Y6Yv7Y;Y>Y>YBYEYEYEYKYLYuMYMYNYQYQYiUYVYWYXYSYY:[Y\Y]Y^Y_Y_YeY5hYjYfkYmYqYZxYxYxyYyY~YYZZJZ^ZZZM Z; Z ZZ2ZZ Z Z"Z$Z(Z,Z,Zv.Z.Z/Z/Z0Z1Z5Z6Z8Zu8Z8Z9Z\ @\C\DD\F\5H\^A^B^C^JF^F^I^HL^qL^M^N^P^T^ X^\X^Y^^^a^gc^g^6g^g^fl^n^p^q^Ur^v^v^`v^sw^x^}^'}^~^"__1__$_(_____Y___W__h___ _A&_n*_V+_,_+._0_{2_ 3_5_:_;_A_B_G_ZH_K_L_|N_`O_P_[P_P_xS_T_V_V_KW_X_Z_Z_~[_\_]_`_`_b_xe_k_(n_n_`o_o_o_o_Hq_ r_ht_v_w_x_7z_~_w` ``` ` `>`s````.`%``7`%"`#`G%`%`(`,`-`-`-`Y0`0`2`u3`3`4`9`]<`<`=`=`j>` ?`3A`E`YM`S`W`wZ`yZ`\```8b`c`f`f`1h``i`i`q`#r`Cr`s`w`x`y`R|`~`aaaaaav a aaaa{aaaaaa a"a3#a*$aY$a%a&a*(a)ad)a*a,a7a:be>eXBeCeaDeyDeDeEeHe6JeSMelQeeSepSeWeXe&Ze[eaeaeceje9kenePnewexexe'{e~eef. fd fffffff`frff@ f| f f#f"$fh%f,f/f/f5f5hhHhhbhhhrhh$hD'h'h'h'h)h.h/hY0h0h2h3h7hP>hrEhEhFhHhHhLhmMhMhCQhRhShTh*\h\h]h_hahfhfh"hhvhhhh jhkhmhnhwohphqhoqhthyh}hQhnitiiiiiiAii< iq i i< iyiisiii7i i/ i!i$i])i,i0ip1i1i 2iI2i5i7i?7i-8i8i9iM;i]nO^n_n`n`nbngnin jnlnmnrndsn@wn_xnq|n|nn|oo'o&oEoo!oo) o o$ oo'oo(ofooo8o}ooR o o"oK%oM(o)o+*oB0o2oh3o9o:o=oDBoCoFoLoNoRoHXoXo9[o^o_odojoko:koloaloZmoqououoSvovowoqxoyopppepsp pzppppp3(p(pm)p*pV+pW+p,p-p5.p.p4p4p9p.>p'?p'CpEpQFp2JpnNpOpOpPQp,RpSp)TpVpWpFWp^p^pbpbpep fpfpgp7gpipjpKkpcopmqp.xpyp1{ppqqqqRqyqq^qqqqq>qqqtqH q#$q&q(q+qJ-q`-qF4qO5q7q7q:qcCqCqNDqDq~HqJqNqPq*RqWqW[qg[q8]q;]q_q_q_qaqbqgqhqiqjqWnq%rqTrq8vqvqyqd|q}q~qqrr7rr rE rY r rj rLrrr;rr<rrrr9rrrErr} r:"r#r#r%r&re(r(r*r+r.r1r1r4r:r:r&s&s*s.s]2sP3s3s:9s9s9sd;si=s>sLsGSsUsXsZs_s+`sdsjsqsqststsvsvs{zsE{s,|s}s_s tW tttttt4tttn t!t!t#t#tj&t&tS't't(t(t6)t$,t-t1t05t)7t4t}BtCtCtEtFtGtHtYHtItPtrTt VtWt,Zt=\t\t]t_t$_t`t`tctdtEjtSltot(ptststzutututut]wtxtxt"yt%ztuu4u;u uw uu>uuuuuuu} u u%u&u+(ui*u,u%0ur0u5uD9uh:un;uBuDuZGuHuKuLuPuPu7RuRu0TuVuXuXueuNju`mu&pu;puru&tuvtutuvu{wuxuzuF}uvvvv@v vvvOvvTvb v v|#v%vm'v)v*v+v3v3vk4v5v6v77v(8vZAvCv EvGvGvcHvKv'Rv_RvSvTvTYv4]v^v_vavVbvbvdv]evivmvnv:ovOpvqvqvYwv|v}vww! wX w w<wbw4wwwwM wF!w'w7+wd.wp/w-0w1w4w6w7w8w&?wCwEwFwGw-HwIw`IwzKwNwOOwOwOwRwUwUwWwjXwXw~YwYwYwZw~[w\w\w^wcwfwhwmwmwnwCowxowrwswtwzuw xw>xwxwxwX{w{w~wx'xlxxxZ xY x x x x x xx;xxxxxQxxxFxT"x#x%x%x7)x)x*xC-xm1x:x;x;xyAyDy EyHyIy>LywMyMyPyPy_RyiRyYyy\y\y^y~^y`yfyjynyoypypyxyyy"yyzz\z.zhzz;z; z z z zz+zzzzsz~zz!z!z"z$z%zc(z3.z.z0z2z53z8zc:z;z"Dz-DzzDzDz EzEzEzEzHHzJzKzqLzOzRzYz_z_z{`zUazczgz=jzQjzjzkzlzqzsz|sztzPvzxz}{z|z}z}z<{{{( { {'{H{Q{${0{{1{!{d#{H&{&{P({y){){){R+{-{.{.{0{1{1{3{5{5{8{8{9{k9{I>{@{F{K{O{P{P{Q{U{WY{Y{\^{1_{@`{a{c{d{f{i{hk{k{n{n{6o{p{r{Ds{s{4v{pw{x{z{|{|{T}{ ||| |||D||||| |||8|a|K|f||| |-#|#|#| $|=)|)|+|-|9.|I0|0|1|2|3|3|4|7|8|;|;|c<|<|3=|A|JB|0G|AT|QV|V|X|X|Y|\|^|`|ob|!c|g|j|n|(o|Fp|Cq|u|Vu|u|u|~|c}}w}d} } } } }}t}}}}}i}}}_}}Q}w!}!}1$}$&}&}+}7+},}-}B1}4}5}7}U7}18}:};} =}EB}}D}E}K}V}-Y}L\}i^}^}_}e}[g}}g}h}zh}Ki}bl}/m}n}*q}oq}r}h|}v|}~}&~~p~m~~ ~> ~@~~~~5~ ~a ~ ~y!~"~$~$~$~%~%~I(~Z(~5.~.~A/~B1~T8~a8~<~|=~uB~C~#C~KH~H~bQ~Q~wW~W~X~Y~]~|a~b~b~c~}c~h~vj~k~p~s~t~gt~v~&x~cx~ y~z~4{~|~|~~~~J~HV 9##!&q&(L)|---E/\/99e:<@fCINOR4S|SKU|U Z]dfmf"h$hiijjmttt{`||Oe m !!'1Z38 <E<<\=?S?@B2BCFDGcHK6NJNOQqU\Z\__bVffgPhnhkllqr4uGu {|FPc3O` R!#$!&((0)*,1556t7:{<<>v?@ABDFGIAJJbP;SkUVYD\]^{bbbb0cc8dd*k mnoqrtwRxYxxxy$ydzz 2 Q 3\N2EP#E%k)){**-r1144`67?7<99=B!CCEDIKMOP,QQ RRVWRYZZ[T\X_``a,g6n^oqDrwxtyRz{{9}U\ Sb0T #~((B)D)+-./<33<5799;(<v==Y?.A@AFHI[KSLrMMM NeQQR S_T WZ[*\]_s`bkcQfhAjuLzV}~~ -!z0(En#_!9$"'v'(a))++. 66+8889<@[C\D^KKPRrV.X(YYZ(cffPijLkkq1wfzs}%K|  { @5#!$T$<(())4*90!34g69:Q;>t??A)CLM^N"ORSTVrVXXYZ^[^pafnSq`qr`suHxgxxxy{|(, R (Fc"G,!#$+%*%*-++-125<=8?Q?@]A9M"NNPP(QRFSWXY[\@];^_dkenooopqQs/vwCxxy6}~+ L S , E> !!#c)-+-.J15566778(95==>@A~C>EK7S_UW#YZ[ _}_$cc;def hlo4qOqq tvwwcz:{A|$ S .XAW!!#%% ''2-.1c2<67=6??A3DD8EWEH"JPKKLNNSsXX>YYC[_`ab?ddfLg"momnors$ttuw7zB||}'~6    !<"l"# &_*K..235 88:;??@qFGJJLLM[NDOSOPPRmSAWXZt[]aaccdehmno(pxzC|}~t s u j_ [##i((--//397:>;R==u@oBBCC0E|FIRKdKEL4ORJSSVX>Y[`ab j v3%Ln( ! "#+-05N556;;fBBrEzJLpMfNO`RRSTTTDUGUX YZZZ\U].fggg-hjkmpq1r.sdsz-{|Y q%Iq %!9!d!(/035=@@E IGIJPS T(Y{Z-[}[\Z^]^_2aNacdefgHllgmmnnr?xxx{: ` R %% ,13336D==6>VDDJ$MOPSVWYYZL\+_gzrsyyQN[r ]ku>%m&'}()O+Z-135+5T6\8b8T9:?}@B'EHIL1MNkOvOgP RSUX\]`d@ffShjklmdt0w|~\MKi Ag (!"#%% &&1I24R6X9:@DF~GCKPRWdXwY[Ueh(j]qq d '(4(l++,I-/18(:;@CDGPILLYLLLMDNgNNN$PkQJVXT_`A`a)ijllm_rDs~sPvv3wwxz|h}k~QYd 3siC^$$%Q(~)*-U0b0001336788$:::(<Y@@AQGfGHILLL7R?WY^z_`Ie}ej(ko5vwyRzz|n~~w({e : <j".#$t% &&()!)&*/12C22 356q89!@?@DEEHGOFP$R>RSbTWXLY]`ac?hPh6kk"q]rr-tDuvw{=l> = v^BxT ##%(v*.1235;<=l>ABEGGHHKTTXXY7Z]Z]_l`ab0cCd efUfffghhjl4mkoHrsuUwxxz{}"WhH ^!!B"y""Z$U%{)})+J..E1|3(8:;;;;i>>?BBFKYK[KKOPuQT6UY9[~]_X`>adgjlmpsuRvv{_ VR@/!%'(o(*q+~+#4+448;???QABFMFvFG2HIIIMQSS#ZZ[\^aacccgjj>ndplss>zEzw lp<B!#'$%'&*&)&*-&..1b66<788AACFQHVIJKN&OOPSRSUVDWwWYnYY^P`Z`cdh?i>jk;lhmKn'oo9psw?y}* .[PF!"$$!%e(./K24o79:;FFIK LLNNO}SUUyVPX`msGttv8y|}~  Vux O#(%;% &&()+++,---0.6:<<<c>AEGGJ.KK L0LqLOPW[=ggoFttv'yNz;|  h$$$))/25)6~7=EEE0H0W)XXZc[]C``IeNim2nnqtv?wz{Fj RQ> !z""'S'''#(*(z(+t-w/071l13X4I9 ;=>>,? F4KMnN+P\^<_`Haecfgi n#nn:ozssyQnFHb^" '7)*-<-1.//6 9b9D:g;;A=>>?@BBCELF^I-L5LYLrN.OORY]]^c&ehijj kkruy{ fC#$G&)*+02d57::;=*EEFG:UVYZ\`b2ff#iikMoQp-rsuwyyQ||(-[vq  - P ! 3F~^ !%&&~''#)()+,0f86:<<<ACEE F~KKLMCORRSWpZ^`ad`efhhi,j|lYmmn oo>q sx>z{{}b}~oN "1xz"$$&''' -0V123_58>@IOOGQRNTWzX\^~_ee,ff hojj5lmm sFsttjz|GPN 1b^@z /!""#;$%^'')))*+.p6=CEGHnIL7N;NNUUXb]]@^_absc e7fhiorasuu2v\yyj{{O' , d  M)nm!.#p$c+V,,g-/ //368X9= ?}?D EHH+J.J;NAPU}WjYY0[^^S_dikkkymnSooGppq s=u`uu v1vvzz{|}R x G *d"#c !W"#&(./1-234369>>@@*CJJOHRRNUyWbX4YY[Z[w]Ea5cddfQgikCnJq"r:ttvvc~{ ?  @##$F&(++,F-.01u555J66(8;>>?@CLEFHIJMOFSUVqWW?\\r]]^``aaDijj)l'mnnosw9yy(zzz{l{{{ |[  FC]{ K&&'((045C9;=>AtDdGK{NN9QQz\\q]]`abi l9mFmdmSp6rsvw| T d $%'*02689<>>AEEFF HUQ TFWX[\7] ^i^_`aCggg5kbkklpsvwzzovG =}Z!"^"$o%&*s002455,:&<?BCH|J"MM!NQT%WWY/Zt\`a)fbfqjopqdrr)tuvvxyzz{{{D|Q}-  U! |?$]%b%*,=.?45@?FABG.H|HdILM\NNPPSPsQ/YYY\ kmntz<} %p0! W Y#!!+";%'k)\*|+|-'//25A666I789;=>bDFBGGJOPzQ0TT]_&bceglBmZmXprvxxy~eG +<R>!(S)n)?6BRCCGHIJPUBVVYe}ffhhi3jvkknmmqrtevvww+xHxay}?`M | y 3j,l"\#+0W5e788b::@Aaddd!jkln]qwz~!  mA!N"i%;&'*+,,22m4445Z6^6.9S9:*=^@_D(IN2PSV[XXuYZ_weg"hh%pqtxxyy4z{t|}  +^ ++!-W-22]346;R<t<3??B'FHFFGGQKLMzMPQWRSUX2ZSZ[}__`C`defg>jm#w'w |c@M~Tot !]&S')*+28=+>jBETGGHK6OQ\UVYZr[[[[c\^c`ehjk*nn0ppu vUv 3aS"&&(&+z,- 22134x555t8!:>>BMDDtEEGGTJJKWMOBQQQ'RVY^`_j``6bbcpf1g"j\mmptsJwzb{{~H #J>?@YB#FHKNNPR[\w\2^ a(ezhkxC&F.GMOQwQTUMV WWYZ\X_`dd ee6hhNiZkpr^r u{fJ VG` 4&!!##$(A()~*j+y+,H.24=99\::ADFaFH{JNPVKXYZ[&]]^IilqWssst6{!}'%eo| It !#)2@556`6p8=?BCDF1HjMIOSjTeXX_%_ b9bch^opur sRtvwyzc}Vya PXj/rzR"# #D$$6%&';(.^/)05-::=J>k@@YA,C)FoGS,SS XZZ[]R^aaac/d0d~fNghhijlkk/nppqrs{uvw_xx{~*VF6 3]fr2".$D+ ,8,/224748I;>BCDE!F%IJJNZP \+]<^^c[egglInnVprRttuuMx{`MX@CY b>fTug/Q _""$p&()*,\01/2b235q5i8;=>?O??+AF-GIINCiHLNOQzQ SWfXY[[\N^z_tadcddfgjmypqqtptyz}~d~^  \ 1VJt%`(('+#--.126r:-;<?ACHIHIRSV_WhWc\obdEjklm"tXuww-xWyC " ACMD"8` W#?$&L((b+,,.0.i.J2B5v5<=N>]LpX Tg4U"%a)M*r+,@-X..0D0_67:=G.JMQMbMnNxOO(Q&UZ\\`iab1deye0gg"i)p5ppEuxx{e}y~~%D2 [ O 0 1 N`f%n&D,-W1124]9;<<I>>?BDDEEFFJHIVL2MXQ[RgTUUVQZa[]`'asbb8c~cilmsu#uvz>| I  G!""$%%9)o668/=t=@[AAEHIJ@KmP Q_T#X]]P_aCcdgi qtyzU}8\b o  M2'!)Q*2,;;<>BTDF+JKKIPQQkRSeUUWXY:]]]'^`atbUkXkkUmm2qcqBrza J r[=4|7%O-25B889:;E;T; <?\BBCD4EF2HJDJKPXXY^^_ggi/iq9ssu}~4O} o    }S#%%F++,./O/13)58e9-:G@@AIIJHMQQQETVY\ah>jmmn+oTovxz&|!  X| m ")*./01&1z112;<a>>>:BILhNOQS ST'TTbU2Y_=`vcehkoppqr>s[w\wy2}W}}g~8S{Y v o1!~..0<23468Q99W<=v>ADtFFIEN>OPOR1XYZZ3[F\`$ac7dhiikIlmno?rrkstvtwFxy_{=k  %.{H%%&(r((z157=y>C|FRR:UWVWYNZ@[^N`Z``bbbYccm ppQq rrssuku}u*wnzz{$|S||};}}T# { ' .0a%f ##(x***+++-u..1W289A(DDF}F.G$HBHJOKkLMNQS&VHVVo_i``a|eevgg!ijnPsutvxay{}e/p l 7O/6ae##o$%%&().136679DuDxEbJ}L}MXOP*TtUVVEWWXX[Y\\^`dgghjkkHmoo{pqrsuAu\v*x]x{$|~VZJL lw& !!!$),-./I1123l78:;.;3;t<<EFFaKFLsOfVVWiXZbKd^egik@nnppqss,uSuvy7~Zsf xPv&#z#1$ )*+,./0=1233:<O>x>7@JCDEfFII KOOAUVXY^>_.abbdJee fFlloqWrrrfu?x?~ 4 f$ # @"J""#%&/768C99`:+;0>?AAFF@JMNbOpWuZUad1fi9jjj lm_n:sstu/ubwdxxz{|}})~< 2 ? - Dj{x'##%K*+t.77 <+<<<MCC=GICJ$KLNN5P&RSTsUVbXXqZZdghyj@kl$mmnDooqIuuvxxyz|O},~~TG w RB>1d!"#' (G367:;|<c=BHIJkL(O!Q\QaQSS.WXX[Q\m\]_`bck2k8kOkSl+mqqrt?uXwx~~w FOVN~sJp"$$$%**A++p,q, .9/}8;{;;<??@BDKKLR5T]W}W:\R__]`|budf8g-hshhklllnqEtswqxxyzzg|O~~AV Pk_Z~C!"@$%z///a00l113476j779<e>^@@MCEDcGGGHpIK/K}LOtPRRTXeY__cZfgk;mpqyr{sstwz:{z{}}N)B % z Z !!!$%i,,P.//03444758s:<nA.C:CDDNFHH:ILZO[OgOV+WXY8\ab"dJf9gjkpqrutttCvxy1}j}K~~OX{ Z (!"x#P)**t,,d./1L2Z24455<6< =EFGHIIJkLHMMSWLY\]^9``UaabIbdadj`kypu'vv{o% E%"A$'' +6011445r68:BEF+I7JiKKKKLLMFOQTTUUY[=\^cdjkpp~stt4vxxy{~P K-.W0;11:@@ApEUGGIENOIP$QjU7X&Z\E]P__wahlllptuuvwR ? w sgj R$m$F%'<(r((',-34566Y7=<6=_>@BC;EE^JKjL?NtRRW_]]aFcegfkBno:puvz }~t _ d$%A(( +"-?-b11666j8;->DaDpGHIgPRU+^^_eCj0llnoooqruKwwixx{ k= & ; <Z 4 H 1"#Z$%%&{(,)+k,.24789h::=?oASBDbEEFGGNPPTTVZ&]+_ bddfijlfnooJO PPRRXDX9YZR[b[ag/ooprRu%y{}$5|Jv/ M ? "*+--|001(557;<4?AuCD,E H\HJJLP4VVTY\^_efZg8jPqtuuwxz{}Z~Q#S ~ i .C0N"u"&p'**+u.Q344::Z;[>DFGHH@INPTVWXQXZY ZX[]]dudd$ee_ffgk%kkno5qqvewz|'}M}~^( + 4 S. _ "a###)+7,W/01234519.;d;@BDGIJPQ\Z\arbce)gh_ilDrsQtt l_% "()L22455*:#;=B-GPG_GwGI#IMNSSTVWXXXbbeggyogp#qs#uwy{}3@W@dst A "j#r#%-X23#4z6:;>?v@uBDEEG5HHPQTOZ^5_P_3` f"AA3FF$H+HLZMNNQUYMZ[5\]baTdVhhk}pshAHJOUVVYYsZ[\b"eiijnpdqjqr.ty}}1] 0 |L &!c$([../0347j88K9@@BDD-GKNPU9VBVYY ZZ=\cc#e{fjknv\xxy!"0z![tX] =#C#%(!)Y)*"+-F. 1D19):Z:v<>nACFFiIMOQNRRSUVXZ[_c` dfimkn}pqqrsmtwx~] U l 'I!!($ (-.p2v2W3Z45?9U9:G:=;<@BCEIK L*MmMQUKUW|Z\!]V^c_df0jq1qXrrmtc O k U#APv$m%%c()O*,+,-.02a67x:;P<AGIJDJ`S!V!XhXZ4^_ bbcfghjIkUkXlmn:x}cb]9k *4u-V !~"%),0012|7,::<'@+B]BmBFVGGKPR{STeUV(WIW\Vblm;no t*tuJv|xy[{{V}b c  P j "-./ 345l889:>>6??NACDEOIJLU]_&`bYb7c2d@fikylobpiqrs/tZw{}}# 5MC r %'(()-c.|112 346\7;99;H<|<<R@@B?CGH IIMJrJlPQSUUV8Z[`bcQede%fjjUttuxxz{~l ! n? ;(!">$X$&))*1+^++m.15W6<>L?$AEFGFHKPqTU{VZ[^`&a~fiZibiolsstWyD|Y|T|~   :O !"5#X**F3<45s59;,<}= FFJJcKJOQJQS1TJULXY[eAiFj)kk#mun quGutuw+yyzQz|~D76 R h ( O2.~] "#%m&%*/++E-44568)999:ACUDD G9GNUV.WX\aaaTbJcqccikklnorrt^uvjxyyp}<~ t ( {!t$$%& '(?*t+},/2M38,9:=AD0JUK\KyLMN9NCQDQRG[ \L\3__X`beiiquuvyVz}~|r} jW!## ((8+J+,\-,33377U;CGGfQT&WX0[[\Tabeej2l=n%rt4vvv|@I] L P (![!!##%&*@-f-67b7P8q9;<=O?ACGIIJKLNR)SjVhXnXr_`Zbbff/hqkcrjrtQv};M TR36^ Z!V##'$*G,@//-0615:;t<==?DzEhF?LMPQtR UnUXXZZ;[^eghjlor&uaz{| }+c|M# l]f<^ +&&''k(--e.07:X?EG'IK_KK!LQQSUNWWWX\^aaggPhjrvrt%v}vww}~z pnO"H&.'v)**-/ 2234556:7%<===?0@r@fARBBD INRiTTT5V[_`a dOeihh[l quyy"z|7}} @ KY}"e!#a$)H/%1N15577L99)::>%AICDuGIJ/KWOOPQRIS)T\E\^aeefj.mm_noUp!s tvHww~f5wk  f rM\O"p""t((.45667.88Z9:->ABHJJ-MXXYGa-c4c|c#d|dfjlNm1oLoZo4qsvvd}~^@ <@' "b$&)+,-12w55678:Z:?ABDSDFH4JJJKKMcPPQRSX [4[9]^aaaIcjYlmn'oppyuKvy@zz {x l~O!<"Z$g'M(),'-Z/l01+777?BE#HJNQ VWYcY_dLefZhiPkclhlmnt#uovvAzFo.11 ' ?0 E#%'k(F,-..//0456[<<>??@AmDqFILxMOUkYY\\ ]]`bbb=ehjjnoqsfw*zC{~yl =]#$%*&&'%)$..//!5M56:EJKKNwO#ShV.[0]^9__ `!ccc$dl~rvt|uvZx_y|x n~A!`$6()*'++-=.456z799i<=@ DADFG.JL*M[NOPhRTqVWYj[]{]a`d0eggUghjPkakkknnrusyJz{P{|9wC y ! I< )!'(e*+,`.l...0$1J2~2:>>>q?@BCDDF/FHIKLLNRDS@TV?]]q^cNee+f`iVnioOpqsLtOu|y{8||? yV+P> ""4%%%&l&*o,A-d-N4X4 67/8v<C=?A0CdFZIJ%LNOnRRXXq[#\?]]]_cehjn9pUuz}{E|N|}~~DT h!oZ!!|##.0F1m348/;7;;=)HI[KCMMPuRDSHSDT^UY[]\;_YdfjkTlstu yy|}}2 ? * R -h!$$E%'''O.798\99f: <>F?!@#AB^CCILbM TrTVY'Z\!]q_1`7abcG_ / Z f"~(:*+,-,.4.Z.^/01V359Q:\::B4CCDG.HIOPRSTVVX[;\\]3`ag\hkmoqqq}iu3 "%&'e(-)C+,,--H001\34.9=2>??4?N@HIJO)ScUU^`df'h6hjqxvzw}}D 1  7kqw!E!&A(n)*._0r1B24466^:=ZBBEEHaIII?PPPRRWW]]3_`d}dhijklbn/q srsvK]M]@ !"#%&'()*+,-/01E7E9E:E<E=E?E@EBECkHkIkJkLkMkNmOmPmQmRmSmTmUVWYZ[\]^`bceflmnpqrtuvwyz{kkkkkkkkkzzzzzƦƧ444444444ŸŹzzzzzzz_H@HHH@@H$HL@H,H\@H0H2Hh@H6H8Ht@H<H|@H@HBH@HFH@HLH@HTHXH@H\H@H`H@HdH@HlHnH@HrHtH@HxHzH|H~HHH@HH@HH@HHHHHHHHHH@HHH\@HHHh@HHHHx@HHH@HHH@HH@HHH@HHHH@HH@HHHHH@HH@HH@HH@HH@H H H@HHHH,@HHHH<@H HD@H$H&HP@H,H.H0Hd@H4Hl@H<H>H@HBHDHFH@HJHLHNHPH@HTHVHXH\H^HbHdHfH<Unknown G*Ax Times New Roman5Symbol3. *Cx Arial7.@ CalibriA. Arial NarrowQ Bernard MT Condensed?Segoe Print7K@Cambria5. .[`)TahomaQ  Minion ProMS Mincho?= *Cx Courier New;WingdingsA BCambria Math#q'G'GR 'M5'v5'v!n20\\? ?QHP $PrA2! xxJCJC|                       Oh+'0$x   JCNormalJC6Microsoft Office Word@ @<C@i%@b)05'՜.+,D՜.+,8 hp  Hewlett-Packardv\  TtuloT 8@ _PID_HLINKSA _ http://www.vaccinesafety.edu/ Uhttp://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table.pdfQhttp://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/latex-table.pdff1 http://www.allergyfreeskin.com/b3http://www.contactderm.org/  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklnopqrstvwxyz{|Root Entry F,L01TablenWordDocument 7hSummaryInformation(mDocumentSummaryInformation8uMsoDataStoreL00L0N2MKUC52SG==2L00L0Item PropertiesUMacrosL0L0VBA L0L0dir   !"#$%&')*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTVWXYZ[^ 0* pHdProjectQ(@= l @Q J< rstdole>stdoleP h%^*\G{00020430-C 0046}#2.0#0#C:\Windows\system32\e2.tlb#OLE Automation`ENormalENCrmaQF  *,\C mA!OfficgODficg!G{2DF8D04C-5BFA-101B-BDE5gAAe42ggram Files\@CommonMicrosoft Shared\OFFICE12\MSO.DLL&#M 1 Ob Libra,ry%xMSBFAs>MSFBs3 @dD452EE1-E08F0A-8-02608C4D0BB4dFM20L'EB &/;"1?D|~ C00}#0B# 5h0 AB19AC9AD-4A34-4F9@9-B6D37A4636A4AE16Users\JC\AppData\Local\Temp\Wo`rd8.0b7.xexdc